000194404812/292024Q3FALSEhttp://fasb.org/us-gaap/2024#OtherAssetsNoncurrenthttp://fasb.org/us-gaap/2024#OtherAssetsNoncurrenthttp://fasb.org/us-gaap/2024#AccruedLiabilitiesCurrenthttp://fasb.org/us-gaap/2024#AccruedLiabilitiesCurrenthttp://fasb.org/us-gaap/2024#OtherLiabilitiesNoncurrenthttp://fasb.org/us-gaap/2024#OtherLiabilitiesNoncurrenthttp://fasb.org/us-gaap/2024#PropertyPlantAndEquipmentNethttp://fasb.org/us-gaap/2024#LongTermDebtP6Y0M0Dxbrli:sharesiso4217:USDiso4217:USDxbrli:shareskvue:Segmentxbrli:pureutr:sqftkvue:note00019440482024-01-012024-09-2900019440482024-11-0100019440482024-09-2900019440482023-12-3100019440482024-07-012024-09-2900019440482023-07-032023-10-0100019440482023-01-022023-10-010001944048us-gaap:CommonStockMember2024-06-300001944048us-gaap:AdditionalPaidInCapitalMember2024-06-300001944048us-gaap:TreasuryStockCommonMember2024-06-300001944048us-gaap:RetainedEarningsMember2024-06-300001944048us-gaap:AccumulatedOtherComprehensiveIncomeMember2024-06-3000019440482024-06-300001944048us-gaap:RetainedEarningsMember2024-07-012024-09-290001944048us-gaap:AccumulatedOtherComprehensiveIncomeMember2024-07-012024-09-290001944048us-gaap:AdditionalPaidInCapitalMember2024-07-012024-09-290001944048us-gaap:CommonStockMember2024-07-012024-09-290001944048us-gaap:TreasuryStockCommonMember2024-07-012024-09-290001944048srt:RevisionOfPriorPeriodReclassificationAdjustmentMemberus-gaap:AdditionalPaidInCapitalMember2024-07-012024-09-290001944048us-gaap:CommonStockMember2024-09-290001944048us-gaap:AdditionalPaidInCapitalMember2024-09-290001944048us-gaap:TreasuryStockCommonMember2024-09-290001944048us-gaap:RetainedEarningsMember2024-09-290001944048us-gaap:AccumulatedOtherComprehensiveIncomeMember2024-09-290001944048us-gaap:CommonStockMember2023-07-020001944048us-gaap:AdditionalPaidInCapitalMember2023-07-020001944048us-gaap:RetainedEarningsMember2023-07-020001944048us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-07-0200019440482023-07-020001944048us-gaap:RetainedEarningsMember2023-07-032023-10-010001944048us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-07-032023-10-010001944048us-gaap:AdditionalPaidInCapitalMember2023-07-032023-10-010001944048us-gaap:CommonStockMember2023-07-032023-10-010001944048srt:RevisionOfPriorPeriodReclassificationAdjustmentMemberus-gaap:AdditionalPaidInCapitalMember2023-07-032023-10-010001944048us-gaap:CommonStockMember2023-10-010001944048us-gaap:AdditionalPaidInCapitalMember2023-10-010001944048us-gaap:RetainedEarningsMember2023-10-010001944048us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-10-0100019440482023-10-010001944048us-gaap:CommonStockMember2023-12-310001944048us-gaap:AdditionalPaidInCapitalMember2023-12-310001944048us-gaap:TreasuryStockCommonMember2023-12-310001944048us-gaap:RetainedEarningsMember2023-12-310001944048us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-12-310001944048us-gaap:RetainedEarningsMember2024-01-012024-09-290001944048us-gaap:AccumulatedOtherComprehensiveIncomeMember2024-01-012024-09-290001944048us-gaap:AdditionalPaidInCapitalMember2024-01-012024-09-290001944048us-gaap:CommonStockMember2024-01-012024-09-290001944048us-gaap:TreasuryStockCommonMember2024-01-012024-09-290001944048srt:RevisionOfPriorPeriodReclassificationAdjustmentMemberus-gaap:AdditionalPaidInCapitalMember2024-01-012024-09-290001944048us-gaap:CommonStockMember2023-01-010001944048us-gaap:AdditionalPaidInCapitalMember2023-01-010001944048us-gaap:RetainedEarningsMember2023-01-010001944048kvue:NetParentInvestmentMember2023-01-010001944048us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-01-0100019440482023-01-010001944048us-gaap:RetainedEarningsMember2023-01-022023-10-010001944048kvue:NetParentInvestmentMember2023-01-022023-10-010001944048us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-01-022023-10-010001944048us-gaap:AdditionalPaidInCapitalMember2023-01-022023-10-010001944048us-gaap:CommonStockMember2023-01-022023-10-010001944048srt:RevisionOfPriorPeriodReclassificationAdjustmentMemberus-gaap:AdditionalPaidInCapitalMember2023-01-022023-10-010001944048kvue:NetParentInvestmentMember2023-10-010001944048us-gaap:IPOMember2023-05-082023-05-0800019440482023-05-080001944048us-gaap:OverAllotmentOptionMember2023-05-082023-05-0800019440482023-05-040001944048kvue:ConsumerHealthBusinessMemberus-gaap:ParentMemberkvue:ConsumerHealthSpinoffMember2023-05-0800019440482023-05-090001944048kvue:KenvueMemberkvue:JohnsonJohnsonMember2023-05-080001944048kvue:KenvueMemberkvue:JohnsonJohnsonMember2023-05-082023-05-080001944048kvue:JohnsonJohnsonMember2023-08-232023-08-2300019440482023-08-232023-08-2300019440482023-08-230001944048kvue:KenvueMemberkvue:JohnsonJohnsonMember2023-08-232023-08-2300019440482024-05-172024-05-170001944048srt:RevisionOfPriorPeriodReclassificationAdjustmentMember2024-09-290001944048srt:RevisionOfPriorPeriodReclassificationAdjustmentMemberkvue:CloudComputingArrangementsMember2024-09-290001944048srt:RevisionOfPriorPeriodReclassificationAdjustmentMemberkvue:CloudComputingArrangementsMember2024-01-012024-09-290001944048kvue:JohnsonJohnsonMember2024-09-290001944048kvue:JohnsonJohnsonMember2023-12-3100019440482023-04-2000019440482024-05-0100019440482024-01-310001944048kvue:Dr.CiLaboAssetImpairmentMember2024-01-012024-09-290001944048kvue:SkillmanFixedAssetImpairmentMember2024-01-012024-09-290001944048kvue:Dr.CiLaboAssetImpairmentMember2024-04-012024-06-300001944048us-gaap:FiniteLivedIntangibleAssetsMemberkvue:Dr.CiLaboAssetImpairmentMember2024-04-012024-06-300001944048kvue:Dr.CiLaboAssetImpairmentMemberus-gaap:PropertyPlantAndEquipmentMember2024-04-012024-06-300001944048kvue:Dr.CiLaboAssetImpairmentMember2024-06-300001944048us-gaap:TrademarksMembersrt:MinimumMember2024-06-300001944048us-gaap:TrademarksMembersrt:MaximumMember2024-06-300001944048us-gaap:MeasurementInputDiscountRateMember2024-06-300001944048kvue:SkillmanFixedAssetImpairmentMember2024-01-012024-03-310001944048us-gaap:VariableInterestEntityPrimaryBeneficiaryMember2024-09-290001944048us-gaap:VariableInterestEntityPrimaryBeneficiaryMember2024-07-012024-09-290001944048us-gaap:VariableInterestEntityPrimaryBeneficiaryMember2023-07-032023-10-010001944048us-gaap:VariableInterestEntityPrimaryBeneficiaryMember2024-01-012024-09-290001944048us-gaap:VariableInterestEntityPrimaryBeneficiaryMember2023-01-022023-10-010001944048us-gaap:ParentMemberkvue:NetEconomicBenefitArrangementsMember2024-09-290001944048us-gaap:ParentMemberkvue:NetEconomicBenefitArrangementsMember2024-07-012024-09-290001944048us-gaap:ParentMemberkvue:NetEconomicBenefitArrangementsMember2023-07-032023-10-010001944048us-gaap:ParentMemberkvue:NetEconomicBenefitArrangementsMember2024-01-012024-09-290001944048us-gaap:ParentMemberkvue:NetEconomicBenefitArrangementsMember2023-01-022023-10-010001944048kvue:PatentsAndTrademarksMember2024-09-290001944048kvue:PatentsAndTrademarksMember2023-12-310001944048us-gaap:CustomerRelationshipsMember2024-09-290001944048us-gaap:CustomerRelationshipsMember2023-12-310001944048us-gaap:OtherIntangibleAssetsMember2024-09-290001944048us-gaap:OtherIntangibleAssetsMember2023-12-310001944048us-gaap:TrademarksMember2024-09-290001944048us-gaap:TrademarksMember2023-12-310001944048us-gaap:OtherIntangibleAssetsMember2024-09-290001944048us-gaap:OtherIntangibleAssetsMember2023-12-310001944048us-gaap:FiniteLivedIntangibleAssetsMemberkvue:Dr.CiLaboAssetImpairmentMember2024-01-012024-09-290001944048kvue:SelfCareMember2023-12-310001944048kvue:SkinHealthAndBeautyMember2023-12-310001944048kvue:EssentialHealthMember2023-12-310001944048kvue:SelfCareMember2024-01-012024-09-290001944048kvue:SkinHealthAndBeautyMember2024-01-012024-09-290001944048kvue:EssentialHealthMember2024-01-012024-09-290001944048kvue:SelfCareMember2024-09-290001944048kvue:SkinHealthAndBeautyMember2024-09-290001944048kvue:EssentialHealthMember2024-09-290001944048kvue:A550NotesDue2025Member2024-09-290001944048kvue:A550NotesDue2025Member2023-12-310001944048kvue:A535NotesDue2026Member2024-09-290001944048kvue:A535NotesDue2026Member2023-12-310001944048kvue:A505NotesDue2028Member2024-09-290001944048kvue:A505NotesDue2028Member2023-12-310001944048kvue:A500NotesDue2030Member2024-09-290001944048kvue:A500NotesDue2030Member2023-12-310001944048kvue:A490NotesDue2033Member2024-09-290001944048kvue:A490NotesDue2033Member2023-12-310001944048kvue:A510NotesDue2043Member2024-09-290001944048kvue:A510NotesDue2043Member2023-12-310001944048kvue:A505NotesDue2053Member2024-09-290001944048kvue:A505NotesDue2053Member2023-12-310001944048kvue:A520NotesDue2063Member2024-09-290001944048kvue:A520NotesDue2063Member2023-12-310001944048us-gaap:OtherDebtSecuritiesMember2024-09-290001944048us-gaap:OtherDebtSecuritiesMember2023-12-310001944048us-gaap:BuildingMember2024-09-290001944048us-gaap:SeniorNotesMember2023-03-220001944048us-gaap:SeniorNotesMember2023-03-222023-03-220001944048us-gaap:CommercialPaperMember2023-03-030001944048us-gaap:CommercialPaperMember2023-03-032023-03-030001944048us-gaap:CommercialPaperMember2023-04-032023-05-030001944048us-gaap:CommercialPaperMember2024-09-290001944048us-gaap:CommercialPaperMember2023-12-310001944048kvue:TheRevolvingCreditFacilityMemberus-gaap:RevolvingCreditFacilityMember2023-03-062023-03-060001944048kvue:TheRevolvingCreditFacilityMemberus-gaap:RevolvingCreditFacilityMember2023-03-060001944048kvue:TheRevolvingCreditFacilityMemberus-gaap:RevolvingCreditFacilityMember2024-09-290001944048kvue:TheRevolvingCreditFacilityMemberus-gaap:RevolvingCreditFacilityMember2023-12-310001944048kvue:FacilityAgreementMemberkvue:JohnsonJohnsonMember2023-04-050001944048kvue:FacilityAgreementMemberkvue:JohnsonJohnsonMember2023-05-082023-05-080001944048us-gaap:PensionPlansDefinedBenefitMember2024-07-012024-09-290001944048us-gaap:PensionPlansDefinedBenefitMember2023-07-032023-10-010001944048us-gaap:PensionPlansDefinedBenefitMember2024-01-012024-09-290001944048us-gaap:PensionPlansDefinedBenefitMember2023-01-022023-10-010001944048us-gaap:AccumulatedTranslationAdjustmentMember2024-06-300001944048us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember2024-06-300001944048kvue:AccumulatedGainLossNetDerivativesAndHedgesParentMember2024-06-300001944048us-gaap:AccumulatedTranslationAdjustmentMember2024-07-012024-09-290001944048us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember2024-07-012024-09-290001944048kvue:AccumulatedGainLossNetDerivativesAndHedgesParentMember2024-07-012024-09-290001944048us-gaap:AccumulatedTranslationAdjustmentMember2024-09-290001944048us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember2024-09-290001944048kvue:AccumulatedGainLossNetDerivativesAndHedgesParentMember2024-09-290001944048us-gaap:AccumulatedTranslationAdjustmentMember2023-07-020001944048us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember2023-07-020001944048kvue:AccumulatedGainLossNetDerivativesAndHedgesParentMember2023-07-020001944048us-gaap:AccumulatedTranslationAdjustmentMember2023-07-032023-10-010001944048us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember2023-07-032023-10-010001944048kvue:AccumulatedGainLossNetDerivativesAndHedgesParentMember2023-07-032023-10-010001944048us-gaap:AccumulatedTranslationAdjustmentMember2023-10-010001944048us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember2023-10-010001944048kvue:AccumulatedGainLossNetDerivativesAndHedgesParentMember2023-10-010001944048us-gaap:AccumulatedTranslationAdjustmentMember2023-12-310001944048us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember2023-12-310001944048kvue:AccumulatedGainLossNetDerivativesAndHedgesParentMember2023-12-310001944048us-gaap:AccumulatedTranslationAdjustmentMember2024-01-012024-09-290001944048us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember2024-01-012024-09-290001944048kvue:AccumulatedGainLossNetDerivativesAndHedgesParentMember2024-01-012024-09-290001944048us-gaap:AccumulatedTranslationAdjustmentMember2023-01-010001944048us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember2023-01-010001944048kvue:AccumulatedGainLossNetDerivativesAndHedgesParentMember2023-01-010001944048us-gaap:AccumulatedTranslationAdjustmentMember2023-01-022023-10-010001944048us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember2023-01-022023-10-010001944048kvue:AccumulatedGainLossNetDerivativesAndHedgesParentMember2023-01-022023-10-010001944048us-gaap:CostOfSalesMember2024-07-012024-09-290001944048us-gaap:CostOfSalesMember2023-07-032023-10-010001944048us-gaap:CostOfSalesMember2024-01-012024-09-290001944048us-gaap:CostOfSalesMember2023-01-022023-10-010001944048us-gaap:SellingGeneralAndAdministrativeExpensesMember2024-07-012024-09-290001944048us-gaap:SellingGeneralAndAdministrativeExpensesMember2023-07-032023-10-010001944048us-gaap:SellingGeneralAndAdministrativeExpensesMember2024-01-012024-09-290001944048us-gaap:SellingGeneralAndAdministrativeExpensesMember2023-01-022023-10-0100019440482024-01-012024-03-310001944048us-gaap:EmployeeStockOptionMember2024-01-012024-03-310001944048us-gaap:EmployeeStockOptionMembersrt:MinimumMember2024-01-012024-03-310001944048us-gaap:EmployeeStockOptionMembersrt:MaximumMember2024-01-012024-03-310001944048us-gaap:RestrictedStockUnitsRSUMember2024-01-012024-03-310001944048us-gaap:RestrictedStockUnitsRSUMembersrt:MinimumMember2024-01-012024-03-310001944048us-gaap:RestrictedStockUnitsRSUMembersrt:MaximumMember2024-01-012024-03-310001944048us-gaap:PerformanceSharesMember2024-01-012024-03-310001944048us-gaap:PerformanceSharesMembersrt:MinimumMember2024-01-012024-03-310001944048us-gaap:PerformanceSharesMembersrt:MaximumMember2024-01-012024-03-310001944048us-gaap:CostOfSalesMemberus-gaap:RelatedPartyMember2023-01-022023-10-010001944048us-gaap:SellingGeneralAndAdministrativeExpensesMemberus-gaap:RelatedPartyMember2023-01-022023-10-010001944048us-gaap:RelatedPartyMember2023-01-022023-10-010001944048us-gaap:ParentMemberkvue:CashPoolingAndGeneralFinancingActivitiesMember2023-01-022023-10-010001944048us-gaap:ParentMemberkvue:CorporateCostAllocationsMember2023-01-022023-10-010001944048us-gaap:ParentMemberkvue:TaxesDeemedSettledWithParentMember2023-01-022023-10-010001944048us-gaap:ParentMemberkvue:NetTransfersToParentCashFlowImpactMember2023-01-022023-10-010001944048us-gaap:ParentMemberkvue:OtherMember2023-01-022023-10-010001944048us-gaap:ParentMemberkvue:NetTransfersToParentEquityImpactMember2023-01-022023-10-010001944048kvue:JohnsonJohnsonMember2024-07-012024-09-290001944048kvue:JohnsonJohnsonMember2023-07-032023-10-010001944048kvue:JohnsonJohnsonMember2024-01-012024-09-290001944048kvue:JohnsonJohnsonMember2023-01-022023-10-010001944048us-gaap:SeniorNotesMember2023-01-022023-07-020001944048us-gaap:CommercialPaperMember2023-01-022023-07-0200019440482023-05-310001944048kvue:KenvueIPOMember2023-05-012023-05-3100019440482023-05-082023-05-0800019440482023-01-022023-07-240001944048us-gaap:ForeignExchangeContractMember2024-09-290001944048us-gaap:FairValueInputsLevel1Memberus-gaap:ForeignExchangeContractMember2024-09-290001944048us-gaap:FairValueInputsLevel2Memberus-gaap:ForeignExchangeContractMember2024-09-290001944048us-gaap:FairValueInputsLevel3Memberus-gaap:ForeignExchangeContractMember2024-09-290001944048us-gaap:ForeignExchangeContractMember2023-12-310001944048us-gaap:FairValueInputsLevel1Memberus-gaap:ForeignExchangeContractMember2023-12-310001944048us-gaap:FairValueInputsLevel2Memberus-gaap:ForeignExchangeContractMember2023-12-310001944048us-gaap:FairValueInputsLevel3Memberus-gaap:ForeignExchangeContractMember2023-12-310001944048us-gaap:CrossCurrencyInterestRateContractMember2024-09-290001944048us-gaap:FairValueInputsLevel1Memberus-gaap:CrossCurrencyInterestRateContractMember2024-09-290001944048us-gaap:FairValueInputsLevel2Memberus-gaap:CrossCurrencyInterestRateContractMember2024-09-290001944048us-gaap:FairValueInputsLevel3Memberus-gaap:CrossCurrencyInterestRateContractMember2024-09-290001944048us-gaap:CrossCurrencyInterestRateContractMember2023-12-310001944048us-gaap:FairValueInputsLevel1Memberus-gaap:CrossCurrencyInterestRateContractMember2023-12-310001944048us-gaap:FairValueInputsLevel2Memberus-gaap:CrossCurrencyInterestRateContractMember2023-12-310001944048us-gaap:FairValueInputsLevel3Memberus-gaap:CrossCurrencyInterestRateContractMember2023-12-310001944048us-gaap:FairValueInputsLevel1Member2024-09-290001944048us-gaap:FairValueInputsLevel2Member2024-09-290001944048us-gaap:FairValueInputsLevel3Member2024-09-290001944048us-gaap:FairValueInputsLevel1Member2023-12-310001944048us-gaap:FairValueInputsLevel2Member2023-12-310001944048us-gaap:FairValueInputsLevel3Member2023-12-310001944048us-gaap:PrepaidExpensesAndOtherCurrentAssetsMember2024-09-290001944048us-gaap:FairValueInputsLevel1Memberus-gaap:PrepaidExpensesAndOtherCurrentAssetsMember2024-09-290001944048us-gaap:FairValueInputsLevel2Memberus-gaap:PrepaidExpensesAndOtherCurrentAssetsMember2024-09-290001944048us-gaap:FairValueInputsLevel3Memberus-gaap:PrepaidExpensesAndOtherCurrentAssetsMember2024-09-290001944048us-gaap:PrepaidExpensesAndOtherCurrentAssetsMember2023-12-310001944048us-gaap:FairValueInputsLevel1Memberus-gaap:PrepaidExpensesAndOtherCurrentAssetsMember2023-12-310001944048us-gaap:FairValueInputsLevel2Memberus-gaap:PrepaidExpensesAndOtherCurrentAssetsMember2023-12-310001944048us-gaap:FairValueInputsLevel3Memberus-gaap:PrepaidExpensesAndOtherCurrentAssetsMember2023-12-310001944048us-gaap:AccountsPayableMember2024-09-290001944048us-gaap:FairValueInputsLevel1Memberus-gaap:AccountsPayableMember2024-09-290001944048us-gaap:FairValueInputsLevel2Memberus-gaap:AccountsPayableMember2024-09-290001944048us-gaap:FairValueInputsLevel3Memberus-gaap:AccountsPayableMember2024-09-290001944048us-gaap:AccountsPayableMember2023-12-310001944048us-gaap:FairValueInputsLevel1Memberus-gaap:AccountsPayableMember2023-12-310001944048us-gaap:FairValueInputsLevel2Memberus-gaap:AccountsPayableMember2023-12-310001944048us-gaap:FairValueInputsLevel3Memberus-gaap:AccountsPayableMember2023-12-310001944048us-gaap:OtherAssetsMember2024-09-290001944048us-gaap:FairValueInputsLevel1Memberus-gaap:OtherAssetsMember2024-09-290001944048us-gaap:FairValueInputsLevel2Memberus-gaap:OtherAssetsMember2024-09-290001944048us-gaap:FairValueInputsLevel3Memberus-gaap:OtherAssetsMember2024-09-290001944048us-gaap:OtherAssetsMember2023-12-310001944048us-gaap:FairValueInputsLevel1Memberus-gaap:OtherAssetsMember2023-12-310001944048us-gaap:FairValueInputsLevel2Memberus-gaap:OtherAssetsMember2023-12-310001944048us-gaap:FairValueInputsLevel3Memberus-gaap:OtherAssetsMember2023-12-310001944048us-gaap:OtherLiabilitiesMember2024-09-290001944048us-gaap:FairValueInputsLevel1Memberus-gaap:OtherLiabilitiesMember2024-09-290001944048us-gaap:FairValueInputsLevel2Memberus-gaap:OtherLiabilitiesMember2024-09-290001944048us-gaap:FairValueInputsLevel3Memberus-gaap:OtherLiabilitiesMember2024-09-290001944048us-gaap:OtherLiabilitiesMember2023-12-310001944048us-gaap:FairValueInputsLevel1Memberus-gaap:OtherLiabilitiesMember2023-12-310001944048us-gaap:FairValueInputsLevel2Memberus-gaap:OtherLiabilitiesMember2023-12-310001944048us-gaap:FairValueInputsLevel3Memberus-gaap:OtherLiabilitiesMember2023-12-310001944048us-gaap:ForeignExchangeContractMemberus-gaap:CashFlowHedgingMemberus-gaap:DesignatedAsHedgingInstrumentMember2024-09-290001944048us-gaap:CrossCurrencyInterestRateContractMemberus-gaap:CashFlowHedgingMemberus-gaap:DesignatedAsHedgingInstrumentMember2024-09-290001944048us-gaap:CashFlowHedgingMemberus-gaap:DesignatedAsHedgingInstrumentMember2024-09-290001944048us-gaap:ForeignExchangeContractMemberus-gaap:CashFlowHedgingMemberus-gaap:DesignatedAsHedgingInstrumentMember2023-12-310001944048us-gaap:CrossCurrencyInterestRateContractMemberus-gaap:CashFlowHedgingMemberus-gaap:DesignatedAsHedgingInstrumentMember2023-12-310001944048us-gaap:CashFlowHedgingMemberus-gaap:DesignatedAsHedgingInstrumentMember2023-12-310001944048us-gaap:ForeignExchangeContractMemberus-gaap:FairValueHedgingMemberus-gaap:DesignatedAsHedgingInstrumentMember2024-09-290001944048us-gaap:CrossCurrencyInterestRateContractMemberus-gaap:FairValueHedgingMemberus-gaap:DesignatedAsHedgingInstrumentMember2024-09-290001944048us-gaap:FairValueHedgingMemberus-gaap:DesignatedAsHedgingInstrumentMember2024-09-290001944048us-gaap:ForeignExchangeContractMemberus-gaap:FairValueHedgingMemberus-gaap:DesignatedAsHedgingInstrumentMember2023-12-310001944048us-gaap:CrossCurrencyInterestRateContractMemberus-gaap:FairValueHedgingMemberus-gaap:DesignatedAsHedgingInstrumentMember2023-12-310001944048us-gaap:FairValueHedgingMemberus-gaap:DesignatedAsHedgingInstrumentMember2023-12-310001944048us-gaap:ForeignExchangeContractMemberus-gaap:NetInvestmentHedgingMemberus-gaap:DesignatedAsHedgingInstrumentMember2024-09-290001944048us-gaap:CrossCurrencyInterestRateContractMemberus-gaap:NetInvestmentHedgingMemberus-gaap:DesignatedAsHedgingInstrumentMember2024-09-290001944048us-gaap:NetInvestmentHedgingMemberus-gaap:DesignatedAsHedgingInstrumentMember2024-09-290001944048us-gaap:ForeignExchangeContractMemberus-gaap:NetInvestmentHedgingMemberus-gaap:DesignatedAsHedgingInstrumentMember2023-12-310001944048us-gaap:CrossCurrencyInterestRateContractMemberus-gaap:NetInvestmentHedgingMemberus-gaap:DesignatedAsHedgingInstrumentMember2023-12-310001944048us-gaap:NetInvestmentHedgingMemberus-gaap:DesignatedAsHedgingInstrumentMember2023-12-310001944048us-gaap:ForeignExchangeContractMemberus-gaap:NondesignatedMember2024-09-290001944048us-gaap:CrossCurrencyInterestRateContractMemberus-gaap:NondesignatedMember2024-09-290001944048us-gaap:NondesignatedMember2024-09-290001944048us-gaap:ForeignExchangeContractMemberus-gaap:NondesignatedMember2023-12-310001944048us-gaap:CrossCurrencyInterestRateContractMemberus-gaap:NondesignatedMember2023-12-310001944048us-gaap:NondesignatedMember2023-12-310001944048us-gaap:ForeignExchangeContractMembersrt:MinimumMember2024-01-012024-09-290001944048us-gaap:ForeignExchangeContractMembersrt:MaximumMember2024-01-012024-09-290001944048us-gaap:ForeignExchangeForwardMember2024-07-012024-09-290001944048us-gaap:ForeignExchangeForwardMember2023-07-032023-10-010001944048us-gaap:ForeignExchangeForwardMember2024-01-012024-09-290001944048us-gaap:ForeignExchangeForwardMember2023-01-022023-10-010001944048kvue:NetSalesMember2024-07-012024-09-290001944048kvue:OtherIncomeExpenseNetMember2024-07-012024-09-290001944048kvue:NetSalesMember2023-07-032023-10-010001944048kvue:OtherIncomeExpenseNetMember2023-07-032023-10-010001944048kvue:NetSalesMember2024-01-012024-09-290001944048kvue:OtherIncomeExpenseNetMember2024-01-012024-09-290001944048kvue:NetSalesMember2023-01-022023-10-010001944048kvue:OtherIncomeExpenseNetMember2023-01-022023-10-010001944048us-gaap:InterestRateSwapMemberkvue:Tranche1Member2023-01-022023-10-010001944048us-gaap:InterestRateSwapMemberkvue:Tranche2Member2023-01-022023-10-010001944048us-gaap:InterestRateSwapMemberkvue:Tranche3Member2023-01-022023-10-010001944048us-gaap:InterestRateSwapMember2023-01-022023-10-010001944048kvue:Tranche1Member2023-01-022023-10-010001944048kvue:Tranche2Member2023-01-022023-10-010001944048kvue:Tranche3Member2023-01-022023-10-0100019440482024-03-310001944048us-gaap:CurrencySwapMember2024-07-012024-09-290001944048us-gaap:CurrencySwapMember2023-07-032023-10-010001944048us-gaap:CurrencySwapMember2024-01-012024-09-290001944048us-gaap:CurrencySwapMember2023-01-022023-10-010001944048us-gaap:ProductConcentrationRiskMemberkvue:CoughColdAndAllergyMemberus-gaap:SalesRevenueNetMemberkvue:SelfCareMember2024-07-012024-09-290001944048us-gaap:ProductConcentrationRiskMemberkvue:CoughColdAndAllergyMemberus-gaap:SalesRevenueNetMemberkvue:SelfCareMember2023-07-032023-10-010001944048us-gaap:ProductConcentrationRiskMemberkvue:CoughColdAndAllergyMemberus-gaap:SalesRevenueNetMemberkvue:SelfCareMember2024-01-012024-09-290001944048us-gaap:ProductConcentrationRiskMemberkvue:CoughColdAndAllergyMemberus-gaap:SalesRevenueNetMemberkvue:SelfCareMember2023-01-022023-10-010001944048us-gaap:ProductConcentrationRiskMemberkvue:PainCareMemberus-gaap:SalesRevenueNetMemberkvue:SelfCareMember2024-07-012024-09-290001944048us-gaap:ProductConcentrationRiskMemberkvue:PainCareMemberus-gaap:SalesRevenueNetMemberkvue:SelfCareMember2023-07-032023-10-010001944048us-gaap:ProductConcentrationRiskMemberkvue:PainCareMemberus-gaap:SalesRevenueNetMemberkvue:SelfCareMember2024-01-012024-09-290001944048us-gaap:ProductConcentrationRiskMemberkvue:PainCareMemberus-gaap:SalesRevenueNetMemberkvue:SelfCareMember2023-01-022023-10-010001944048us-gaap:ProductConcentrationRiskMemberkvue:OtherSelfCareMemberus-gaap:SalesRevenueNetMemberkvue:SelfCareMember2024-07-012024-09-290001944048us-gaap:ProductConcentrationRiskMemberkvue:OtherSelfCareMemberus-gaap:SalesRevenueNetMemberkvue:SelfCareMember2023-07-032023-10-010001944048us-gaap:ProductConcentrationRiskMemberkvue:OtherSelfCareMemberus-gaap:SalesRevenueNetMemberkvue:SelfCareMember2024-01-012024-09-290001944048us-gaap:ProductConcentrationRiskMemberkvue:OtherSelfCareMemberus-gaap:SalesRevenueNetMemberkvue:SelfCareMember2023-01-022023-10-010001944048us-gaap:ProductConcentrationRiskMemberkvue:FaceAndBodyCareMemberus-gaap:SalesRevenueNetMemberkvue:SkinHealthAndBeautyMember2024-07-012024-09-290001944048us-gaap:ProductConcentrationRiskMemberkvue:FaceAndBodyCareMemberus-gaap:SalesRevenueNetMemberkvue:SkinHealthAndBeautyMember2023-07-032023-10-010001944048us-gaap:ProductConcentrationRiskMemberkvue:FaceAndBodyCareMemberus-gaap:SalesRevenueNetMemberkvue:SkinHealthAndBeautyMember2024-01-012024-09-290001944048us-gaap:ProductConcentrationRiskMemberkvue:FaceAndBodyCareMemberus-gaap:SalesRevenueNetMemberkvue:SkinHealthAndBeautyMember2023-01-022023-10-010001944048us-gaap:ProductConcentrationRiskMemberkvue:HairSunAndOtherMemberus-gaap:SalesRevenueNetMemberkvue:SkinHealthAndBeautyMember2024-07-012024-09-290001944048us-gaap:ProductConcentrationRiskMemberkvue:HairSunAndOtherMemberus-gaap:SalesRevenueNetMemberkvue:SkinHealthAndBeautyMember2023-07-032023-10-010001944048us-gaap:ProductConcentrationRiskMemberkvue:HairSunAndOtherMemberus-gaap:SalesRevenueNetMemberkvue:SkinHealthAndBeautyMember2024-01-012024-09-290001944048us-gaap:ProductConcentrationRiskMemberkvue:HairSunAndOtherMemberus-gaap:SalesRevenueNetMemberkvue:SkinHealthAndBeautyMember2023-01-022023-10-010001944048us-gaap:ProductConcentrationRiskMemberkvue:OralCareMemberus-gaap:SalesRevenueNetMemberkvue:EssentialHealthMember2024-07-012024-09-290001944048us-gaap:ProductConcentrationRiskMemberkvue:OralCareMemberus-gaap:SalesRevenueNetMemberkvue:EssentialHealthMember2023-07-032023-10-010001944048us-gaap:ProductConcentrationRiskMemberkvue:OralCareMemberus-gaap:SalesRevenueNetMemberkvue:EssentialHealthMember2024-01-012024-09-290001944048us-gaap:ProductConcentrationRiskMemberkvue:OralCareMemberus-gaap:SalesRevenueNetMemberkvue:EssentialHealthMember2023-01-022023-10-010001944048us-gaap:ProductConcentrationRiskMemberkvue:BabyCareMemberus-gaap:SalesRevenueNetMemberkvue:EssentialHealthMember2024-07-012024-09-290001944048us-gaap:ProductConcentrationRiskMemberkvue:BabyCareMemberus-gaap:SalesRevenueNetMemberkvue:EssentialHealthMember2023-07-032023-10-010001944048us-gaap:ProductConcentrationRiskMemberkvue:BabyCareMemberus-gaap:SalesRevenueNetMemberkvue:EssentialHealthMember2024-01-012024-09-290001944048us-gaap:ProductConcentrationRiskMemberkvue:BabyCareMemberus-gaap:SalesRevenueNetMemberkvue:EssentialHealthMember2023-01-022023-10-010001944048us-gaap:ProductConcentrationRiskMemberkvue:OtherEssentialHealthMemberus-gaap:SalesRevenueNetMemberkvue:EssentialHealthMember2024-07-012024-09-290001944048us-gaap:ProductConcentrationRiskMemberkvue:OtherEssentialHealthMemberus-gaap:SalesRevenueNetMemberkvue:EssentialHealthMember2023-07-032023-10-010001944048us-gaap:ProductConcentrationRiskMemberkvue:OtherEssentialHealthMemberus-gaap:SalesRevenueNetMemberkvue:EssentialHealthMember2024-01-012024-09-290001944048us-gaap:ProductConcentrationRiskMemberkvue:OtherEssentialHealthMemberus-gaap:SalesRevenueNetMemberkvue:EssentialHealthMember2023-01-022023-10-010001944048kvue:SelfCareMember2024-07-012024-09-290001944048kvue:SelfCareMember2023-07-032023-10-010001944048kvue:SelfCareMember2023-01-022023-10-010001944048kvue:SkinHealthAndBeautyMember2024-07-012024-09-290001944048kvue:SkinHealthAndBeautyMember2023-07-032023-10-010001944048kvue:SkinHealthAndBeautyMember2023-01-022023-10-010001944048kvue:EssentialHealthMember2024-07-012024-09-290001944048kvue:EssentialHealthMember2023-07-032023-10-010001944048kvue:EssentialHealthMember2023-01-022023-10-010001944048us-gaap:OperatingSegmentsMemberkvue:SelfCareMember2024-07-012024-09-290001944048us-gaap:OperatingSegmentsMemberkvue:SelfCareMember2023-07-032023-10-010001944048us-gaap:OperatingSegmentsMemberkvue:SelfCareMember2024-01-012024-09-290001944048us-gaap:OperatingSegmentsMemberkvue:SelfCareMember2023-01-022023-10-010001944048us-gaap:OperatingSegmentsMemberkvue:SkinHealthAndBeautyMember2024-07-012024-09-290001944048us-gaap:OperatingSegmentsMemberkvue:SkinHealthAndBeautyMember2023-07-032023-10-010001944048us-gaap:OperatingSegmentsMemberkvue:SkinHealthAndBeautyMember2024-01-012024-09-290001944048us-gaap:OperatingSegmentsMemberkvue:SkinHealthAndBeautyMember2023-01-022023-10-010001944048us-gaap:OperatingSegmentsMemberkvue:EssentialHealthMember2024-07-012024-09-290001944048us-gaap:OperatingSegmentsMemberkvue:EssentialHealthMember2023-07-032023-10-010001944048us-gaap:OperatingSegmentsMemberkvue:EssentialHealthMember2024-01-012024-09-290001944048us-gaap:OperatingSegmentsMemberkvue:EssentialHealthMember2023-01-022023-10-010001944048us-gaap:OperatingSegmentsMember2024-07-012024-09-290001944048us-gaap:OperatingSegmentsMember2023-07-032023-10-010001944048us-gaap:OperatingSegmentsMember2024-01-012024-09-290001944048us-gaap:OperatingSegmentsMember2023-01-022023-10-0100019440482024-05-060001944048kvue:ITAndProjectRelatedCostsMember2024-05-062024-05-060001944048us-gaap:EmployeeSeveranceMember2024-05-062024-05-060001944048us-gaap:OtherRestructuringMember2024-05-062024-05-060001944048kvue:A2024MultiYearRestructuringInitiativeMember2024-07-012024-09-290001944048kvue:A2024MultiYearRestructuringInitiativeMember2024-01-012024-09-290001944048us-gaap:EmployeeSeveranceMember2024-07-012024-09-290001944048us-gaap:EmployeeSeveranceMember2024-01-012024-09-290001944048us-gaap:EmployeeSeveranceMember2024-09-290001944048kvue:ITAndProjectRelatedCostsMember2024-07-012024-09-290001944048kvue:ITAndProjectRelatedCostsMember2024-01-012024-09-290001944048kvue:ITAndProjectRelatedCostsMember2024-09-290001944048us-gaap:OtherRestructuringMember2024-07-012024-09-290001944048us-gaap:OtherRestructuringMember2024-01-012024-09-290001944048us-gaap:OtherRestructuringMember2024-09-290001944048us-gaap:EmployeeSeveranceMember2023-12-310001944048kvue:ITAndProjectRelatedCostsMember2023-12-310001944048us-gaap:OtherRestructuringMember2023-12-31

美國
證券交易委員會
華盛頓特區20549
表格 10-Q
☑根據《1934年證券交易法》第13或15(d)條款的季度報告
截至2024年6月30日季度結束 2024年9月29日
或
☐根據證券交易法案第13或15(d)條條文提交的過渡報告
過渡期由            至
委員會檔案編號： 001-41697
Kenvue Inc.
（依憑章程所載的完整登記名稱）
特拉華州88-1032011
(依據所在地或其他管轄區)
的註冊地或組織地點)		(國稅局雇主識別號碼)
識別號碼)
199 Grandview Road
斯基爾曼, 新澤西州 08558
(總部辦公地址)
註冊者的電話號碼，包括區域號碼: (908) 874-1200
根據法案第12(b)條規定註冊的證券：
每種類別的名稱交易標的（s）註冊在每個交易所上的名稱
普通股，面值 $0.01KVUE紐約證券交易所
請勾選勾號表示：（1）在過去12個月（或公司需提交相關報告的較短時間內）內，公司已經按照1934年證券交易法第13條或第15(d)條的要求提交了所有報告，且（2）公司在過去90天內一直遵守有關報告要求。☑ 是 ☐ 否
請標示是否公司已根據S-t條例第405條規定的要求，在過去12個月（或公司被要求提交此類文件的較短期間）內按時提交了所有應提交的互動數據文件。 ☑ 是 ☐ 否
請勾選指示登記者是否為大型快速提交人、快速提交人、非快速提交人、較小的報告公司或新興成長型公司。請參閱交易所法規120億2條，了解「大型快速提交人」、「快速提交人」、「較小的報告公司」和「新興成長型公司」的定義。
大型加速歸檔人☐加速進入文件 ☐
非加速歸檔人☑較小的報告公司 ☐
新興成長型公司 ☐
如果是新興成長型企業，在符合任何依據證券交易法第13(a)條所提供的任何新的或修改的財務會計準則的遵循的延伸過渡期方面，是否選擇不使用核准記號進行指示。☐
勾選的方式表示公司是否為一個外殼公司（根據交易所法120億2條規定）。☐ 是 ☑ 無
2024年11月1日， 1,917,257,438 普通股股份，面值0.01美元，現時已發行。


目 錄
 頁面
 不


關於前瞻性聲明的注意事項
本季度報告表格10-Q和Kenvue公司（“Kenvue”， “公司”或“我們”）的其他公開文件包含根據美國1995年私人證券訴訟改革法的安全港條款的前瞻性陳述。 前瞻性陳述並不嚴格涉及歷史或目前的事實，而是反映管理層對未來的假設、觀點、計劃、目標和預測。 可以通過使用“計劃”、“預期”、“將”、“預期”、“估計”等詞語來識別前瞻性陳述，這些詞語與其他事項一起使用，包括對未來運營的討論； 預期的運營結果和財務表現； 計劃收購和處分的影響； 我們的增長和節省成本的策略； 產品開發活動； 監管批准； 市場定位； 開支； 以及《簡明綜合財務報表》中包含的關於我們業務的《公司概況和重要會計政策摘要》註釋1定義中所述的《分離》對我們業務的影響。
因為前瞻性述詞是基於目前對未來事件的信念、預期和假設，因此受到難以預測的風險、不確定性和變化的影響，其中許多是我們控制範圍之外的。您應該認識到，如果基本假設被證明不準確，或者已知或未知的風險或不確定性實現，我們實際結果和財務狀況可能與我們前瞻性述詞中所表達或暗示的預期和預測有顯著差異。風險和不確定性包括但不限於:
•我們有能力在全球擴張，實施我們的數位優先策略，並適當應對競爭壓力，包括來自自有品牌和非品牌通用產品、市場趨勢、成本增加，以及顧客和消費者偏好；
•零售業務景觀迅速變化，包括我們對重要零售商的依賴、零售業客戶政策、電子商務和其他替代零售渠道的崛起，以及創新和研發方面的挑戰；
•商品的可靠性、安全性和/或效力引起擔憂，無論是否基於科學或事實證據，可能導致政府調查、監管行動（包括但不限於製造工廠停工、產品重新標示或市場撤銷產品）、私人索賠和訴訟、重大糾正和相關成本、安全警示、產品短缺、產品召回、銷售下滑、聲譽損害和股價影響。
•2024多年重組計畫（見第16項「重組費用及營運模式優化計畫」，收錄於此處的簡明合併基本報表）或任何其他計劃中或已完成的重組或節省成本計畫、收購或出售行動的預期好處和機會可能實現的潛力，或可能實現的時間長於預期。
•我們能建立、維護、保護和執行智慧產權，並應對假冒產品威脅、侵犯我們的知識產權以及我們產品的其他未經授權版本。
•指控我們的產品侵犯第三方的知識產權;
•負面宣發和失敗的行銷努力對影響的影響；
•製造業中遇到的困難和延遲，可能導致業務中斷、產品短缺、市場產品撤回或暫停，以及潛在的監管行動;
•Our reliance on third-party relationships, global supply chains, and production and distribution processes, which may adversely affect supply, sourcing, and pricing of materials used in our products, and impact our ability to forecast product demand;
•Interruptions, breakdowns, invasions, corruptions, destruction, and breaches of our information technology systems or those of a third party;
•The potential for labor disputes, strikes, work stoppages, and similar labor relations matters, and the impact of minimum wage increases;
•Our ability to attract and retain talented, highly skilled employees and a diverse workforce, and to implement succession plans for our senior management;
•Climate change, extreme weather, and natural disasters, or legal, regulatory or market measures to address climate change;
•The impact of increasing scrutiny and rapidly evolving expectations from stakeholders regarding environmental, social, and governance matters;
•The potential for insurance to be unavailable or insufficient to cover losses we may incur;
3

•Legal proceedings related to talc or talc-containing products, such as Johnson’s® Baby Powder, sold outside the United States and Canada and other risks and uncertainties related to talc or talc-containing products, including our former parent Johnson & Johnson’s (“J&J”) ability to fully satisfy its obligation to indemnify us in the United States and Canada for the Talc-Related Liabilities (as defined in Note 14, “Commitments and Contingencies,” to the Condensed Consolidated Financial Statements included herein);
•The impact of legal proceedings and the uncertainty of their outcome, whether or not we believe they have merit;
•Changes to applicable laws, regulations, policies, and related interpretations;
•Changes in tax laws and regulations, increased audit scrutiny by tax authorities and exposures to additional tax liabilities potentially in excess of existing reserves;
•The impact of inflation and fluctuations in interest rates and currency exchange rates;
•Potential changes in export/import and trade laws, regulations, and policies;
•The impact of a natural disaster, catastrophe, epidemic, pandemic, and global tension, including armed conflict such as the ongoing military conflict between Russia and Ukraine, the military conflicts in the Middle East, or other event;
•The impact of impairment of our goodwill and other intangible assets;
•Our ability to access credit markets and maintain satisfactory credit ratings;
•Our ability to achieve the expected benefits of the Separation from J&J and related transactions;
•Certain J&J executive officers continuing to serve as our directors, which may create conflicts of interest or the appearance thereof;
•Restrictions on our business, potential tax and indemnification liabilities and substantial charges in connection with the Separation and related transactions;
•Failure of our rebranding efforts in connection with the Separation to achieve market acceptance, and the impact of our continued use of legacy J&J branding, including the “Johnson’s®” brand; and
•Our substantial indebtedness, including the restrictions and covenants in our debt agreements.
Additional information about these factors and about the material factors or assumptions underlying such forward-looking statements may be found under the sections entitled “Cautionary Note Regarding Forward-Looking Statements” and “Risk Factors” in our Annual Report on Form 10-K for the fiscal twelve months ended December 31, 2023 filed on March 1, 2024 with the U.S. Securities and Exchange Commission (the “SEC”) and in our other filings with the SEC. You should understand that it is not possible to predict or identify all such factors and you should not consider the risks described above to be a complete statement of all potential risks and uncertainties. We do not undertake to publicly update any forward-looking statement that may be made from time to time, whether as a result of new information or future events or developments, except as required by law.
4

Part I—FINANCIAL INFORMATION
Item 1. FINANCIAL STATEMENTS
KENVUE INC.
CONDENSED CONSOLIDATED BALANCE SHEETS
(Unaudited; Dollars in Millions, Except Per Share Data; Shares in Thousands)
September 29, 2024December 31, 2023
Assets
Current assets  
Cash and cash equivalents$1,057 $1,382 
Trade receivables, less allowances for credit losses ($26 and $25 as of September 29, 2024 and December 31, 2023, respectively)
2,394 2,073 
Inventories
1,820 1,851 
Prepaid expenses and other receivables460 567 
Other current assets210 265 
Total current assets5,941 6,138 
Property, plant, and equipment, net1,776 2,042 
Intangible assets, net8,887 9,619 
Goodwill 9,297 9,271 
Deferred taxes on income228 158 
Other assets796 623 
Total Assets26,925 27,851 
Liabilities and Equity
Current liabilities  
Loans and notes payable1,648 599 
Accounts payable2,274 2,489 
Accrued liabilities
1,164 1,456 
Accrued rebates, returns, and promotions697 795 
Accrued taxes on income163 142 
Total current liabilities5,946 5,481 
Employee-related obligations
362 360 
Long-term debt7,053 7,687 
Deferred taxes on income2,378 2,621 
Other liabilities542 491 
Total liabilities16,281 16,640 
Commitments and contingencies (Note 14)
Equity  
Preferred stock, $0.01 par value, 750,000 shares authorized; no shares issued and outstanding as of September 29, 2024 and December 31, 2023
— — 
Common stock, $0.01 par value, 12,500,000 shares authorized; 1,922,328 and 1,916,278 shares issued and outstanding as of September 29, 2024, respectively; 1,915,407 and 1,915,057 shares issued and outstanding as of December 31, 2023, respectively
19 19 
Additional paid-in capital16,098 16,147 
Treasury stock, 6,050 and 350 shares at cost as of September 29, 2024 and December 31, 2023, respectively
(121)(7)
Retained earnings7 429 
Accumulated other comprehensive loss(5,359)(5,377)
Total equity10,644 11,211 
Total Liabilities and Equity$26,925 $27,851 
See accompanying Notes to Condensed Consolidated Financial Statements.
5

KENVUE INC.
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
(Unaudited; Dollars in Millions, Except Per Share Data; Shares in Millions)
 Fiscal Three Months EndedFiscal Nine Months Ended
September 29, 2024October 1, 2023September 29, 2024October 1, 2023
Net sales$3,899 $3,915 $11,793 $11,778 
Cost of sales1,617 1,665 4,904 5,178 
Gross profit2,282 2,250 6,889 6,600 
Selling, general, and administrative expenses1,590 1,531 4,804 4,555 
Restructuring expenses
31 — 120 — 
Impairment charges
— — 578 — 
Other operating expense (income), net7 9 29 (7)
Operating income654 710 1,358 2,052 
Other (income) expense, net(19)25 6 65 
Interest expense, net96 100 283 154 
Income before taxes577 585 1,069 1,833 
Provision for taxes 194 147 332 496 
Net income $383 $438 $737 $1,337 
Net income per share
Basic $0.20 $0.23 $0.38 $0.73 
Diluted $0.20 $0.23 $0.38 $0.73 
Weighted average number of shares outstanding
Basic
1,9151,9161,9151,823
Diluted
1,9241,9201,9211,827
See accompanying Notes to Condensed Consolidated Financial Statements.
6

KENVUE INC.
CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME
(Unaudited; Dollars in Millions)
Fiscal Three Months EndedFiscal Nine Months Ended
September 29, 2024October 1, 2023September 29, 2024October 1, 2023
Net income $383 $438 $737 $1,337 
Other comprehensive income (loss), net of taxes
Foreign currency translation
473 (251)41 (260)
Employee benefit plans
(7)15 (1)19 
Derivatives and hedges
10 (4)(22)27 
Other comprehensive income (loss)476 (240)18 (214)
Comprehensive income $859 $198 $755 $1,123 
See accompanying Notes to Condensed Consolidated Financial Statements.
7

KENVUE INC.
CONDENSED CONSOLIDATED STATEMENTS OF EQUITY
(Unaudited; Dollars in Millions; Shares in Thousands)
Fiscal Three Months Ended September 29, 2024
Common StockAdditional Paid-In CapitalTreasury StockRetained EarningsAccumulated Other Comprehensive LossTotal Equity
Shares AmountSharesAmount
Balance, June 30, 2024
1,915,064 $19 $16,075 4,950 $(98)$17 $(5,835)$10,178 
Net income— — — — — 383 — 383 
Other comprehensive income— — — — — — 476 476 
Cash dividends on common stock— — — — — (393)— (393)
Stock-based compensation— — 58 — — — — 58 
Issuance of common stock under the Kenvue 2023 Plan, net
2,314 — 41 — — — — 41 
Purchase of treasury stock(1,100)— — 1,100 (23)— — (23)
Separation-related adjustments
— — (76)— — — — (76)
Balance, September 29, 2024
1,916,278 $19 $16,098 6,050 $(121)$7 $(5,359)$10,644 

Fiscal Three Months Ended October 1, 2023
Common StockAdditional Paid-In CapitalRetained EarningsAccumulated Other Comprehensive LossTotal Equity
SharesAmount
Balance, July 2, 2023
1,914,894 $19 $16,184 $430 $(5,502)$11,131 
Net income— — — 438 — 438 
Other comprehensive loss— — — — (240)(240)
Cash dividends on common stock— — — (383)— (383)
Stock-based compensation— — 2 — — 2 
Issuance of common stock under the Kenvue 2023 Plan, net
16 — — — — — 
Separation-related adjustments— — (55)— — (55)
Balance, October 1, 2023
1,914,910 $19 $16,131 $485 $(5,742)$10,893 

Fiscal Nine Months Ended September 29, 2024
Common StockAdditional Paid-In CapitalTreasury StockRetained EarningsAccumulated Other Comprehensive LossTotal Equity
SharesAmountSharesAmount
Balance, December 31, 2023
1,915,057 $19 $16,147 350 $(7)$429 $(5,377)$11,211 
Net income— — — — — 737 — 737 
Other comprehensive income— — — — — — 18 18 
Cash dividends on common stock— — — — — (1,159)— (1,159)
Stock-based compensation— — 200 — — — — 200 
Issuance of common stock under the Kenvue 2023 Plan, net
6,921 — 35 — — — — 35 
Purchase of treasury stock(5,700)— — 5,700 (114)— — (114)
Separation-related adjustments
— — (284)— — — — (284)
Balance, September 29, 2024
1,916,278 $19 $16,098 6,050 $(121)$7 $(5,359)$10,644 

8

Fiscal Nine Months Ended October 1, 2023(1)
Common StockAdditional Paid-In CapitalRetained EarningsNet Investment from J&JAccumulated Other Comprehensive LossTotal Equity
SharesAmount
Balance, January 1, 2023
— $— $— $— $25,425 $(5,455)$19,970 
Net income— — — 868 469 — 1,337 
Other comprehensive loss— — — — — (214)(214)
Cash dividends on common stock— — — (383)— — (383)
Net transfers to J&J— — — — (308)— (308)
Stock-based compensation— — 40 — 35 — 75 
Distribution to J&J in connection with the Separation— — (13,788)— — — (13,788)
Issuance of common stock in connection with the Kenvue IPO
1,914,894 19 4,222 — — — 4,241 
Issuance of common stock under the Kenvue 2023 Plan, net
16 — — — — — — 
Reclassification of Net Investment from J&J— — 25,712 — (25,712)— — 
Separation-related adjustments— — (55)— 91 (73)(37)
Balance, October 1, 2023
1,914,910 $19 $16,131 $485 $— $(5,742)$10,893 
(1) Prior to April 4, 2023, the Company operated as a segment of J&J and not as a separate entity. The Company’s financial statements prior to April 4, 2023 were prepared on a combined basis and were derived from J&J’s historical consolidated financial statements and accounting records as if the Company had been operated on a standalone basis. See Note 1, “Description of the Company and Summary of Significant Accounting Policies—Basis of Presentation,” for more information.

See accompanying Notes to Condensed Consolidated Financial Statements.

9

KENVUE INC.
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
(Unaudited; Dollars in Millions)
 Fiscal Nine Months Ended
September 29, 2024October 1, 2023
Cash flows from operating activities  
Net income$737 $1,337 
Adjustments to reconcile net income to cash flows from operating activities
Depreciation and amortization472 453 
Stock-based compensation200 75 
Deferred income taxes(245)(128)
Impairment charges
578 — 
Other67 (11)
Net changes in assets and liabilities  
Trade receivables(343)(97)
Inventories13 275 
Other current and non-current assets29 (418)
Accounts payable and accrued liabilities
(573)1,008 
Employee related obligations5 7 
Accrued taxes on income
9 (53)
Other liabilities27 (230)
Net cash flows from operating activities976 2,218 
Cash flows used in investing activities  
Purchases of property, plant, and equipment(302)(246)
Transfer of funds to J&J pursuant to the Facility Agreement
— (8,941)
Proceeds from J&J upon repayment of the Facility Agreement— 8,941 
Proceeds from sale of assets— 14 
Other investing activities9 9 
Net cash flows used in investing activities(293)(223)
Cash flows used in financing activities  
Proceeds from (payments of) loans and notes payables9 (14)
Proceeds from Commercial Paper Program, net of issuance cost258 497 
Proceeds from issuance of Senior Notes, net of issuance cost— 7,686 
Proceeds from Kenvue IPO, net— 4,241 
Distribution to J&J in connection with the Separation
— (13,788)
Dividends paid(1,159)(383)
Net transfers to J&J— (274)
Purchases of treasury shares
(114)— 
Other financing activities28 (109)
Net cash flows used in financing activities(978)(2,144)
Effect of exchange rate changes on cash and cash equivalents
(30)(20)
Cash and cash equivalents, beginning of period
1,382 1,231 
Net decrease in cash and cash equivalents(325)(169)
Cash and cash equivalents, end of period
$1,057 $1,062 
See accompanying Notes to Condensed Consolidated Financial Statements.
10

KENVUE INC.
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(Unaudited)
1. Description of the Company and Summary of Significant Accounting Policies

Description of the Company and Business Segments

Kenvue Inc. (“Kenvue” or the “Company”) is a pure play consumer health company with iconic brands including Aveeno®, BAND-AID® Brand, Johnson’s®, Listerine®, Neutrogena®, Tylenol®, and Zyrtec®. The Company is organized into three business segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment includes a broad product range such as pain care; cough, cold, and allergy; digestive health; smoking cessation; eye care; and other products. The Skin Health and Beauty segment is focused on face and body care, as well as hair, sun, and other products. The Essential Health segment includes oral care, baby care, women’s health, wound care, and other products.

Kenvue was initially formed as a wholly owned subsidiary of Johnson & Johnson (“J&J”). In November 2021, J&J announced its intention to separate its Consumer Health segment (the “Consumer Health Business”) into a new, publicly traded company (the “Separation”). Prior to the Kenvue IPO (as defined below), the Company primarily represented J&J’s Consumer Health Business. The Company also included certain other product lines previously reported in another segment of J&J. On April 4, 2023, in connection with the Separation, J&J completed in all material respects the transfer of the assets and liabilities of the Consumer Health Business to the Company and its subsidiaries (such transfer, the “Consumer Health Business Transfer”), other than the transfer of certain Deferred Local Businesses (as defined below in “—Variable Interest Entities and Net Economic Benefit Arrangements”).

On May 3, 2023, the registration statement related to the initial public offering of Kenvue’s common stock was declared effective, and on May 4, 2023, Kenvue’s common stock began trading on the New York Stock Exchange under the ticker symbol “KVUE” (the “Kenvue IPO”).

On May 8, 2023, the Kenvue IPO was completed through the sale of 198,734,444 shares of common stock, par value $0.01 per share, including the underwriters’ full exercise of their option to purchase 25,921,884 shares to cover over-allotments, at an initial public offering price of $22 per share for net proceeds of $4.2 billion after deducting underwriting discounts and commissions of $131 million. On May 8, 2023, in conjunction with the Consumer Health Business Transfer, the Company distributed $13.8 billion to J&J from 1) the net proceeds received from the sale of the common stock in the Kenvue IPO, 2) the net proceeds received from the Debt Financing Transactions as defined in Note 4, “Borrowings—Commercial Paper Program,” and 3) any cash and cash equivalents in excess of the $1.17 billion retained by the Company immediately following the Kenvue IPO. As of the closing of the Kenvue IPO, J&J owned 1,716,160,000 shares of Kenvue common stock, or approximately 89.6% of the total outstanding shares of Kenvue common stock.

On July 24, 2023, J&J announced an exchange offer (the “Exchange Offer”) under which its shareholders could exchange shares of J&J common stock for shares of Kenvue common stock owned by J&J. On August 23, 2023, J&J completed the Exchange Offer through which J&J accepted an aggregate of 190,955,435 shares of J&J common stock in exchange for 1,533,830,450 shares of Kenvue common stock, representing approximately 80.1% of Kenvue’s outstanding common stock as of August 23, 2023. As a result, Kenvue became a fully independent company, and as of the completion of the Exchange Offer, J&J owned approximately 9.5% of the outstanding shares of Kenvue common stock.

On May 17, 2024, J&J completed an additional exchange offer (the “Debt for Equity Exchange”) through which J&J exchanged indebtedness of J&J for 182,329,550 shares of Kenvue common stock owned by J&J. Following the completion of the Debt for Equity Exchange, J&J no longer owned any shares of Kenvue common stock.

Basis of Presentation

Effective April 4, 2023, the Company’s financial statements are presented on a consolidated basis, as J&J completed the Consumer Health Business Transfer on such date. The unaudited financial statements for all periods presented, including the historical results of the Company prior to April 4, 2023, are referred to as the “Condensed Consolidated Financial Statements.”

The accompanying unaudited Condensed Consolidated Financial Statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”) pursuant to the rules and regulations of the U.S. Securities and Exchange Commission (the “SEC”) for interim financial information. Accordingly, they do not include all of the information and footnotes required by U.S. GAAP for complete financial statements. In the opinion of management, the
11

Condensed Consolidated Financial Statements reflect all adjustments, consisting of normal and recurring adjustments, necessary for a fair statement of the financial condition, results of operations, and cash flows for the periods indicated. These financial statements should be read in conjunction with the audited consolidated financial statements and related disclosures for the fiscal twelve months ended December 31, 2023 included in the Company’s Annual Report on Form 10-K filed on March 1, 2024 with the SEC.

Intercompany balances and transactions have been eliminated. The Condensed Consolidated Financial Statements include the accounts of the Company and its affiliates and entities consolidated under the variable interest and voting models.

During the fiscal nine months ended September 29, 2024, the Company recorded out-of-period adjustments primarily related to the Separation, which corrected an overstatement in Additional paid-in capital of $284 million, including the $94 million ($71 million net of tax) related to certain cloud computing arrangements described below. This amount did not have an impact on the operating results for the fiscal nine months ended September 29, 2024. The Company concluded that these adjustments were not material to the Condensed Consolidated Financial Statements for either the current period or prior periods.

As of September 29, 2024, the Condensed Consolidated Balance Sheet reflects an adjustment for a change in classification from Property, plant, and equipment, net of $300 million to Other assets and Additional paid-in capital of $171 million and $94 million, respectively, related to certain cloud computing arrangements, net of amortization of $35 million. The Company concluded that this adjustment was not material to the Condensed Consolidated Financial Statements for either the current period or prior periods.

Periods prior to the Consumer Health Business Transfer

Prior to April 4, 2023, the Company operated as a segment of J&J and not as a separate entity. The Company’s financial statements prior to April 4, 2023 were prepared on a combined basis and were derived from J&J’s historical consolidated financial statements and accounting records as if the Company had been operated on a standalone basis.

Prior to the Kenvue IPO, the Company relied on J&J’s corporate and other support functions. Therefore, certain corporate and shared costs were allocated to the Company including the assets, liabilities, revenues, and expenses that J&J’s management determined were specifically or primarily identifiable to the Company, as well as direct and indirect costs that were attributable to the operations of the Company. Indirect costs are the costs of support functions that were provided on a centralized or geographic basis by J&J and its affiliates, which included, but were not limited to, facilities, insurance, logistics, quality, compliance, finance, human resources, benefits administration, procurement support, information technology, legal, corporate strategy, corporate governance, other professional services, and general commercial support functions.

Indirect costs were allocated to the Company for the purposes of preparing condensed combined financial statements prior to the Kenvue IPO, based on a specific identification basis or, when specific identification was not practicable, a proportional cost allocation method, primarily net sales, headcount, or other allocation methodologies that were considered to be a reasonable reflection of the utilization of services provided or benefit received by the Company during the periods presented, depending on the nature of the services received. Management considers that such allocations were made on a reasonable basis consistent with benefits received but may not necessarily be indicative of the costs that would have been incurred if the Company had been operated on a standalone basis for the periods presented.

Cash generated from the Company’s operations prior to April 4, 2023 was generally managed by J&J’s centralized treasury function and was swept into J&J and its affiliates’ bank accounts. Cash and cash equivalents on the Condensed Consolidated Balance Sheet represented balances in accounts specifically identifiable to the Company that were not swept into J&J and its affiliates’ bank accounts. J&J’s third-party interest expense was not allocated for any of the periods prior to April 4, 2023 as the Company was not the legal obligor of the debt and the borrowings were not directly attributable to the Company’s operations.

The Company’s equity balance in these financial statements prior to April 4, 2023 represents the excess of total assets over total liabilities. Equity was impacted by changes in comprehensive income and contributions from or to J&J prior to the Kenvue IPO, which was the result of treasury activities and net funding provided by or distributed to J&J.

J&J calculated foreign currency translation on its consolidated assets and liabilities, which included assets and liabilities of the Company prior to April 4, 2023. Foreign currency translation recorded during the fiscal nine months ended September 29, 2024 and October 1, 2023 was based on currency movements specific to the Condensed Consolidated Financial Statements.

12

The income tax amounts in the Condensed Consolidated Financial Statements prior to the Kenvue IPO have been calculated based on a separate return methodology and presented as if the Company’s operations were reported by separate taxpayers in the jurisdictions in which the Company operates. See Note 11, “Income Taxes,” for further discussion.

Prior to the Kenvue IPO, all transactions between the Company and J&J were considered to be effectively settled for cash in the Condensed Consolidated Financial Statements at the time the transaction was recorded. The effects of the settlement of these transactions between the Company and J&J were reflected in the Condensed Consolidated Statements of Cash Flows as “Net transfers to J&J” within financing activities, and in the Condensed Consolidated Statements of Equity as “Net transfers to J&J.”

Use of Estimates

The preparation of the Condensed Consolidated Financial Statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the financial statements, and revenue and expenses during the periods reported. Estimates are used when accounting for, among other things, sales discounts, trade promotions, rebates, allowances and incentives, product liabilities, income taxes and related valuation allowance, withholding taxes, pension, postretirement benefits, fair value of financial instruments, stock-based compensation assumptions, depreciation, amortization, employee benefits, contingencies, allocations of cost and expenses from J&J and its affiliates, and the valuation of goodwill, intangible assets, and liabilities. Actual results may or may not differ from those estimates.

Trade Receivable and Allowance for Credit Losses

A summary of the change in the allowance for credit losses during the fiscal nine months ended September 29, 2024 and October 1, 2023 is presented below:

Fiscal Nine Months Ended
(Dollars in Millions)September 29, 2024October 1, 2023
Allowance for credit losses, beginning of period$(25)$(35)
Provision(3)(8)
Utilization2 15 
Currency translation adjustment — 1 
Allowance for credit losses, end of period$(26)$(27)

Separation-Related Costs

The Company and J&J incurred certain non-recurring separation-related costs in the establishment of Kenvue as a standalone public company (“Separation-related costs”). Costs incurred by the Company and those costs that were incurred by J&J prior to April 4, 2023 determined to be for the benefit of the Company were included in the Condensed Consolidated Financial Statements. These Separation-related costs were $85 million and $133 million for the fiscal three months ended September 29, 2024 and October 1, 2023, respectively, and $231 million and $333 million for the fiscal nine months ended September 29, 2024 and October 1, 2023, respectively. The Separation-related costs are included within Cost of sales and Selling, general, and administrative expenses in the Condensed Consolidated Statements of Operations.

Research and Development

Research and development expenses are expensed as incurred and included within Selling, general, and administrative expenses. Research and development costs were $97 million and $78 million for the fiscal three months ended September 29, 2024 and October 1, 2023, respectively, and $302 million and $266 million for the fiscal nine months ended September 29, 2024 and October 1, 2023, respectively.

Leases

The Company has operating leases for space, vehicles, manufacturing equipment, and data processing equipment. In connection with the Separation, J&J and Kenvue also entered into various lease agreements, in which the Company subleased properties from J&J. The Company has finance leases, which primarily include the Company’s new global corporate headquarters in Summit, New Jersey (as described in the “—Global Headquarters Lease” section below). Lease terms may include options to extend or terminate the lease. These options are included in the lease term when it is reasonably certain that the Company will
13

exercise the option. The Company’s lease agreements do not contain any significant residual value guarantees or restrictive covenants.

Operating Lease Assets and Liabilities

Right of Use (“ROU”) assets and lease liabilities associated with the Company’s operating leases are included on the Condensed Consolidated Balance Sheets as of September 29, 2024 and December 31, 2023 as follows:

Operating Leases
(Dollars in Millions)
September 29, 2024(1)
December 31, 2023(2)
ROU assets included in:
Other assets
$122 $139 
Total ROU assets
122 139 
Lease liabilities included in:
Accrued liabilities
40 44 
Other liabilities
86 97 
Total lease liabilities$126 $141 
(1) Includes leases with J&J of $40 million of ROU assets, $12 million of current lease liabilities, and $28 million of non-current lease liabilities.
(2) Includes leases with J&J of $52 million of ROU assets, $13 million of current lease liabilities, and $39 million of non-current lease liabilities.

Global Headquarters Lease

On April 20, 2023, the Company entered into a long-term lease for a newly renovated corporate office building and a newly constructed research and development building in Summit, New Jersey (the “Global Headquarters Lease”). When completed, the campus will encompass approximately 290,000 square feet and serve as the Company’s new global corporate headquarters and research and development center. The Global Headquarters Lease collectively includes the lease associated with the corporate office building (the “Corporate Office Lease”), the lease associated with the land where the research and development building will be constructed (the “State-of-the-Art Lab Facility Lease”), and the lease associated with land to be used for amenities (the “Amenities Lease”). The relocation to this campus is expected to begin in the first fiscal quarter of 2025 for the corporate office building and continue through 2026 for the new research and development building. The Company will continue operating from its interim corporate headquarters in Skillman, New Jersey, until that time.

The Corporate Office Lease and the State-of-the-Art Lab Facility Lease, each accounted for as a finance lease, commenced in January 2024 and May 2024, respectively. Each lease includes an initial term of 15 years as well as renewal options, which the Company is reasonably certain to exercise, that will extend the term of each lease through 2060. Each finance lease liability was calculated utilizing an incremental borrowing rate of 4.75% to discount lease payments over the expected term.

The Amenities Lease is expected to commence in January 2026.

ROU assets and lease liabilities associated with the Corporate Office Lease and the State-of-the-Art Lab Facility Lease are included on the Condensed Consolidated Balance Sheet as of September 29, 2024 as follows:

(Dollars in Millions)September 29, 2024
ROU assets included in:
Property, plant, and equipment, net
$106 
Lease liabilities included in:
Long-term debt
$112 

14

Other information related to the Corporate Office Lease and State-of-the-Art Lab Facility Lease for the fiscal nine months ended September 29, 2024 were as follows:

Fiscal Nine Months Ended
(Dollars in Millions)September 29, 2024
ROU assets obtained in exchange for the new finance lease liabilities
$109 

Impairment Charges

Impairment charges for the fiscal nine months ended September 29, 2024 consisted of:

Fiscal Nine Months Ended
(Dollars in Millions)September 29, 2024
Dr.Ci:Labo® asset impairment(1)
$488 
Skillman fixed asset impairment(2)
68 
Other asset impairment(3)
22 
Impairment charges
$578 
(1) Represents the impairment charge recognized during the fiscal three months ended June 30, 2024 in relation to Dr.Ci:Labo® long-lived assets. See “—Dr.Ci:Labo® Asset Impairment” below and Note 3, “Intangible Assets and Goodwill,” for more information.
(2) Represents the impairment charge recorded during the fiscal three months ended March 31, 2024 on the held for sale asset associated with the Company’s interim corporate headquarters in Skillman, New Jersey. See “—Assets Held for Sale” below.
(3) Represents the impairment charge recognized during the fiscal three months ended June 30, 2024 related to certain software development assets.

No impairment charges were recognized during the fiscal three months ended September 29, 2024.

Dr.Ci:Labo® Asset Impairment

During the fiscal three months ended June 30, 2024, there was a significant change in the senior leadership of the Dr.Ci:Labo® business, resulting in a new strategic plan with a key focus on increased brand marketing expense designed to allow the brand to reach more consumers and appropriately address evolving market dynamics, including shifts in consumer sentiment in China as well as changing shopping patterns in the region. Following the change to the Company’s strategy for the brand, the Company made revisions to the internal forecasts relating to the Dr.Ci:Labo® asset group and concluded that the changes in circumstances, which impacted the forecasted cash flows in relation to this business, resulted in a triggering event, requiring an interim impairment review of the Dr.Ci:Labo® asset group. As a result of the interim impairment test, the Company concluded that the carrying value of long-lived assets of the asset group, consisting primarily of intangible assets, including trademarks and other intangibles, and property, plant, and equipment, exceeded their estimated fair value, resulting in impairment charges of $488 million recognized in the fiscal three months ended June 30, 2024, of which $463 million related to definite-lived intangible assets and $25 million related to property, plant, and equipment. Following the impairment charge, the carrying value of the Dr.Ci:Labo® asset group was $118 million.

The Company estimated the fair value of the definite-lived intangible assets within the Dr.Ci:Labo® asset group based on an income approach using the relief-from-royalty method. This valuation required significant judgments and estimates by management regarding several key inputs, including future cash flows consistent with management’s plans, sales growth rates, the selection of royalty rates, and a discount rate. The Company selected the assumptions used in the financial forecasts of cash flows specific to the remaining useful lives of the trademarks ranging from six to 15 years using historical data, supplemented by current and anticipated market conditions and estimated growth rates. The Company utilized a discount rate of 8%. As the fair value measurements were based on significant inputs not observable in the market, they represented Level 3 measurements within the fair value hierarchy.

Assets Held for Sale

The Company classifies assets as held for sale when: 1) management has committed to a plan to sell the assets, 2) the assets are available for immediate sale, 3) there is an active program to locate a buyer, and 4) the sale and transfer of the asset is probable within one year. On February 21, 2024, the Company listed its interim corporate headquarters in Skillman, New Jersey for sale,
15

which met the criteria to be classified as held for sale at that date. The held for sale asset is measured at the lower of the carrying amount or the fair value less costs to sell.

The results of the impairment test performed upon classification as held for sale indicated that the carrying value of the Skillman, New Jersey facility exceeded its estimated fair value less costs to sell by $68 million. As a result, the Company recorded an impairment charge equivalent to that amount within Other operating expense (income), net in the Condensed Consolidated Statement of Operations for the fiscal three months ended March 31, 2024. The fair value of the held for sale asset was determined utilizing third-party sales pricing as an input. The inputs utilized in the analysis are classified as Level 3 inputs within the fair value hierarchy.

The Company recorded the remaining asset held for sale balance related to the Skillman, New Jersey facility within Other current assets on the Condensed Consolidated Balance Sheet as of September 29, 2024.

Supplier Finance Program

The Company has facilitated a voluntary supplier finance program to provide some of its suppliers with the opportunity to sell receivables due from the Company (the Company’s accounts payables) to participating financial institutions at the sole discretion of both the suppliers and the financial institutions. The Company is not a party to the arrangements between the suppliers and the third-party financial institutions. The Company’s obligations to its suppliers, including amounts due, and scheduled payment dates (which have general payment terms of 90 days), are not affected by a participating supplier’s decision to participate in the program. As of September 29, 2024 and December 31, 2023, the Company’s Accounts payable balances included $239 million and $227 million, respectively, related to invoices from suppliers participating in the supplier finance program.

Variable Interest Entities and Net Economic Benefit Arrangements

When the Company makes an initial investment in or establishes other variable interests in an entity, the entity is first evaluated to determine if it is a Variable Interest Entity (“VIE”) and if the Company is the primary beneficiary of the VIE, and therefore subject to consolidation regardless of percentage ownership. The primary beneficiary of a VIE is a party that meets both of the following criteria: 1) it has the power to direct the activities that most significantly impact the economic performance of the VIE; and 2) it has the obligation to absorb losses or the right to receive benefits that could be potentially significant to the VIE. Periodically, the Company assesses whether any change in its interest in or relationship with the entity affects the determination as to whether the entity is a VIE, and, if so, whether the Company is the primary beneficiary.

In connection with the Separation, J&J and Kenvue entered into a separation agreement (the “Separation Agreement”) on May 3, 2023. Under the Separation Agreement, transfer of certain assets and liabilities of the Consumer Health Business in certain jurisdictions (each, a “Deferred Local Business”) was not completed prior to the Kenvue IPO and was deferred due to certain precedent conditions, which include ensuring compliance with applicable law and obtaining necessary governmental approvals and other consents, and for other business reasons. At the Kenvue IPO and until the Deferred Local Business transfers to the Company, J&J 1) holds and operates the Deferred Local Businesses on behalf of and for the benefit of the Company, and 2) will use reasonable best efforts to treat and operate, insofar as reasonably practicable and to the extent permitted by applicable law, each such Deferred Local Business in the ordinary course of business in all material respects consistent with past practice. The benefits and costs related to these Deferred Local Businesses will be assumed by the Company (see below “—Net Economic Benefit Arrangements”). In addition, the Company and J&J will use reasonable best efforts to take all actions to transfer each Deferred Local Business as promptly as reasonably practicable. When the precedent conditions are met, the Deferred Local Businesses will be transferred as per the terms of the arrangement with J&J.

The Company determined that certain Deferred Local Businesses that are legal entities (“Deferred Legal Entities”) are VIEs for which Kenvue is the primary beneficiary, since Kenvue has the power to direct the activities that most significantly impact such Deferred Legal Entities’ economic performance, as well as to obtain all the economic benefits and losses of such entities. These significant activities include, but are not limited to, product pricing, marketing and sales strategy, supply chain strategy, material supply and vendor management, budget planning, and labor and overhead management. Accordingly, the assets and liabilities of these entities are recognized on the Condensed Consolidated Balance Sheets at their historical carrying amounts as of the date when the Company entered into the arrangement, since the primary beneficiary of the VIEs and the VIEs themselves were under common control. Additionally, the results of the operations and cash flows are included within the Condensed Consolidated Financial Statements.

16

All Deferred Legal Entities are exposed to similar operational risks and are therefore monitored and evaluated on a similar basis by management. Accordingly, the financial information for Deferred Legal Entities has been aggregated and the following table summarizes the consolidated assets and liabilities of these entities, on the Condensed Consolidated Balance Sheets. The amounts represented in this table are only those assets of the VIEs that can be used to settle only the VIE’s obligations and the VIE’s creditors (or beneficial interest holders) have no recourse against the general credit of the primary beneficiary.

(Dollars in Millions)September 29, 2024
Assets
Current assets 
Cash and cash equivalents$107 
Trade receivables, less allowances for credit losses
60 
Inventories
25 
Prepaid expenses and other receivables3 
Total current assets195 
Property, plant, and equipment, net2 
Deferred taxes on income2 
Other assets1 
Total assets$200 
Liabilities
Current liabilities
Accounts payable$1 
Accrued liabilities
11 
Accrued rebates, returns, and promotions15 
Total current liabilities27 
Total liabilities$27 

The Company recognized Net income of $6 million and $46 million for the fiscal three months ended September 29, 2024 and October 1, 2023, respectively, and $12 million and $78 million for the fiscal nine months ended September 29, 2024 and October 1, 2023, respectively, related to the Deferred Legal Entities in the Condensed Consolidated Statements of Operations.

Net Economic Benefit Arrangements

With respect to certain Deferred Legal Entities and the Deferred Local Businesses that are not legal entities (“Deferred Markets”), the Company and J&J entered into net economic benefit arrangements effective on April 4, 2023, pursuant to which, among other things, J&J will transfer to the Company the net profits from the operations of each of the Deferred Markets (or, in the event the operations of any such Deferred Markets result in net losses to J&J, the Company will reimburse J&J for the amount of such net losses).

The Company recognized a net payable to J&J of $24 million in relation to the net economic benefit arrangements as of September 29, 2024 on the Condensed Consolidated Balance Sheet. The Company recognized Net income of $7 million and $15 million for the fiscal three months ended September 29, 2024 and October 1, 2023, respectively, and $40 million and $31 million for the fiscal nine months ended September 29, 2024 and October 1, 2023, respectively, in relation to the net economic benefit arrangements in the Condensed Consolidated Statements of Operations.

Reclassifications

Certain prior period amounts have been reclassified to conform to current fiscal year presentation.

Recent Accounting Standards

SEC Release No. 33-11275, The Enhancement and Standardization of Climate-Related Disclosures for Investors

In March 2024, the SEC adopted final rules under SEC Release No. 33-11275, The Enhancement and Standardization of Climate-Related Disclosures for Investors, which requires disclosure of governance, risk management, and strategy related to material climate-related risks as well as disclosure of material greenhouse gas emissions in registration statements and annual
17

reports. In addition, certain disclosures as they relate to severe weather events and other natural conditions and carbon offsets and renewable energy credits would also be required. The SEC voluntarily stayed the final rules pending completion of judicial review following legal challenges. The rules are effective for large accelerated filers for annual periods ending December 31, 2025, pending resolution of the stay. The Company is currently assessing the impact of these rules on the Condensed Consolidated Financial Statements.

Accounting Standards Update (“ASU”) 2023-09—Income Taxes (Topic 740): Improvements to Income Tax Disclosures

In December 2023, the Financial Accounting Standards Board (the “FASB”) issued ASU 2023-09—Income Taxes (Topic 740): Improvements to Income Tax Disclosures (“ASU 2023-09”). ASU 2023-09 enhances the transparency of income tax disclosures, primarily by requiring public business entities to disclose 1) consistent categories and greater disaggregation of information in the rate reconciliations and 2) the disclosure of income taxes paid disaggregated by jurisdiction, among other requirements. This guidance is effective for public entities for the fiscal years beginning after December 15, 2024, and early adoption is permitted. The amendments are applicable on a prospective basis, although retrospective basis is also permitted. The Company is currently evaluating this guidance and the impact on its income tax disclosures.

ASU 2023-07—Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures

In November 2023, the FASB issued ASU 2023-07—Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures (“ASU 2023-07”). ASU 2023-07 scopes in entities with a single reportable segment and requires those entities to provide all disclosures required in Topic 280. Among other various new disclosures, ASU 2023-07 additionally requires that current annual disclosures about a reportable segment’s profit or loss and assets also be provided in interim periods. Enhanced reporting requirements for all entities include disclosure of 1) significant segment expenses, 2) the title and position of the chief operating decision maker (the “CODM”), and 3) how the CODM uses disclosed measure(s) of a segment’s profit or loss in assessing segment performance and allocating resources. This guidance is effective for public entities for fiscal years beginning after December 15, 2023 and for interim periods within fiscal years beginning after December 15, 2024. Companies are required to apply the amendments retrospectively to all prior periods presented in the financial statements, and early adoption is permitted. The Company is currently evaluating this guidance and expects that adoption will result in new disclosures, including significant segment expenses.

ASU 2024-03—Income Statement—Reporting Comprehensive Income—Expense Disaggregation Disclosures (Subtopic 220-40): Disaggregation of Income Statement Expenses

In November 2024, the FASB issued ASU 2024-03—Income Statement—Reporting Comprehensive Income—Expense Disaggregation Disclosures (Subtopic 220-40): Disaggregation of Income Statement Expenses (“ASU 2024-03”). Among other various new disclosures, ASU 2024-03 requires public entities to disaggregate operating expenses included in certain expense captions presented on the face of the income statement into specific categories (including purchases of inventory, employee compensation, depreciation, and intangible asset amortization) to provide enhanced transparency into the nature of expenses. This guidance is effective for public entities for fiscal years beginning after December 15, 2026, and for interim periods within fiscal years beginning after December 15, 2027. Companies are required to apply the amendments either 1) prospectively to financial statements issued for reporting periods after the effective date of this ASU or 2) retrospectively to all periods presented in the financial statements. Early adoption is permitted. The Company is currently evaluating this guidance and the impact on its disclosures.

No other new accounting standards that were issued or became effective during the fiscal nine months ended September 29, 2024 had, or are expected to have, a significant impact on the Condensed Consolidated Financial Statements.

2. Inventories

As of September 29, 2024 and December 31, 2023, inventories were comprised of:

(Dollars in Millions)September 29, 2024December 31, 2023
Raw materials and supplies$311 $304 
Goods in process103 115 
Finished goods1,406 1,432 
Total inventories$1,820 $1,851 

18

3. Intangible Assets and Goodwill

As of September 29, 2024 and December 31, 2023, the gross and net amounts of intangible assets were:

September 29, 2024December 31, 2023
(Dollars in Millions)Gross Carrying AmountAccumulated AmortizationNet Carrying AmountGross Carrying AmountAccumulated AmortizationNet Carrying Amount
Definite-lived intangible assets:
Patents and trademarks$4,225 $(1,849)$2,376 $4,444 $(1,698)$2,746 
Customer relationships2,101(1,191)9102,125(1,151)974
Other intangibles1,313(706)6071,320(669)651
Total definite-lived intangible assets$7,639 $(3,746)$3,893 $7,889 $(3,518)$4,371 
Indefinite-lived intangible assets:
Trademarks$4,938 $— $4,938 $5,187 $— $5,187 
Other56—5661—61
Total intangible assets, net$12,633 $(3,746)$8,887 $13,137 $(3,518)$9,619 

Gross carrying amount changes for the fiscal nine months ended September 29, 2024 were primarily driven by the impact of $479 million in intangible asset impairments, of which $463 million related to impairment charges recognized in relation to Dr.Ci:Labo® definite-lived intangible assets, including trademarks and other intangibles, as described in Note 1, “Description of the Company and Summary of Significant Accounting Policies—Impairment Charges.” The change was further driven by the impact of currency translations.

No intangible asset impairments were recognized for both the fiscal three and nine months ended October 1, 2023.

Amortization expense for the Company’s amortizable assets, which is included in Cost of sales, was $66 million and $82 million for the fiscal three months ended September 29, 2024 and October 1, 2023, respectively, and $212 million and $242 million for the fiscal nine months ended September 29, 2024 and October 1, 2023, respectively.

Goodwill by reportable segment was as follows:

(Dollars in Millions)Self CareSkin Health and BeautyEssential HealthTotal
Goodwill as of December 31, 2023
$5,308 $2,315 $1,648 $9,271 
Currency translation
17 1 8 26 
Goodwill as of September 29, 2024
$5,325 $2,316 $1,656 $9,297 

19

4. Borrowings

The components of the Company’s debt as of September 29, 2024 and December 31, 2023 were as follows:

(Dollars in Millions)September 29, 2024December 31, 2023
Senior Notes
5.50% Senior Notes due 2025
$750 $750 
5.35% Senior Notes due 2026
750 750 
5.05% Senior Notes due 2028
1,000 1,000 
5.00% Senior Notes due 2030
1,000 1,000 
4.90% Senior Notes due 2033
1,250 1,250 
5.10% Senior Notes due 2043
750 750 
5.05% Senior Notes due 2053
1,500 1,500 
5.20% Senior Notes due 2063
750 750 
Other(1)
118 9 
Discounts and debt issuance costs(65)(72)
Total
$7,803 $7,687 
Less: Current portion of long-term debt—principal amount
(750)— 
Total long-term debt$7,053 $7,687 
Current portion of long-term debt—principal amount
750 — 
Commercial paper 890 600 
Discounts and debt issuance costs (3)(1)
Other
11 — 
Total loans and notes payable$1,648 $599 
Total debt$8,701 $8,286 
(1) As of September 29, 2024, Other includes $112 million of finance lease liabilities associated with the Global Headquarters Lease. See Note 1, “Description of the Company and Summary of Significant Accounting Policies—Leases,” for more information.

Senior Notes

On March 22, 2023, the Company issued eight series of senior unsecured notes (the “Senior Notes”) in an aggregate principal amount of $7.75 billion. The net proceeds to the Company from the Senior Notes were approximately $7.7 billion after deductions of discounts and issuance costs of $77 million. Upon release from escrow, these funds were loaned to J&J through a facility agreement (the “Facility Agreement”) dated April 5, 2023. See “—Facility Agreement” below for additional details.

The Company’s Senior Notes are governed by an indenture and supplemental indenture between the Company and a trustee (collectively, the “Indenture”). The Indenture contains certain covenants, including limitations on the Company and certain of its subsidiaries’ ability to incur liens or engage in certain sale leaseback transactions. The Indenture also contains restrictions on the Company’s ability to consolidate, merge, or sell substantially all of its assets. In addition, the Indenture contains other customary terms, including certain events of default, upon the occurrence of which the Senior Notes may be declared immediately due and payable.

Commercial Paper Program

On March 3, 2023, the Company entered into a commercial paper program (the “Commercial Paper Program”). The Company’s Board of Directors has authorized the issuance of up to $4.0 billion in an aggregate principal amount of commercial paper under the Commercial Paper Program. Any such issuance will mature within 364 days from date of issue. The Commercial Paper Program contains representations and warranties, covenants, and defaults that are customary for this type of financing. The commercial paper notes issued under the Commercial Paper Program are unsecured notes ranking at least pari passu with all of the Company’s other senior unsecured indebtedness.

Prior to the Kenvue IPO, the Company issued $1.25 billion under its Commercial Paper Program which, collectively with the Senior Notes, are referred to as the “Debt Financing Transactions.” As of September 29, 2024, the Company had $887 million of outstanding balances under its Commercial Paper Program, net of a related discount of $3 million. As of December 31, 2023,
20

the Company had $599 million of outstanding balances under its Commercial Paper Program, net of a related discount of $1 million.

Revolving Credit Facility

On March 6, 2023, the Company entered into a credit agreement providing for a five-year senior unsecured revolving credit facility (the “Revolving Credit Facility”) in an aggregate principal amount of $4.0 billion to be made available in U.S. dollars and Euros. As of both September 29, 2024 and December 31, 2023, the Company had no outstanding balances under its Revolving Credit Facility.

Facility Agreement

On April 5, 2023, the Company and J&J entered into the Facility Agreement, allowing the Company to lend the proceeds from the issuance of debt (including commercial paper) in an aggregate amount of $8.9 billion to J&J.

Upon completion of the Kenvue IPO on May 8, 2023, the Facility Agreement was terminated and the balance of the loans, and all accrued interest, were repaid by J&J for a total cash inflow of $9.0 billion. The Company earned interest income of $33 million for the fiscal nine months ended October 1, 2023 in relation to the Facility Agreement. The Company remitted this cash back to J&J as a distribution in connection with the Separation.

Interest Expense, Net

The amount included in Interest expense, net in the Condensed Consolidated Statements of Operations consists of the following:

Fiscal Three Months EndedFiscal Nine Months Ended
(Dollars in Millions)September 29, 2024October 1, 2023September 29, 2024
October 1, 2023
Interest expense$108 $115 $323 $244 
Interest income(1)
(12)(15)(40)(90)
Total interest expense, net$96 $100 $283 $154 
(1) Includes interest income of $33 million for the fiscal nine months ended October 1, 2023 recognized in relation to the Facility Agreement.

Fair Value of Debt

The Company’s debt was recorded at the carrying amount. The estimated fair value of the Company’s Senior Notes was $8.0 billion as of September 29, 2024. Fair value was estimated using market prices using quoted prices in active markets which would be considered Level 2 in the fair value hierarchy. The carrying value of the commercial paper notes approximated the fair value as of September 29, 2024 due to the nature and short-term duration of the instrument.

Compliance with Covenants

As of September 29, 2024, the Company was in compliance with all debt covenants, and no default or event of default has occurred.

21

5. Pensions

Single Employer Plans

Net periodic benefit costs for the Company’s defined benefit retirement plans sponsored by the Company for the fiscal three and nine months ended September 29, 2024 and October 1, 2023 included the following components:

Fiscal Three Months EndedFiscal Nine Months Ended
(Dollars in Millions)September 29, 2024October 1, 2023September 29, 2024October 1, 2023
Service cost$7 $6 $22 $16 
Interest cost7 8 21 18 
Amortization of loss (gain)1 (1)3 (1)
Special events
— 8 — 8 
Expected return on plan assets(8)(8)(26)(18)
Total net periodic benefit cost
$7 $13 $20 $23 

The service cost component of net periodic benefit cost is presented in the same line items in the Condensed Consolidated Statements of Operations where other employee compensation costs are reported, including Cost of sales and Selling, general, and administrative expenses. All other components of net periodic benefit costs are presented as part of Other (income) expense, net in the Condensed Consolidated Statements of Operations. During the fiscal three months ended October 1, 2023, the Company converted a defined benefit plan to a defined contribution plan, which resulted in a settlement loss of $10 million, partially offset by a curtailment gain of $2 million. The net balance is disclosed in “Special events” within Net periodic benefit cost.

Participation in J&J Plans

J&J has defined benefit pension plans covering eligible employees in the United States and certain foreign jurisdictions. J&J also provides medical benefits, principally to its U.S. retirees and their dependents through its other postretirement benefit plans. Prior to the Separation, the Company’s employees participated in J&J’s defined benefit pension plans, which were accounted for as multiemployer plans, and assets and liabilities associated with these plans were not reflected on the Condensed Consolidated Balance Sheets. After the Separation, the Company no longer had any multiemployer plans, as they were all converted to a multiple employer pension plan or a single-employer pension plan. The Condensed Consolidated Statements of Operations for the fiscal three and nine months ended October 1, 2023 include expense allocations for these benefits, which were determined using a proportional allocation method. Total benefit plan expense allocated to the Company amounted to $0 million and $17 million for the fiscal three and nine months ended October 1, 2023, respectively.

In connection with the completion of the Separation, J&J transferred certain pension plans to the Company during the fiscal nine months ended October 1, 2023, resulting in the transfer of net pension assets of $162 million and net pension liabilities of $21 million.

22

6. Accrued and Other Liabilities

Accrued liabilities consisted of:

(Dollars in Millions)September 29, 2024December 31, 2023
Accrued expenses$349 $465 
Accrued compensation and benefits325406
Operating lease liabilities
4044
Tax indemnification liability(1)
86113
Other accrued liabilities
364428
Total accrued liabilities
$1,164 $1,456 

Other liabilities, non-current, consisted of:

(Dollars in Millions)September 29, 2024December 31, 2023
Accrued income taxes
$184 $188 
Operating lease liabilities
8697
Tax indemnification liability(1)
150141
Other accrued liabilities
12265
Total other liabilities
$542 $491 
(1) The balances primarily relate to the Tax Matters Agreement (as defined in Note 9, “Relationship with J&J—Tax Indemnification”) entered into with J&J on May 3, 2023 that governs the parties’ respective rights, responsibilities, and obligations with respect to tax liabilities and benefits, tax attributes, the preparation and filing of tax returns, the control of audits and other tax proceedings, and other matters regarding taxes. See Note 9, “Relationship with J&J—Tax Indemnification,” for more information.

23

7. Accumulated Other Comprehensive Loss

Components of Accumulated other comprehensive loss consisted of the following:

(Dollars in Millions)
Foreign Currency Translation
Employee Benefit Plans
Gain on Derivatives and Hedges(1)
Total Accumulated Other Comprehensive Loss
June 30, 2024$(5,689)$(161)$15 $(5,835)
Other comprehensive income (loss) before reclassifications473 (8)12 477 
Amounts reclassified to the Condensed Consolidated Statement of Operations
— 1 (2)(1)
Net current period Other comprehensive income (loss)473 (7)10 476 
September 29, 2024$(5,216)$(168)$25 $(5,359)
July 2, 2023$(5,485)$(57)$40 $(5,502)
Other comprehensive (loss) income before reclassifications(251)1610 (225)
Amounts reclassified to the Condensed Consolidated Statement of Operations
— (1)(14)(15)
Net current period Other comprehensive (loss) income(251)15 (4)(240)
October 1, 2023$(5,736)$(42)$36 $(5,742)
(1) For the fiscal three months ended September 29, 2024 and October 1, 2023, the Company recorded a total after-tax change in Accumulated other comprehensive loss of $11 million and $(4) million, respectively, related to its cash flow hedge portfolio.

24

(Dollars in Millions)
Foreign Currency Translation
Employee Benefit Plans(1)
Gain on Derivatives and Hedges(2)
Total Accumulated Other Comprehensive Loss
December 31, 2023$(5,257)$(167)$47 $(5,377)
Other comprehensive income (loss) before reclassifications41 (4)(12)25 
Amounts reclassified to the Condensed Consolidated Statement of Operations
— 3 (10)(7)
Net current period Other comprehensive income (loss)41 (1)(22)18 
September 29, 2024$(5,216)$(168)$25 $(5,359)
January 1, 2023$(5,476)$12 $9 $(5,455)
Other comprehensive (loss) income before reclassifications(260)(53)48 (265)
Amounts reclassified to the Condensed Consolidated Statement of Operations
— (1)(21)(22)
Net current period Other comprehensive (loss) income(260)(54)27 (287)
October 1, 2023$(5,736)$(42)$36 $(5,742)
(1) Net change for the fiscal nine months ended October 1, 2023 includes Separation adjustments of $73 million in connection with transfers of certain pension plans by J&J to the Company.
(2) For the fiscal nine months ended September 29, 2024 and October 1, 2023, the Company recorded a total after-tax change in Accumulated other comprehensive loss of $(22) million and $27 million, respectively, related to its cash flow hedge portfolio.

Amounts in Accumulated other comprehensive loss are presented net of the related tax impact. Foreign currency translation is not adjusted for income taxes where it relates to permanent investments in international operations. For additional details on comprehensive income, see the Condensed Consolidated Statements of Comprehensive Income.

The provision (benefit) for taxes allocated to the components of Accumulated other comprehensive loss before reclassification was as follows:

Fiscal Three Months EndedFiscal Nine Months Ended
(Dollars in Millions)
September 29, 2024October 1, 2023September 29, 2024October 1, 2023
Foreign currency translation(1)
$(7)$(10)$(12)$(4)
Employee benefit plans
— 1 — (16)
Gain on derivatives and hedges
— (2)11 7 
 Total (benefit) for taxes recognized in Accumulated other comprehensive loss$(7)$(11)$(1)$(13)
(1) The provision (benefit) for taxes for the fiscal three and nine months ended October 1, 2023 has been adjusted to remove the foreign currency translation on deferred tax balances. The amounts disclosed include only the provision (benefit) for taxes allocated to foreign currency translation and are comparable to the amounts disclosed for the fiscal three and nine months ended September 29, 2024. The net amount of foreign currency translation was unaffected by the adjustment.

The provision (benefit) for taxes allocated to the reclassifications from Accumulated other comprehensive loss to the Condensed Consolidated Statements of Operations was not significant for both the fiscal three and nine months ended September 29, 2024 and October 1, 2023.

25

8. Stock-Based Compensation

The 2023 Long-Term Incentive Plan (the “Kenvue 2023 Plan”) provides for the grant of non-qualified stock options, incentive stock options, stock appreciation rights, restricted stock units (“RSUs”), performance stock units (“PSUs”), other stock-based awards, and cash awards to eligible employees, non-employee directors, independent contractors, and consultants of the Company and its subsidiaries and affiliated entities.

For the fiscal three and nine months ended September 29, 2024, stock-based compensation expense was recognized resulting from the grant of stock-based awards under the Kenvue 2023 Plan, which were denominated in shares of Kenvue common stock.

On August 23, 2023 (the “Conversion Date”), J&J equity-based awards held by Kenvue employees were accounted for as if they were forfeited by J&J and generally replaced by Kenvue equity-based awards under the Kenvue 2023 Plan with terms consistent with those applicable to the J&J awards, subject to adjustments to the number of underlying awards and option exercise prices to preserve the award’s value, except for certain performance-based awards that were replaced with Kenvue RSU awards.

Prior to the Conversion Date, stock-based compensation expense was driven by stock-based awards granted under J&J’s long-term incentive plans, which were denominated in shares of J&J common stock.

The classification of stock-based compensation expense for the fiscal three and nine months ended September 29, 2024 and October 1, 2023 was as follows:

Fiscal Three Months EndedFiscal Nine Months Ended
(Dollars in Millions)September 29, 2024October 1, 2023September 29, 2024October 1, 2023
Cost of sales$26 $2 $89 $18 
Selling, general, and administrative expenses32 — 111 57 
Total stock-based compensation expense
$58 $2 $200 $75 

The increase in stock-based compensation expense for the fiscal three and nine months ended September 29, 2024 as compared to the prior fiscal periods was primarily driven by the deemed cancelation of stock options, PSUs, and RSUs granted under J&J’s long-term incentive plans prior to the Conversion Date that had not yet vested which resulted in a one-time reversal of $148 million of previously recognized stock-based compensation expense in the fiscal three months ended October 1, 2023. The increase was also driven by a higher grant date fair value and shorter expense attribution period of the converted Kenvue stock-based awards outstanding in the current fiscal periods as compared to stock-based awards outstanding in the prior fiscal periods, which were granted under J&J’s long-term incentive plans prior to the Conversion Date, as well as the grant of the Founder Shares (as defined in Note 15, “Segments of Business—Segment Net Sales and Segment Adjusted Operating Income”) on October 2, 2023, and stock options, RSUs, and PSUs awarded as part of the annual grant of stock-based awards under the Kenvue 2023 Plan that occurred during the fiscal three months ended March 31, 2024.

Grant activity for the fiscal nine months ended September 29, 2024 primarily relates to stock options, RSUs, and PSUs awarded as part of the annual grant of stock-based awards under the Kenvue 2023 Plan that occurred during the fiscal three months ended March 31, 2024.

There was no significant grant activity during the fiscal three months ended September 29, 2024.

Stock Options

There was no significant activity related to the granting of stock options during the fiscal three months ended September 29, 2024.

During the fiscal three months ended March 31, 2024, the Company granted 13,496,000 stock options. The stock options expire 10 years from the grant date and vest over service periods that range from one year to four years.

26

The weighted average grant date fair value of stock options granted during the fiscal three months ended March 31, 2024 was $3.17. The grant date fair value of each stock option is estimated using the Black-Scholes option valuation model. The weighted average assumptions used in calculating the grant date fair value of stock options granted during the fiscal three months ended March 31, 2024 were as follows:

Fiscal Three Months Ended
March 31, 2024
Expected volatility(1)
21.3 %
Expected dividend yield(2)
3.9 %
Risk-free rate(3)
4.1 %
Expected term(4)
6 years
(1) Expected volatility is based on the historical volatility of a selected group of the Company’s peers and other factors.
(2) Expected dividend yield is calculated using the assumed dividend payout per common share as a percentage of the average Kenvue common share price for the prior three-month period, which is then annualized.
(3) Risk-free rate is based on the U.S. Treasury yield curve in effect as of the grant date for options granted.
(4) Given the lack of trading history of Kenvue common stock as of the time of valuation, the expected term is calculated as the average of the vesting periods and the contractual terms of the stock options.

Restricted Stock Units and Performance Stock Units

There was no significant activity related to the granting of RSUs or PSUs during the fiscal three months ended September 29, 2024.

During the fiscal three months ended March 31, 2024, the Company granted 6,963,000 RSUs which vest over service periods that range from one year to three years. The weighted average grant date fair value of RSUs granted during the fiscal three months ended March 31, 2024 was $19.02. The grant date fair value of RSUs granted is equivalent to the close price of Kenvue common stock on the New York Stock Exchange on the grant date. All RSUs granted have dividend participation rights during the vesting period.

During the fiscal three months ended March 31, 2024, the Company granted 1,180,000 PSUs which are paid in shares of Kenvue’s common stock after the end of a three-year performance period. The vesting of PSUs is tied to the completion of a three-year service period and the achievement, over a three-year period, of specified performance metrics as well as the relative total shareholder return for Kenvue common stock. The number of shares earned at the end of the three-year performance period will vary, based on actual performance, from 0% to 200% of the target number of PSUs granted. The grant date fair value of each PSU, inclusive of the fair value associated with the achievement of the specified performance metrics and the relative total shareholder return goal, was estimated on the grant date using a Monte Carlo valuation model. The weighted average grant date fair value of PSUs granted during the fiscal three months ended March 31, 2024 was $18.60. During the three-year performance period, stock-based compensation expense for the PSUs will be adjusted based on the Company’s best estimate of achievement of the specified performance metrics. The cumulative effect on current and prior periods of a change in the estimated number of PSUs that are expected to be earned will be recognized as an adjustment to stock-based compensation expense in the period of the adjustment.

9. Relationship with J&J

On August 23, 2023, Kenvue became a fully independent company upon the completion of the Exchange Offer (see Note 1, “Description of the Company and Summary of Significant Accounting Policies—Description of the Company and Business Segments”), and J&J ceased to be a related party on that date. The Company continues to have material agreements with J&J—see “—Transactions with J&J, Including the Separation Agreement” section within this footnote for additional details of these material agreements that govern the Company’s relationship with J&J.

Cost Allocations from J&J Prior to Kenvue IPO

Prior to the Kenvue IPO, J&J provided significant support functions to the Company. The Condensed Consolidated Financial Statements reflect an allocation of these costs. Similarly, certain of the Company’s operations provided support to J&J’s affiliates and related costs for support were charged to J&J’s affiliates. Allocated costs included in Cost of sales in the Condensed Consolidated Statements of Operations related to enterprise-wide support primarily consisting of facilities, insurance, logistics, quality, and compliance, which were predominantly allocated based on Net sales. Allocated costs included
27

in Selling, general, and administrative expenses primarily related to finance, human resources, benefits administration, procurement support, information technology, legal, corporate strategy, corporate governance, other professional services, and general commercial support functions, and were predominantly allocated based on Net sales or headcount. See Note 1, “Description of the Company and Summary of Significant Accounting Policies—Basis of Presentation.”

Prior to Kenvue becoming a fully independent company, the allocations (excluding stock-based compensation expense), net of costs charged to J&J’s affiliates reflected in the Condensed Consolidated Statements of Operations for the fiscal nine months ended October 1, 2023 were as follows:

Fiscal Nine Months Ended
(Dollars in Millions)October 1, 2023
Cost of sales$25 
Selling, general, and administrative expenses120 
Total costs allocated
$145 

Management believes these cost allocations are a reasonable reflection of the utilization of services provided to, or the benefit derived by, the Company during the period presented. The allocations may not, however, be indicative of the actual expenses that would have been incurred had the Company operated as a standalone public company. Actual costs that may have been incurred if the Company had been a standalone public company would depend on a number of factors, including the chosen organizational structure, whether functions were outsourced or performed by the Company’s employees, and strategic decisions made in areas such as manufacturing, selling and marketing, research and development, information technology, and infrastructure. No allocations were made subsequent to the fiscal three months ended July 2, 2023.

Net Transfers to J&J

Net transfers to J&J are included in Net investment from J&J in the Condensed Consolidated Statement of Equity and within financing activities in the Condensed Consolidated Statement of Cash Flows and represent the net effect of transactions between the Company and J&J. No transactions were recorded in Net transfers to J&J subsequent to the fiscal three months ended July 2, 2023.

The components of Net transfers to J&J for the fiscal nine months ended October 1, 2023 were as follows:

Fiscal Nine Months Ended
(Dollars in Millions)October 1, 2023
Cash pooling and general financing activities$(446)
Corporate cost allocations145 
Taxes deemed settled with J&J
27 
Net transfers to J&J as reflected in the Condensed Consolidated Statement of Cash Flows
$(274)
Other
(34)
Net transfers to J&J as reflected in the Condensed Consolidated Statement of Equity
$(308)

Transactions with J&J, Including the Separation Agreement

In connection with the Separation, Kenvue entered into various agreements with J&J, including the Separation Agreement. In connection with the terms of the Separation Agreement, certain assets and liabilities included on the pre-Separation balance sheet were retained by J&J and certain assets and liabilities not included on the pre-Separation balance sheet were transferred to Kenvue. Separation-related adjustments have been recognized in Net investment from J&J, the net impact of which resulted in an increase in net assets and total equity by $91 million for the fiscal nine months ended October 1, 2023. The impact on net assets primarily represents 1) recognition of balances with J&J including indemnification matters, 2) changes to income tax assets and liabilities as a result of change in the basis of presentation, 3) contribution of certain liabilities including pension and employee-related obligations from J&J, 4) the retention of assets and liabilities by J&J of certain Deferred Local Businesses (as defined in Note 1, “Description of the Company and Summary of Significant Accounting Policies—Variable Interest Entities
28

and Net Economic Benefit Arrangements”), and 5) other assets and liability transfers between Kenvue and J&J in connection with the Separation.

The Separation Agreement sets forth certain agreements between J&J and Kenvue regarding, among other matters:

•the principal corporate actions and internal reorganization pursuant to which J&J transferred the Consumer Health Business to Kenvue;
•the allocation of assets and liabilities to J&J and Kenvue;
•J&J’s and Kenvue’s respective rights and obligations with respect to the Kenvue IPO;
•certain matters with respect to any subsequent distribution or other disposition by J&J of the shares of Kenvue common stock owned by J&J following the Kenvue IPO (the “Distribution”); and
•other agreements governing aspects of Kenvue’s relationship with J&J following the Kenvue IPO.

In connection with the Kenvue IPO, J&J and Kenvue also entered into various other material agreements. These agreements were entered into on May 3, 2023, unless otherwise indicated, and consist of the following:

•a tax matters agreement (the “Tax Matters Agreement”), which governs J&J’s and Kenvue’s respective rights, responsibilities and obligations with respect to all tax matters, including tax liabilities, tax attributes, tax contests, and tax returns (See “—Tax Indemnification” below);
•an employee matters agreement, which addresses certain employment, compensation, and benefits matters, including the allocation and treatment of certain assets and liabilities relating to Kenvue’s employees and compensation and benefit plans and programs in which Kenvue’s employees participate prior to the date of the Distribution;
•an intellectual property agreement, which governs J&J’s and Kenvue’s respective rights, responsibilities and obligations with respect to intellectual property matters, excluding certain intellectual property matters with respect to trademarks;
•a trademark phase-out license agreement, dated as of April 3, 2023, and pursuant to which J&J granted to Kenvue a license to use certain trademarks owned by J&J on a transitional basis following the completion of the Kenvue IPO;
•a transition services agreement (the “Transition Services Agreement”), pursuant to which J&J provides to Kenvue certain services for terms of varying duration following the Kenvue IPO;
•a transition manufacturing agreement (the “Transition Manufacturing Agreement”), pursuant to which J&J provides to Kenvue certain manufacturing services for terms of varying duration following the Kenvue IPO; and
•a registration rights agreement, pursuant to which Kenvue granted to J&J certain registration rights with respect to the shares of Kenvue common stock owned by J&J following the completion of the Kenvue IPO.

In connection with the Separation, J&J and Kenvue also entered into various operating lease agreements, in which the Company subleased properties from J&J. See Note 1, “Description of the Company and Summary of Significant Accounting Policies—Leases,” for more information.

The Company had the following balances and transactions with J&J and its affiliates, primarily in connection with the Tax Matters Agreement, Transition Services Agreement, and the Transition Manufacturing Agreement, reported in the Condensed Consolidated Financial Statements:

(Dollars in Millions)September 29, 2024December 31, 2023
Prepaid expenses and other receivables$103 $213 
Accounts payable and accrued liabilities
$314 $486 
Other assets$85 $87 
Other liabilities$150 $153 

Fiscal Three Months EndedFiscal Nine Months Ended
(Dollars in Millions)September 29, 2024October 1, 2023September 29, 2024October 1, 2023
Cost of sales$44 $56 $153 $95 
Selling, general, and administrative expenses$45 $47 $167 $94 

29

Tax Indemnification

The Company entered into the Tax Matters Agreement with J&J on May 3, 2023 that governs the parties’ respective rights, responsibilities, and obligations with respect to tax liabilities and benefits, tax attributes, the preparation and filing of tax returns, the control of audits and other tax proceedings, and other matters regarding taxes.

Allocation of Taxes

With respect to taxes other than those incurred in connection with the Separation and the Distribution, the Tax Matters Agreement provides that Kenvue will generally indemnify J&J for 1) any taxes of Kenvue for all periods after the Distribution and 2) any taxes of Kenvue or J&J for periods prior to the Distribution to the extent attributable to the Consumer Health Business. J&J will generally indemnify Kenvue for 1) any taxes of J&J for all periods after the Distribution and 2) any taxes of Kenvue or J&J for periods prior to the Distribution to the extent attributable to the business and operations conducted by J&J other than the Consumer Health Business. Furthermore, subject to certain exceptions, the Company is required to reimburse J&J for certain tax refunds it receives with respect to taxes paid prior to the effective date of the Tax Matters Agreement.

Preservation of the Intended Tax Treatment of Certain Steps of the Separation and the Distribution

With respect to taxes incurred in connection with the Separation and the Distribution, Kenvue will generally be required to indemnify J&J for any taxes resulting from the failure of certain steps of the Separation and the Distribution to qualify for their intended tax treatment, where such taxes are attributable to actions or omissions by Kenvue. In addition, during the time period ending two years after the date of the Distribution, August 23, 2025, covenants are in place that will limit or restrict certain actions, including share issuances, business combinations, sales of assets, and similar transactions by Kenvue. The Company does not believe that the above covenants have a material impact on the Company to date. The Company believes that it has complied with these requirements to date.

The Company recorded a net liability totaling approximately $140 million for income and non-income indemnification tax payables and refunds, unrecognized tax benefits and associated interest due to J&J as Prepaid expenses and other receivables and Accrued liabilities for current assets and current liabilities, respectively, and to Other assets and Other liabilities for non-current assets and non-current liabilities, respectively, on the Condensed Consolidated Balance Sheet as of September 29, 2024.

Debt Financing Transactions and Kenvue IPO Consideration

During the fiscal six months ended July 2, 2023, the Company received debt proceeds of approximately $7.7 billion from the issuance of the Senior Notes and received initial proceeds from its Commercial Paper Program of $1.2 billion. The Company loaned the total proceeds to J&J through the Facility Agreement. Upon the completion of the Kenvue IPO on May 8, 2023, the Facility Agreement was terminated and the balance of the loans, and all accrued interest, were repaid by J&J for a total cash inflow of $9.0 billion. The Company remitted this cash back to J&J as a distribution in connection with the Separation.

30

10. Other Operating Expense (Income), Net and Other (Income) Expense, Net

Other operating expense (income), net for the fiscal three and nine months ended September 29, 2024 and October 1, 2023 consisted of:

Fiscal Three Months EndedFiscal Nine Months Ended
(Dollars in Millions)September 29, 2024October 1, 2023September 29, 2024October 1, 2023
Litigation (income) expense $(3)$— $1 $20 
Royalty income (7)(15)(24)(23)
Gain on disposal of fixed assets— — — (9)
Impact of Deferred Markets(1)
11 10 49 34 
Contingent liability reversal(2)
— (2)— (45)
Other(3)
6 16 3 16 
Total other operating expense (income), net$7 $9 $29 $(7)
(1) Includes the provision for taxes, minority interest expense, and service fees to be paid to J&J under the net economic benefit arrangements. See Note 1, “Description of the Company and Summary of Significant Accounting Policies—Variable Interest Entities and Net Economic Benefit Arrangements,” for more information regarding Deferred Markets.
(2) Includes the reversal of a contingent liability that was no longer considered to be probable.
(3) Includes impact of foreign derivative contracts, pension-related, and other miscellaneous operating (income) expenses.

Other (income) expense, net for the fiscal three and nine months ended September 29, 2024 and October 1, 2023 consisted of:

Fiscal Three Months EndedFiscal Nine Months Ended
(Dollars in Millions)September 29, 2024October 1, 2023September 29, 2024
October 1, 2023
Currency losses (gains) on transactions$1 $23 $(3)$51 
Losses on investments— — 31 7 
Tax indemnification release(1)
(21)— (21)— 
Other(2)
1 2 (1)7 
Total other (income) expense, net$(19)$25 $6 $65 
(1) Includes the release of tax indemnification reserves that were no longer considered to be probable.
(2) Other consists primarily of net periodic benefit costs other than service cost components and miscellaneous non-operating (income) expenses.

11. Income Taxes

For interim financial statement purposes, U.S. GAAP provision (benefit) for taxes related to ordinary income is determined by applying an estimated annual effective income tax rate against a company’s ordinary income, subject to certain limitations on the benefit of losses. Provision (benefit) for taxes related to items not characterized as ordinary income is recognized as a discrete item when incurred. The estimation of the Company’s income tax provision requires the use of management forecasts and other estimates, the application of statutory income tax rates, and an evaluation of valuation allowances. The Company’s estimated annual effective income tax rate may be revised, if necessary, in each interim period.

The worldwide effective income tax rates were 33.6% and 25.1% for the fiscal three months ended September 29, 2024 and October 1, 2023, respectively, and 31.1% and 27.1% for the fiscal nine months ended September 29, 2024 and October 1, 2023, respectively. The increase for the fiscal three months ended September 29, 2024 as compared to the fiscal three months ended October 1, 2023 was primarily the result of changes to the jurisdictional mix of income and shortfall on stock-based compensation recorded during the fiscal three months ended September 29, 2024, as well as fewer releases of tax reserves due to the expiration of certain statutes of limitations and reduced tax benefits derived from the Separation as compared to the fiscal three months ended October 1, 2023. The increase for the fiscal nine months ended September 29, 2024 as compared to the fiscal nine months ended October 1, 2023 was primarily the result of reduced tax benefits derived from the Separation as compared to the fiscal nine months ended October 1, 2023, return to provision adjustments and shortfall on stock-based compensation recorded during the fiscal nine months ended September 29, 2024, as well as changes to the jurisdictional mix of
31

income. These increases were offset by the impairment to the Dr.Ci:Labo® skin health business and the corresponding reversal of a deferred tax liability and the remeasurement of the state deferred tax liability as a result of a change in the Company’s state tax rate.

As discussed in Note 1, “Description of the Company and Summary of Significant Accounting Policies—Basis of Presentation,” prior to April 4, 2023, the Company operated as a segment of J&J and not as a separate entity. Accordingly, the effective worldwide income tax rate for the fiscal nine months ended October 1, 2023 was calculated using the separate return method as if the Company filed income tax returns on both a standalone basis and on a carve-out basis. This resulted in the inclusion of certain hypothetical foreign tax credit benefits that did not exist following the Kenvue IPO.

As of September 29, 2024, the Company had approximately $184 million of liabilities from unrecognized tax benefits. The Company conducts business and files tax returns in numerous countries. The Company and J&J currently have tax audits in progress in several jurisdictions, which remain open from 2013 and forward. With respect to the United States, per the Tax Matters Agreement between J&J and the Company, J&J remains liable for all liabilities related to the final settlement of any U.S. federal income tax audits in which the Company is part of J&J’s federal consolidated return. In other major jurisdictions where the Company conducts business, the years that remain open to tax audits range from 2015 and forward. The Company believes it is possible that certain tax audits in major jurisdictions where the Company conducts business outside of the United States may be completed over the next 12 months by their respective taxing authorities. However, the Company is not able to provide a reasonably reliable estimate of the timing of any future tax payments or the amount of possible changes to the total unrecognized tax benefits associated with any audit closures or other events. The Company classifies liabilities for unrecognized tax benefits and related interest and penalties as long-term liabilities on the Condensed Consolidated Balance Sheets. Interest expense and penalties related to unrecognized tax benefits are classified as provision for taxes in the Condensed Consolidated Statements of Operations.

On August 16, 2022, the United States enacted the Inflation Reduction Act of 2022 (“IRA”), which, among other things, introduces a 15% minimum tax based on adjusted financial statement income of certain large corporations with a three-year average adjusted financial statement income in excess of $1 billion, an excise tax on corporate stock buybacks, and several tax incentives to promote clean energy. Based on the Company’s current analysis, as well as recently published guidance by the U.S. Treasury and by the Internal Revenue Service, the IRA did not have a significant impact on the Condensed Consolidated Financial Statements. The Company will continue to evaluate the impact of this law as additional guidance and clarification become available.

The Company has included the estimated impact of enacted legislation related to the Organization for Economic Co-operation Development’s (“OECD”) Pillar Two Inclusive Framework in its provision for taxes beginning in the current fiscal year. While the estimated impact is not material, it is possible that further OECD implementation guidance, or legislation in countries in which the Company operates, could have a material effect on the Company’s provision for taxes in the future.

12. Net Income Per Share

The Company had 1,922,328,058 shares of common stock issued and 1,916,278,058 shares of common stock outstanding as of September 29, 2024. Prior to the completion of the Kenvue IPO, the Company had 1,716,160,000 shares of common stock outstanding, of which 1,716,159,990 shares were issued to J&J through a subscription agreement in May 2023. On May 8, 2023, the Kenvue IPO was completed through the sale of 198,734,444 shares of common stock, including the underwriters’ full exercise of their option to purchase 25,921,884 shares to cover over-allotments. For all periods prior to the Kenvue IPO, the shares issued through the subscription agreement are being treated akin to shares attributable to a stock split and, as a result, are being retrospectively presented for all of the periods.

Diluted net income per share is computed by giving effect to all potentially dilutive equity instruments or equity awards that are outstanding during the period. The Company had 52,282,020 and 59,712,143 shares during the fiscal three and nine months ended September 29, 2024, respectively, and 38,386,962 shares during both the fiscal three and nine months ended October 1, 2023 that were determined to be anti-dilutive under the treasury stock method and therefore were excluded from the diluted net income per share calculation. For both the fiscal three and nine months ended September 29, 2024 and both the fiscal three and nine months ended October 1, 2023, the majority of anti-dilutive shares related to stock options. There were no equity awards of the Company outstanding prior to the Kenvue IPO and no dilutive equity instruments of the Company outstanding prior to the Exchange Offer.

32

Net income per share for the fiscal three and nine months ended September 29, 2024 and October 1, 2023 was calculated as follows:

Fiscal Three Months EndedFiscal Nine Months Ended
(In Millions, Except Per Share Data)
September 29, 2024October 1, 2023September 29, 2024October 1, 2023
Net income$383 $438 $737 $1,337 
Basic weighted average number of shares outstanding 1,915 1,916 1,915 1,823 
Diluted effects of stock-based awards
9 4 6 4 
Diluted weighted average number of shares outstanding1,924 1,920 1,921 1,827 
Net income per share:
Basic $0.20 $0.23 $0.38 $0.73 
Diluted $0.20 $0.23 $0.38 $0.73 

13. Fair Value Measurements

Fair value measurements are estimated based on valuations techniques and inputs categorized as follows:

•Level 1 – Quoted prices in active markets for identical assets or liabilities
•Level 2 – Significant other observable inputs
•Level 3 – Significant unobservable inputs

If the inputs used to measure the financial assets and liabilities fall within more than one level described above, the categorization is based on the lowest level input that is significant to the fair value measurement of the instrument.

The following fair value hierarchy table presents the components and classification of the Company’s financial assets and liabilities measured at fair value on a recurring basis:

September 29, 2024December 31, 2023
(Dollars in Millions)Carrying ValueLevel 1Level 2Level 3Carrying ValueLevel 1Level 2Level 3
Assets:
Forward foreign exchange contracts$72 $— $72 $— $63 $— $63 $— 
Cross currency swap contracts
1 — 1 — — — — — 
Total assets
$73 $— $73 $— $63 $— $63 $— 
Liabilities:
Forward foreign exchange contracts$(65)$— $(65)$— $(50)$— $(50)$— 
Cross currency swap contracts
(22)— (22)— (25)— (25)— 
Total liabilities
$(87)$— $(87)$— $(75)$— $(75)$— 
Net amount presented in Prepaid expenses and other receivables:$18 $— $18 $— $18 $— $18 $— 
Net amount presented in Accounts payable:
$(21)$— $(21)$— $(30)$— $(30)$— 
Net amount presented in Other assets:
$5 $— $5 $— $— $— $— $— 
Net amount presented in Other liabilities:
$(16)$— $(16)$— $— $— $— $— 

33

As of September 29, 2024 and December 31, 2023, cash equivalents were $168 million and $329 million, respectively, which were primarily comprised of time deposits and money market funds.

The carrying amount of Cash and cash equivalents, Trade receivables, Prepaid expenses and other receivables, and Loans and notes payable approximated fair value as of September 29, 2024 and December 31, 2023. The fair value of forward foreign exchange contracts is the aggregation by currency of all future cash flows discounted to its present value at the prevailing market interest rates and subsequently converted to the U.S. dollar at the current spot foreign exchange rate. The cross currency swap contracts are recorded at fair value that is derived from observable market data, including foreign exchange rates and yield curves.

The fair value of the Company’s derivative assets is included in Prepaid expenses and other receivables and Other Assets on the Condensed Consolidated Balance Sheets. The fair value of the Company’s derivative liabilities is included in Accounts payable and Other liabilities on the Condensed Consolidated Balance Sheets.

There were no transfers between Level 1, Level 2, or Level 3 during the fiscal three and nine months ended September 29, 2024 and the fiscal twelve months ended December 31, 2023.

The following table sets forth the notional amounts of the Company’s outstanding derivative instruments:

September 29, 2024December 31, 2023
(Dollars in Millions)Forward foreign exchange contracts
Cross currency swap contracts
Total notional amount
Forward foreign exchange contracts
Cross currency swap contracts
Total notional amount
Cash flow hedges
$4,333 $— $4,333 $3,522 $— $3,522 
Fair value hedges$66 $— $66 $— $— $— 
Net investment hedges$— $1,500 $1,500 $— $500 $500 
Undesignated hedging instruments
$610 $— $610 $588 $— $588 

Cash Flow Hedges

For the fiscal three and nine months ended September 29, 2024, the Company recorded a total after-tax change in Accumulated other comprehensive loss of $11 million and $(22) million, respectively, related to its cash flow hedge portfolio. For the fiscal three and nine months ended October 1, 2023, the Company recorded a total after-tax change in Accumulated other comprehensive loss of $(4) million and $27 million, respectively, related to its cash flow hedge portfolio.

Forward Foreign Exchange Contracts

In certain jurisdictions, the Company uses forward foreign exchange contracts to manage its exposures to the variability of foreign exchange rates. Changes in the fair value of derivatives are recorded each period in earnings or Other comprehensive income (loss), depending on whether the derivative is designated as part of a hedge transaction, and if so, the type of hedge transaction.

Since 2022, the Company has entered into forward foreign exchange contracts to hedge a portion of forecasted cash flows denominated in foreign currency. The terms of these contracts are generally 12 months to 18 months. These contracts are designated as cash flow hedging relationships at the date of contract inception, in accordance with the appropriate accounting guidance. At inception, all designated hedging relationships are expected to be highly effective. These contracts are accounted for using the forward method, and all gains/losses associated with these contracts are recorded in Other comprehensive income (loss). The Company reclassifies the gains and losses related to these contracts at the time the inventory is sold to the customer into Net sales or Cost of sales and Other (income) expense, net in the Condensed Consolidated Statements of Operations, as applicable.

The Company expects that substantially all of the amounts related to forward foreign exchange contracts will be reclassified into earnings over the next 12 months as a result of transactions that are expected to occur over that period. The maximum length of time over which the Company is hedging transaction exposure is 18 months. The amount ultimately realized in
34

earnings may differ as foreign exchange rates change. Realized gains and losses are ultimately determined by actual exchange rates at maturity of the derivative.

The following table is a summary of the gains and losses recognized on forward foreign exchange contracts designated as cash flow hedges within Other comprehensive income (loss) and the gains and losses reclassified into earnings:

Fiscal Three Months EndedFiscal Nine Months Ended
(Dollars in Millions)
September 29, 2024October 1, 2023September 29, 2024October 1, 2023
 Gain (loss) recognized in Other comprehensive income (loss)$14 $7 $(1)$7 
Gain reclassified from Other comprehensive income (loss) into earnings$— $11 $7 $16 

The following table is a summary of the gains and losses reclassified from Other comprehensive income (loss) into earnings related to the forward foreign exchange contracts for the fiscal three and nine months ended September 29, 2024 and October 1, 2023:

Fiscal Three Months Ended
September 29, 2024October 1, 2023
(Dollars in Millions)
Net sales
Cost of sales
Other (income) expense, net
Net sales
Cost of sales
Other (income) expense, net
(Loss) gain reclassified from Other comprehensive income (loss) into earnings$(1)$— $1 $— $11 $— 

Fiscal Nine Months Ended
September 29, 2024October 1, 2023
(Dollars in Millions)
Net sales
Cost of sales
Other (income) expense, net
Net sales
Cost of sales
Other (income) expense, net
(Loss) gain reclassified from Other comprehensive income (loss) into earnings$(1)$12 $(4)$— $18 $(2)

Forward Starting Interest Rate Swaps

Beginning in the fiscal three months ended January 1, 2023, the Company entered into forward starting interest rate swaps in contemplation of securing long-term financing for the Separation or for other long-term financing purposes in the event the Separation did not occur. The Company designated these derivatives as cash flow hedges to reduce future interest rate exposure related to changes in the benchmark interest rate on forecasted 5-year, 10-year, and 30-year bonds that the Company issued in 2023. During the fiscal nine months ended October 1, 2023, the Company recorded a gain of $48 million in Accumulated other comprehensive loss, of which $38 million was related to the settlement of its forward starting interest rate swaps upon the issuance of the forecasted debt. The $38 million gain in Accumulated other comprehensive loss will be amortized and recorded in Interest expense, net in the Condensed Consolidated Statements of Operations over the life of the 5-year, 10-year, and 30-year bonds. For the fiscal three and nine months ended September 29, 2024 and October 1, 2023, the amounts reclassified from Other comprehensive income (loss) to the Condensed Consolidated Statements of Operations were not significant.

Fair Value Hedges

Forward Foreign Exchange Contracts

Beginning in the fiscal three months ended March 31, 2024, the Company entered into forward foreign exchange contracts to hedge against the risk of changes in the fair value of foreign-denominated intercompany debt attributable to foreign exchange
35

rate fluctuations. These contracts are designated as fair value hedging relationships at the date of contract inception in accordance with the appropriate accounting guidance. At inception, all designated fair value hedging relationships are expected to be highly effective. The contracts are accounted for using the spot method with changes in the fair value of the contract attributable to the changes in spot rates recorded within Other (income) expense, net in the Condensed Consolidated Statements of Operations. The Company has elected to exclude the changes in the fair value attributable to the difference between the spot price and the forward price, as well as any cross currency basis spread, from the assessment of hedge effectiveness (the “Excluded Components”). The Excluded Components are excluded from the assessment of the hedge effectiveness. The value of the Excluded Components was not significant to the Condensed Consolidated Financial Statements in the current period. The changes in fair value attributable to the Excluded Components are recorded in Accumulated other comprehensive loss and are recognized in Other (income) expense, net in the Condensed Consolidated Statements of Operations on a systematic and rational basis over the life of the hedging instrument.

Net Investment Hedges

Forward Foreign Exchange Contracts

The Company designated certain forward foreign exchange contracts as net investment hedges to mitigate foreign exchange exposure related to non-U.S. dollar net investments in certain foreign subsidiaries against changes in foreign exchange rates.
During the fiscal three and nine months ended October 1, 2023, the Company designated forward foreign exchange contracts as a net investment hedge to sell foreign currency (denominated in the local currency of the affiliate) at specified forward rates. These contracts were accounted for using the spot method with changes in the fair value of the contracts attributable to changes in spot rates recorded within Cumulative Translation Adjustments (“CTA”) as a component of Other comprehensive income (loss). The Company has elected to exclude the changes in the fair value attributable to time value (the “Excluded Net Investment Hedge Components on Forward Foreign Exchange Contracts”) from the assessment of the hedge effectiveness. The changes in fair value attributable to the Excluded Net Investment Hedge Components on Forward Foreign Exchange Contracts were initially recorded within CTA as a component of Other comprehensive income (loss) and were recognized into Other (income) expense, net in the Condensed Consolidated Statements of Operations ratably over the life of the contract. The forward foreign exchange contracts designated as a net investment hedge were settled during the fiscal three months ended October 1, 2023.

Cross Currency Swap Contracts

During the fiscal three months ended December 31, 2023 and the fiscal three months ended March 31, 2024, the Company designated cross currency swap contracts as net investment hedges to hedge exposure in foreign subsidiaries with local functional currencies. These contracts were accounted for using the spot method with changes in the fair value of the contracts attributable to changes in spot rates recorded within CTA as a component of Other comprehensive income (loss) and will remain there until the hedged net investments are sold or substantially liquidated. The Company has elected to exclude the changes in the fair value attributable to time value and spot-forward rate differences (the “Excluded Net Investment Hedge Components on Cross Currency Swap Contracts”) from the assessment of the hedge effectiveness. The Excluded Net Investment Hedge Components on Cross Currency Swap Contracts associated with the net investment hedge entered into during the fiscal three months ended December 31, 2023 had an initial value of $7 million in the period of inception, and the Excluded Net Investment Hedge Components on Cross Currency Swap Contracts associated with the net investment hedge entered into during the fiscal three months ended March 31, 2024 had an initial value of $(7) million in the period of inception. The changes in fair value attributable to the Excluded Net Investment Hedge Components on Cross Currency Swap Contracts are recognized into Interest expense, net in the Condensed Consolidated Statements of Operations on a systematic and rational basis through the swap accrual over the life of the hedging instrument.

The following table is a summary of the gains and losses recognized within Other comprehensive income (loss) related to the cross currency swap contracts designated as net investment hedges:

Fiscal Three Months EndedFiscal Nine Months Ended
(Dollars in Millions)
September 29, 2024October 1, 2023September 29, 2024October 1, 2023
(Loss) gain recognized in CTA within Other comprehensive income (loss)$(76)$— $4 $— 

36

Other than amounts excluded from effectiveness testing, the Company did not reclassify any gains or losses from CTA within Other comprehensive income (loss) to earnings during the fiscal three and nine months ended September 29, 2024 and October 1, 2023 related to the cross currency swap contracts.

Undesignated Hedging Instruments

Undesignated Forward Foreign Exchange Contracts

Since 2022, the Company has entered into forward foreign exchange contracts to offset the foreign currency exposure related to the settlement of payables and receivables of the Company. These contracts are not designated as cash flow hedging relationships, and the net allocated gains and losses related to these contracts were recognized within Other (income) expense, net in the Condensed Consolidated Statements of Operations. As of September 29, 2024 and December 31, 2023, respectively, the Company held forward foreign exchange contracts that were not designated in cash flow hedging relationships with a fair value of $2 million and $4 million, respectively.

The following table is a summary of the gains and losses recognized within Other (income) expense, net related to the undesignated forward foreign exchange contracts for the fiscal three and nine months ended September 29, 2024 and October 1, 2023:

Fiscal Three Months EndedFiscal Nine Months Ended
(Dollars in Millions)
September 29, 2024October 1, 2023September 29, 2024October 1, 2023
Gain (loss) recognized in Other (income) expense, net$2 $(3)$(4)$1 

Effectiveness

On an ongoing basis, the Company assesses whether each derivative continues to be highly effective in offsetting changes of hedged items. When a derivative is no longer expected to be highly effective, hedge accounting is discontinued.

Statement of Cash Flows

Cash flows from derivatives designated in hedging relationships are reflected in the Condensed Consolidated Statements of Cash Flows consistent with the presentation of the hedged item. Cash flows from derivatives that were not accounted for as designated hedging relationships reflect the classification of the cash flows associated with the activities being economically hedged.

Credit Risk

The Company is exposed to the risk of credit loss in the event of nonperformance by counterparties to financial instrument contracts; however, nonperformance is considered unlikely and any nonperformance is unlikely to be material as it is the Company’s policy to contract with diverse, creditworthy counterparties based upon both strong credit ratings and other credit considerations. The Company has negotiated International Swaps and Derivatives Association, Inc. master agreements with its counterparties, which contain master netting provisions providing the legal right and ability to offset exposures across trades with each counterparty. Given the rights provided by these contracts, the Company presents derivative balances based on its “net” counterparty exposure. These agreements do not require the posting of collateral.

Investments in Equity Securities

The Company measures equity investments without readily determinable fair values at cost minus impairment, if any, plus or minus changes resulting from observable price changes in orderly transactions for the identical or a similar investment of the same issuer. As of September 29, 2024 and December 31, 2023, such investments totaled $41 million and $71 million, respectively, and were included in Other assets on the Condensed Consolidated Balance Sheets.

14. Commitments and Contingencies

The Company and/or certain of its subsidiaries are involved from time to time in various lawsuits and claims relating to product liability, labeling, marketing, advertising, pricing, intellectual property, commercial contracts, foreign exchange controls,
37

antitrust and trade regulation, labor and employment, indemnification, data privacy and security, environmental, health and safety, tax matters, governmental investigations, and other legal proceedings that arise in the ordinary course of their business.

The Company records accruals for loss contingencies associated with these legal matters when it is probable that a liability has been incurred, and the amount of the loss can be reasonably estimated. As of September 29, 2024, the Company has determined that the liabilities associated with certain litigation matters are probable and can be reasonably estimated. The Company has accordingly accrued for those contingent liabilities and will continue to monitor each related legal issue and adjust accruals as might be warranted based on new information and further developments. Accrued liabilities related to litigation matters are included in Accrued liabilities and Other liabilities on the Condensed Consolidated Balance Sheets. For these and other litigation and regulatory matters discussed below for which a loss is probable or reasonably possible, the Company is unable to estimate the possible loss or range of loss beyond the amounts accrued. Amounts accrued for legal contingencies often result from a complex series of judgments about future events and uncertainties that rely heavily on estimates and assumptions including timing of related payments. The ability to make such estimates and judgments can be affected by various factors including whether, among other things, damages sought in the proceedings are unsubstantiated or indeterminate; scientific and legal discovery has commenced or is complete; proceedings are in early stages; matters present legal uncertainties; significant facts are in dispute; procedural or jurisdictional issues exist; the number of potential claims is certain or predictable; comprehensive multi-party settlements are achievable; there are complex related cross-claims and counterclaims; and/or there are numerous parties involved.

In the Company’s opinion, based on its examination of these matters, its experience to date and discussions with counsel, the ultimate outcome of legal proceedings, net of liabilities accrued on the Condensed Consolidated Balance Sheets, is not expected to have a material adverse effect on the Company’s financial position. However, the resolution of, or increase in accruals for, one or more of these matters in any reporting period may have a material adverse effect on the Company’s results of operations and cash flows for that period.

Product Liability

The Company and/or certain of its subsidiaries are involved in numerous product liability claims and lawsuits involving multiple products. Claimants in these cases seek substantial compensatory and, where available, punitive damages. While the Company believes it has substantial defenses, it is not feasible to predict the ultimate outcome of litigation. From time to time, even if it has substantial defenses, the Company considers isolated settlements based on a variety of circumstances. The Company may accrue an estimate of the legal defense costs needed to defend each matter when those costs are probable and can be reasonably estimated. For certain of these matters, the Company may accrue additional amounts such as estimated costs associated with settlements, damages, and other losses. Product liability accruals can represent projected product liability for thousands of claims around the world, each in different litigation environments and with different fact patterns. Changes to the accruals may be required in the future as additional information becomes available.

Claims for personal injury have been made against the Company’s subsidiary Johnson & Johnson Consumer Inc. (“JJCI”), along with other third-party sellers of acetaminophen-containing products, in federal court alleging that in utero exposure to acetaminophen (the active ingredient in Tylenol®, an over-the-counter (“OTC”) pain medication) is associated with the development of autism spectrum disorder and/or attention-deficit/hyperactivity disorder in children. In October 2022, lawsuits filed in federal courts in the United States were organized as a multi-district litigation in the U.S. District Court for the Southern District of New York. In February 2024, the court entered final judgment in favor of JJCI and the other sellers of acetaminophen-containing products and dismissed the majority of cases then pending in the multi-district litigation. A Notice of Appeal was filed for those cases in March 2024. In August 2024, all remaining cases then pending in the multi-district litigation were dismissed. As of September 2024, all cases were on appeal. Product liability lawsuits continue to be filed, and the Company continues to receive information with respect to potential costs and the anticipated number of cases. In addition, lawsuits have been filed in state court against JJCI, the Company and J&J, and lawsuits have been filed in Canada against the Company’s subsidiary Johnson & Johnson Inc. (Canadian affiliate) (“JJI”) and J&J. At this stage in these proceedings, the Company is unable to reasonably estimate either the likelihood or the magnitude of its potential liability arising out of these claims and lawsuits.

General Litigation

In 2006, J&J acquired Pfizer’s OTC business including the U.S. rights to OTC Zantac, which were on-sold to Boehringer Ingelheim (“BI”) as a condition to merger control approval such that BI assumed product liability risk for U.S. sales from and after December 2006. J&J received indemnification from BI and gave Pfizer indemnification in connection with the transfer of the Zantac business to BI from Pfizer, through J&J. In November 2019, J&J received a demand for indemnification from Pfizer, pursuant to the 2006 Stock and Asset Purchase Agreement between J&J and Pfizer. In January 2020, J&J received a demand for
38

indemnification from BI, pursuant to the 2006 Asset Purchase Agreement among J&J, Pfizer, and BI. Pursuant to the agreements, Pfizer and BI have asserted indemnification claims against J&J ostensibly related to Zantac sales by Pfizer. In November 2022, J&J received a demand for indemnification from GlaxoSmithKline LLC, pursuant to the 2006 Stock and Asset Purchase Agreement between J&J and Pfizer, and certain 1993, 1998, and 2002 agreements between Glaxo Wellcome and Warner-Lambert entities. The notices seek indemnification for legal claims related to OTC Zantac (ranitidine) products. Plaintiffs in the underlying actions allege that Zantac and other OTC medications that contain ranitidine may degrade and result in unsafe levels of NDMA (N-nitrosodimethylamine) and can cause or have caused various cancers in individuals using the products and seek declaratory and monetary relief. J&J has rejected all the demands for indemnification relating to the underlying actions. No J&J entity sold Zantac in the United States.

In 2016, JJI sold the Canadian Zantac business to Sanofi Consumer Health, Inc. (“Sanofi”). Under the 2016 Asset Purchase Agreement between JJI and Sanofi (the “2016 Purchase Agreement”), Sanofi assumed certain liabilities including those pertaining to Zantac (ranitidine) product sold by Sanofi after closing and losses arising from or relating to recalls, withdrawals, replacements or related market actions or post-sale warning in respect of products sold by Sanofi after the closing, and JJI is required to indemnify Sanofi for certain other excluded liabilities. In November 2019, JJI received a notice reserving rights to claim indemnification from Sanofi pursuant to the 2016 Purchase Agreement. The notice refers to indemnification for legal claims in class actions and various individual personal injury actions with similar allegations to the U.S. litigation related to OTC Zantac (ranitidine) products.

J&J and/or JJI have also been named in two of the five outstanding putative class actions filed in Canada with similar allegations regarding Zantac or ranitidine use. Of the two outstanding putative class actions naming J&J and/or JJI, the Quebec Superior Court action has been stayed, and the Ontario Superior Court of Justice action is pending, but not currently active. JJI was also named as a defendant, along with other manufacturers, in various personal injury actions in Canada related to Zantac products. JJI has provided Sanofi notice reserving rights to claim indemnification pursuant to the 2016 Purchase Agreement related to the class actions and personal injury actions. At this stage in these proceedings, the Company is unable to reasonably estimate either the likelihood or the magnitude of its potential liability arising out of these claims and lawsuits.

Beginning in May 2021, multiple putative class actions were filed in state and federal courts (California, Florida, New York, and New Jersey) against various J&J entities alleging violations of state consumer fraud statutes based on nondisclosure of alleged benzene contamination of certain Neutrogena® and Aveeno® sunscreen products and the affirmative promotion of those products as “safe”; and, in at least one case, alleging strict liability manufacturing defect, and failure to warn claims, asserting that the named plaintiffs suffered unspecified injuries as a result of alleged exposure to benzene. The Judicial Panel on Multi-District Litigation consolidated all pending actions, except one case pending in New Jersey state court, in the U.S. District Court for the Southern District of Florida, Fort Lauderdale Division. In October 2021, an affiliate of the Company reached an agreement in principle for the settlement of a nationwide class, encompassing the claims of the consolidated actions, subject to approval by the Florida federal Court. In December 2021, plaintiffs in the consolidated actions filed a motion for preliminary approval of a nationwide class settlement. In February 2023, an order granting final approval of the settlement, certifying the settlement class and awarding attorney’s fees, was entered. A Notice of Appeal was filed in April 2023. In June 2024, the U.S. Court of Appeals for the Eleventh Circuit reversed the final approval order due to an intervening change in law and directed the lower court to reconsider the issues in light of recent appellate precedent.

In September 2023, the Nonprescription Drugs Advisory Committee (the “NDAC”) of the U.S. Food and Drug Administration (“FDA”) met to discuss new data on the effectiveness of orally administered phenylephrine (“PE”) and concluded that the current scientific data do not support that the recommended dosage of orally administered PE is effective as a nasal decongestant. Neither FDA nor the NDAC raised concerns about safety issues with use of oral PE at the recommended dose. FDA has stated it will consider the input of the NDAC, and the evidence, before taking any action on the status of oral PE. Beginning in September 2023, following the NDAC vote, putative class actions were filed against the Company and its affiliates, along with other third-party sellers and manufacturers of PE-containing products, asserting various causes of action including violation of consumer protection statutes, negligence and unjust enrichment. The complaints seek damages and injunctive relief. In December 2023, lawsuits filed in federal courts in the United States were organized as a multi-district litigation in the U.S. District Court for the Eastern District of New York. Separately, putative Canadian class actions were filed beginning in September 2023 against the Company’s affiliates, along with other third-party sellers and manufacturers of PE-containing products, alleging false, misleading representations, and seeking damages and declaratory relief based on similar causes of action.

Additionally, beginning in October 2023, two putative securities class actions were filed in the U.S. District Court for the District of New Jersey against the Company and certain of its officers, among other defendants. In December 2023, the two cases were consolidated as In re Kenvue Inc. Securities Litigation and a lead plaintiff was appointed. In March 2024, a consolidated amended complaint was filed that named the Company’s directors as defendants in addition to the defendants
39

named in the initial complaints. The consolidated amended complaint brings claims under the Securities Act of 1933, as amended. It alleges that the Company’s registration statements and prospectuses filed with the SEC in connection with the Kenvue IPO on Form S-1 and the Exchange Offer on Form S-4 contained misleading statements and omissions about PE. It seeks damages for all shareholders who acquired shares pursuant to the Kenvue IPO and the Exchange Offer registration statements and prospectuses.

Finally, in January 2024, shareholder derivative complaints were filed in the U.S. District Court for the District of New Jersey against the Company as the nominal defendant and the Company’s directors and certain of its officers as defendants, among other defendants. The derivative complaints allege breaches of fiduciary duties based on disclosures in the Company’s SEC filings regarding PE, and they seek damages and equitable relief. The derivative complaints have been consolidated as In re Kenvue, Inc. Derivative Litigation and have been stayed. At this stage in these proceedings, the Company is unable to reasonably estimate either the likelihood or the magnitude of its potential liability arising out of these claims and lawsuits.

In March 2024, following the filing of a Citizen Petition with FDA by Valisure LLC that included testing results purporting to show that benzoyl peroxide (“BPO”) OTC acne products can degrade into benzene at levels well above the alleged limit of two parts per million, putative class actions were filed against the Company and its affiliates, along with other third-party sellers and manufacturers of BPO-containing acne products, asserting various causes of action including violation of consumer protection statutes, negligence, breach of express and implied warranties, and unjust enrichment. The complaints, pending in the U.S. District Court for the District of New Jersey, seek damages and injunctive relief. At this stage in these proceedings, the Company is unable to reasonably estimate either the likelihood or the magnitude of its potential liability arising out of these claims and lawsuits.

JJCI, along with more than 120 other companies, is a defendant in a cost recovery and action brought by Occidental Chemical Corporation in June 2018 in the U.S. District Court for the District of New Jersey, related to the clean-up of a section of the Lower Passaic River in New Jersey. Certain defendants (not including JJCI) have executed a settlement with the U.S. Environmental Protection Agency and U.S. Department of Justice, which is subject to confirmation through a judicial Consent Decree approval action that is currently pending. The case has been administratively closed but can be re-opened upon request, following a decision on the Consent Decree.

The Company or its subsidiaries are also parties to various proceedings brought under the Comprehensive Environmental Response, Compensation, and Liability Act, commonly known as Superfund, and comparable state, local, or foreign laws in which the primary relief sought is the Company’s agreement to implement remediation activities at designated hazardous waste sites or to reimburse the government or third parties for the costs they have incurred in performing remediation at such sites.

Other

A significant number of personal injury claims alleging that talc causes cancer were made against J&J and certain of its affiliates arising out of the use of body powders containing talc, primarily Johnson’s® Baby Powder. These personal injury suits were filed primarily in state and federal courts in the United States and in Canada.

Pursuant to the Separation Agreement, J&J has retained all liabilities on account of or relating to harm arising out of, based upon or resulting from, directly or indirectly, the presence of or exposure to talc or talc-containing products sold by J&J or its affiliates in the United States and Canada (the “Talc-Related Liabilities”) and, as a result, has agreed to indemnify the Company for the Talc-Related Liabilities and any costs associated with resolving such claims. The Company will, however, remain responsible for all liabilities on account of or relating to harm arising out of, based upon or resulting from, directly or indirectly, the presence of or exposure to talc or talc-containing products sold outside the United States or Canada.

15. Segments of Business

The Company historically operated as part of J&J and reported under J&J’s segment structure. Prior to the Separation, the Company’s CODM was J&J’s Consumer Health Segment Operating Committee. As the Company transitioned into an independent, publicly traded company, the Company’s CODM was determined to be the chief executive officer.

Segment profit is based on Operating income, excluding depreciation, amortization of intangible assets, Separation-related costs, restructuring and operating model optimization initiatives, impairment charges, the impact of the conversion of stock-based awards, issuance of Founder Shares (as defined below), Other operating expense (income), net, and unallocated general corporate administrative expenses (referred to herein as “Segment adjusted operating income”), as management excludes these items in assessing segment financial performance. General corporate/unallocated expenses, which include expenses related to treasury, legal operations, and certain other expenses, along with gains and losses related to the overall management of the
40

Company, are not allocated to the segments. In assessing segment performance and managing operations, management does not review segment assets.

The Company operates the business through the following three reportable business segments:

Reportable SegmentsProduct Categories
Self Care
Cough, Cold, and Allergy
Pain Care
Other Self Care (Digestive Health, Smoking Cessation, Eye Care, and Other)
Skin Health and BeautyFace and Body Care
Hair, Sun, and Other
Essential HealthOral Care
Baby Care
Other Essential Health (Women’s Health, Wound Care, and Other)

The Company’s product categories as a percentage of Net sales for the fiscal three and nine months ended September 29, 2024 and October 1, 2023 were as follows:

Fiscal Three Months EndedFiscal Nine Months Ended
Product Categories
September 29, 2024October 1, 2023September 29, 2024October 1, 2023
Cough, Cold, and Allergy13 %13 %14 %14 %
Pain Care 14 14 13 13 
Other Self Care 15 14 15 15 
Face and Body Care20 21 19 20 
Hair, Sun, and Other
7 8 9 9 
Oral Care11 10 10 10 
Baby Care9 9 9 9 
Other Essential Health11 11 11 10 
Total100 %100 %100 %100 %

Segment Net Sales and Segment Adjusted Operating Income

Segment net sales and Segment adjusted operating income for the fiscal three and nine months ended September 29, 2024 and October 1, 2023 were as follows:

Segment Net Sales
Fiscal Three Months EndedFiscal Nine Months Ended
(Dollars in Millions)September 29, 2024October 1, 2023September 29, 2024October 1, 2023
Self Care$1,625 $1,613 $4,958 $4,914 
Skin Health and Beauty1,072 1,119 3,229 3,377 
Essential Health1,202 1,183 3,606 3,487 
Total net sales
$3,899 $3,915 $11,793 $11,778 

41

Segment Adjusted Operating Income
Fiscal Three Months EndedFiscal Nine Months Ended
(Dollars in Millions)September 29, 2024October 1, 2023September 29, 2024October 1, 2023
Self Care$557 $604 $1,692 $1,762 
Skin Health and Beauty191 180 502 530 
Essential Health291 275 914 736 
Segment adjusted operating income(1)(2)
$1,039 $1,059 $3,108 $3,028 
Reconciliation to Income before taxes
Less:
Depreciation(3)
94 72 238 211 
Amortization of intangible assets
66 81 212 242 
Separation-related costs
85 133 231 333 
Restructuring and operating model optimization initiatives38 3 146 3 
Impairment charges
— — 578 — 
Conversion of stock-based awards(4)
6 (25)34 (25)
Founder Shares(5)
7 — 24 — 
Other operating expense (income), net7 9 29 (7)
General corporate/unallocated expenses82 76 258 219 
Operating income$654 $710 $1,358 $2,052 
Other (income) expense, net(19)25 6 65 
Interest expense, net
96 100 283 154 
Income before taxes$577 $585 $1,069 $1,833 
(1) Effective in the fiscal three months ended September 29, 2024, the Company adjusted the allocation for certain brand marketing expenses within Selling, general, and administrative expenses to align with segment financial results as measured by the Company, including the CODM. Accordingly, the Company has updated its segment disclosures to reflect the updated presentation in all prior periods. Total Adjusted operating income did not change as a result of this update.
(2) Effective in the fiscal three months ended June 30, 2024, the Company adjusted the allocation for certain Research and development costs within Selling, general, and administrative expenses to align with segment financial results as measured by the Company, including the CODM. Accordingly, the Company has updated its segment disclosures to reflect the updated presentation in all prior periods. Total Adjusted operating income did not change as a result of this update.
(3) Depreciation includes the amortization of integration and development costs capitalized in connection with cloud computing arrangements.
(4) Segment adjusted operating income excludes the impact of the conversion of stock-based awards that occurred on August 23, 2023. The adjustment represents the net impact of the gain on reversal of previously recognized stock-based compensation expense, offset by stock-based compensation expense recognized in the fiscal three and nine months ended September 29, 2024 relating to employee services provided prior to the Separation.
(5) On August 25, 2023, the Company’s Compensation & Human Capital Committee approved equity grants to individuals employed by Kenvue as of October 2, 2023 (the “Founder Shares”). On October 2, 2023, the Founder Shares were granted to all Kenvue employees in the form of stock options and PSUs to executive officers and either stock options and PSUs or RSUs to non-executive individuals.

16. Restructuring Expenses and Operating Model Optimization Initiatives

As part of the Company’s continued transformation to a fit-for-purpose consumer company, in the fiscal year 2024, the Company began to take steps intended to enhance organizational efficiencies and better position Kenvue for future growth. On May 6, 2024, the Company’s Board of Directors approved a multi-year initiative (the “2024 Multi-Year Restructuring Initiative”) to build on the Company’s strengths and optimize its cost structure by rebalancing resources to better position the Company for future growth. These initiatives primarily include global workforce reductions, changes in management structure, and the transition to centralized shared-service functions in lower-cost locations.

42

The 2024 Multi-Year Restructuring Initiative is expected to result in pre-tax restructuring expenses and other charges totaling approximately $550 million, consisting of IT and project-related costs (approximately 50%), employee-related costs (approximately 40%), and other implementation costs (approximately 10%). These charges are expected to be funded primarily through cash flows generated from operations. The Company planned to incur approximately $275 million in pre-tax restructuring expenses and other charges in each of fiscal year 2024 and fiscal year 2025. The Company currently anticipates lower than expected spend in fiscal year 2024 due to the shift in timing of certain IT and project-related costs to fiscal year 2025 and lower than expected employee-related costs relating to severance spend due to employee redeployment and voluntary exits.

Certain costs incurred associated with the restructuring activities related to the 2024 Multi-Year Restructuring Initiative, including one-time termination benefits and employee-related costs, are accounted for in accordance with Accounting Standards Codification Topic 420, Exit or Disposal Cost Obligations. The Company recognizes a liability and the related expense for these restructuring costs when the liability is incurred and can be measured. The related expense for these restructuring costs is recorded in the Restructuring expenses line item in the Condensed Consolidated Statements of Operations. Other charges are recorded in the Cost of sales or Selling, general, and administrative expenses line items in the Condensed Consolidated Statements of Operations, as applicable. Segment profit is based on Operating income and management excludes restructuring expenses and other charges associated with the 2024 Multi-Year Restructuring Initiative in assessing segment financial performance.

The following table summarizes the classification of pre-tax restructuring expenses and other charges incurred related to the 2024 Multi-Year Restructuring Initiative during the fiscal three and nine months ended September 29, 2024:

Fiscal Three Months EndedFiscal Nine Months Ended
(Dollars in Millions)September 29, 2024September 29, 2024
Restructuring expenses
$31 $120 
Cost of sales
4 19 
Selling, general, and administrative expenses
3 7 
Total pre-tax restructuring expenses and other charges
$38 $146 

The following table summarizes the pre-tax restructuring expenses and other charges incurred by cost type related to the 2024 Multi-Year Restructuring Initiative during the fiscal three and nine months ended September 29, 2024 and inception to date through September 29, 2024:

Fiscal Three Months EndedFiscal Nine Months Ended
Inception To Date Through September 29, 2024
(Dollars in Millions)September 29, 2024September 29, 2024
Employee-related costs(1)
$17 $81 $81 
IT and project-related costs(2)
18 49 49 
Other implementation costs(3)
3 16 16 
Total pre-tax restructuring expenses and other charges
$38 $146 $146 
(1) Employee-related costs primarily include severance and other termination benefits.
(2) IT and project-related costs primarily include advisory costs to operationalize the initiative.
(3) Other implementation costs primarily include costs to terminate contracts, impairments of assets, and other associated costs to exit.

43

The following table summarizes the activity related to accrued restructuring expenses and other charges for the 2024 Multi-Year Restructuring Initiative during the fiscal nine months ended September 29, 2024:

Accrued Restructuring Expenses and Other Charges
(Dollars in Millions)
Employee-related Costs(1)
IT and Project-Related Costs(2)
Other Implementation Costs(3)
Total Costs
Accrued restructuring expenses and other charges as of December 31, 2023
$— $— $— $— 
Charges to earnings
81 49 16 146 
Cash payments
(45)(19)(6)(70)
Non-cash charges
— — (6)(6)
Accrued restructuring expenses and other charges as of September 29, 2024
$36 $30 $4 $70 
(1) Employee-related costs primarily include severance and other termination benefits.
(2) IT and project-related costs primarily include advisory costs to operationalize the initiative.
(3) Other implementation costs primarily include costs to terminate contracts, impairments of assets, and other associated costs to exit.

44

Item 2. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS
This discussion contains forward-looking statements that involve risks and uncertainties. The forward-looking statements are not historical facts, but rather are based on current expectations, estimates, assumptions, and projections about our industry, business, and future financial results. Our actual results could differ materially from the results contemplated by these forward-looking statements due to a number of factors, including those discussed in the section entitled “Risk Factors” in our Annual Report on Form 10-K for the fiscal twelve months ended December 31, 2023 filed on March 1, 2024 with the SEC (the “Annual Report”) and the section entitled “Cautionary Note Regarding Forward-Looking Statements” included herein.

This discussion should be read in conjunction with our accompanying Condensed Consolidated Financial Statements as of September 29, 2024 and for the fiscal three and nine months ended September 29, 2024 and October 1, 2023, which have been prepared in accordance with U.S. GAAP and the rules and regulations of the SEC for interim financial statements, and our audited consolidated financial statements for the fiscal twelve months ended December 31, 2023, which are included in the Annual Report. In our opinion, the Condensed Consolidated Financial Statements reflect all adjustments, consisting of normal and recurring adjustments, necessary for a fair statement of the financial condition, results of operations, and cash flows for the periods indicated. All currency amounts are expressed in U.S. dollars unless otherwise noted.

Overview

Company Overview

At Kenvue, our purpose is to realize the extraordinary power of everyday care. As a global leader at the intersection of healthcare and consumer goods, we are the world’s largest pure-play consumer health company by revenue with $15.4 billion in Net sales in 2023. By combining the power of science with meaningful human insights and digital-first approach, we empower consumers to live healthier lives every day. Trusted by generations, our differentiated portfolio of iconic brands—including Tylenol®, Neutrogena®, Listerine®, Johnson’s®, BAND-AID® Brand, Aveeno®, Zyrtec®, and Nicorette®—is backed by science and recommended by healthcare professionals, which further reinforces our consumers’ connections to our brands.

Our portfolio includes Self Care, Skin Health and Beauty, and Essential Health products, allowing us to connect with consumers globally—in their daily rituals and the moments that matter most.

Our global scale and the breadth of our brand portfolio are complemented by our well-developed capabilities and accelerated through our digital-first approach, allowing us to dynamically capitalize on and respond to current trends impacting our categories and geographic markets.

With a sole focus on consumer health, our marketing organization operates efficiently by leveraging our precision marketing, e-commerce, and broader digital capabilities to develop unique consumer insights and further enhance the relevance of our brands. Similarly, our research and development organization combines these consumer insights with deep, multi-disciplinary scientific expertise, and engagement with healthcare professionals, to drive innovative new products, solutions, and experiences centered around consumer health.

Our Business Segments

We operate our business through the following three reportable business segments:

•Self Care. Our Self Care product categories include: Pain Care; Cough, Cold, and Allergy; and Other Self Care (Digestive Health, Smoking Cessation, Eye Care, and Other). Major brands in the segment include Tylenol®, Motrin®, Nicorette®, Benadryl®, Zyrtec®, Zarbee’s®, ORSLTM, Rhinocort®, and Calpol®.
•Skin Health and Beauty. Our Skin Health and Beauty product categories include: Face and Body Care; and Hair, Sun, and Other. Major brands in the segment include Neutrogena®, Aveeno®, Dr.Ci:Labo®, OGX®, Le Petit Marseillais®, Lubriderm®, and Rogaine®.
•Essential Health. Our Essential Health product categories include: Oral Care; Baby Care; and Other Essential Health (Women’s Health, Wound Care, and Other). Major brands in the segment include Listerine®, Johnson’s®, BAND-AID® Brand, Stayfree®, o.b.® tampons, Carefree®, and Desitin®.

45

For additional information about our three reportable business segments, see “—Key Factors Affecting Our Results—Our Brands and Product Portfolio” and Note 15, “Segments of Business,” to the Condensed Consolidated Financial Statements included herein.

Separation from Johnson & Johnson

In November 2021, Johnson & Johnson (“J&J”), our former parent company, announced its intention to separate its Consumer Health segment (the “Consumer Health Business”) into an independent publicly traded company (the “Separation”). Kenvue was incorporated in Delaware in February 2022, as a wholly owned subsidiary of J&J, to serve as the ultimate parent company of J&J’s Consumer Health Business. In April 2023, J&J completed the transfer of substantially all of the assets and liabilities of the Consumer Health Business to us and our subsidiaries. In May 2023, we completed an initial public offering (the “Kenvue IPO”) of approximately 10.4% of our outstanding common stock and began trading on the New York Stock Exchange under the ticker symbol “KVUE.” Following the Kenvue IPO, J&J owned approximately 89.6% of our outstanding common stock. In July 2023, J&J announced an exchange offer (the “Exchange Offer”) under which its shareholders could exchange shares of J&J common stock for shares of our common stock owned by J&J. In August 2023, J&J completed the Exchange Offer and exchanged shares representing approximately 80.1% of our common stock, completing the Separation from J&J and transition to being a fully independent public company. In May 2024, J&J completed an additional exchange offer (the “Debt for Equity Exchange”) through which J&J exchanged indebtedness of J&J for shares of our common stock owned by J&J. Following the completion of the Debt for Equity Exchange, J&J no longer owned any shares of our common stock.

See Note 1, “Description of the Company and Summary of Significant Accounting Policies—Description of the Company and Business Segments,” to the Condensed Consolidated Financial Statements for additional information.

We are incurring certain non-recurring separation-related costs in connection with our establishment as a standalone public company (the “Separation-related costs”). We expect the Separation-related costs will continue through the first half of fiscal year 2025. For additional information about the Separation, see Note 1, “Description of the Company and Summary of Significant Accounting Policies,” and Note 9, “Relationship with J&J,” to the Condensed Consolidated Financial Statements included herein.

Relationship with J&J

We have entered into the Separation Agreement and various other agreements with J&J for the purpose of effecting the Separation. These agreements provide a framework for our relationship with J&J and govern various interim and ongoing relationships between us and J&J that follow the completion of the Kenvue IPO. See Note 9, “Relationship with J&J,” to the Condensed Consolidated Financial Statements included herein for additional information on these agreements.

Kenvue Global Headquarters

On April 20, 2023, we entered into a long-term lease for a newly renovated corporate office building and a newly constructed research and development building in Summit, New Jersey (the “Global Headquarters Lease”). When completed, the campus will encompass approximately 290,000 square feet and serve as our new global corporate headquarters and research and development center. The Global Headquarters Lease collectively includes the lease associated with the corporate office building (the “Corporate Office Lease”), the lease associated with the land where the research and development building will be constructed (the “State-of-the-Art Lab Facility Lease”), and the lease associated with land to be used for amenities (the “Amenities Lease”). The relocation to this campus is expected to occur in 2025 for the corporate office building and continue through 2026 for the new research and development building. We will continue operating from our interim corporate headquarters in Skillman, New Jersey, until that time.

On February 21, 2024, we listed our interim corporate headquarters in Skillman, New Jersey for sale, which met the criteria to be classified as held for sale at that date. For the fiscal three months ended March 31, 2024, an impairment charge of $68 million was recorded on the held for sale asset associated with the interim corporate headquarters in Skillman. See Note 1, “Description of the Company and Summary of Significant Accounting Policies—Assets Held for Sale,” to the Condensed Consolidated Financial Statements included herein for more information.

Key Factors Affecting Our Results

We believe that our performance and future success depend on a number of factors that present significant opportunities for us but also pose risks and challenges, including those discussed below and in the section entitled “Risk Factors” in our Annual Report.
46

Our Brands and Product Portfolio

We have a world-class, global portfolio of iconic and modern brands, and for over 135 years, we have been making and investing in consumer products that are trusted by generations of consumers. Our business is balanced and resilient with leading brands across categories and geographic markets. Our brands are widely recognized and represent a combination of global powerhouses and regional brands, many of which hold leading positions in their respective categories. Our brands are built for moments that uniquely matter; these moments of care create an emotional connection to our products that creates deep bonds between consumers and our brands.

Consumers, customers, and third-party partners value and trust the reputation, reliability, and status of our brands and the quality, performance, and functionality of our products, and we believe there are significant opportunities to further increase our category and brand penetration by continuing to deepen our brand relevance and salience across our portfolio, continually earning a place for our products in consumers’ hearts and homes.

Increased Competition

Our products are sold in a highly competitive global marketplace, which, in recent years, has experienced increased retail trade concentration, the emergence of retail buying alliances, the rapid growth of e-commerce, and the integration of traditional and digital operations at key retail trade customers. One of our customers accounted for approximately 12% of our total Net sales for both the fiscal three and nine months ended September 29, 2024 and approximately 12% and 13% of our total Net sales for the fiscal three and nine months ended October 1, 2023, respectively. Our top 10 customers represented approximately 38% and 41% of our total Net sales for the fiscal three and nine months ended September 29, 2024, respectively, and approximately 40% and 42% of our total Net sales for the fiscal three and nine months ended October 1, 2023, respectively. As a result of these trends, certain large-format retail trade customers have significant bargaining strength and represent a significant portion of our total Net sales.

Macroeconomic Trends

Global economic challenges, including the impact from acts of war, military actions, terrorist attacks, or civil unrest, such as the ongoing military conflict between Russia and Ukraine (the “Russia-Ukraine War”) or the ongoing conflict in the Middle East, may continue to cause economic uncertainty and volatility. The impact of these issues may adversely affect prevailing economic conditions and our business, results of operations, or financial condition.

Russia-Ukraine War

Although the long-term implications of the Russia-Ukraine War are difficult to predict at this time, the financial impact of the conflict during the fiscal nine months ended September 29, 2024 and October 1, 2023 was not significant to our results of operations. For both the fiscal three and nine months ended September 29, 2024 and both the fiscal three and nine months ended October 1, 2023, our Ukrainian business represented 0.2% of our Net sales. As of both September 29, 2024 and December 31, 2023, our Ukrainian business represented 0.1% of our assets. For both the fiscal three and nine months ended September 29, 2024 and both the fiscal three and nine months ended October 1, 2023, our Russian business represented 1.0% of our Net sales. As of both September 29, 2024 and December 31, 2023, our Russian business represented 0.7% of our assets.

In the fiscal three months ended April 3, 2022, we announced our decision to suspend supply of all of our products into Russia other than our over-the-counter medicines within our Self Care segment, which we continued to supply as patients rely on many of these products for healthcare purposes. Supply of the suspended products terminated during the fiscal three months ended July 3, 2022. We also suspended all advertising, all clinical trials, and any additional investment in Russia. We will continue to monitor the geopolitical situation in Russia and evaluate our activities and future operations in Russia.

Acquisitions and Divestitures

We did not complete any significant acquisitions or divestitures during the fiscal three and nine months ended September 29, 2024 and October 1, 2023.

Legal Proceedings

See Note 14, “Commitments and Contingencies,” to the Condensed Consolidated Financial Statements included herein for additional information regarding our current legal proceedings.
47

Restructuring

On May 6, 2024, our Board of Directors (our “Board”) approved a multi-year initiative (the “2024 Multi-Year Restructuring Initiative”) to build on our strengths and optimize our cost structure by rebalancing resources to better position us for future growth. These initiatives primarily include global workforce reductions, changes in management structure, and the transition to centralized shared-service functions in lower-cost locations. See Note 16, “Restructuring Expenses and Operating Model Optimization Initiatives,” to the Condensed Consolidated Financial Statements included herein for further information.

Results of Operations

Fiscal Three Months Ended September 29, 2024 Compared with Fiscal Three Months Ended October 1, 2023

Our results for the fiscal three months ended September 29, 2024 and October 1, 2023 were as follows:

Fiscal Three Months Ended
Change In Fiscal Period
September 29, 2024October 1, 2023
Change 2023 to 2024
(Dollars in Millions)AmountPercent
Net sales$3,899 $3,915 $(16)(0.4)%
Cost of sales1,617 1,665 (48)(2.9)
Gross profit2,282 2,250 32 1.4 
Selling, general, and administrative expenses1,590 1,531 59 3.9 
Restructuring expenses31 — 31 *
Other operating expense, net7 9 (2)(22.2)
Operating income654 710 (56)(7.9)
Other (income) expense, net(19)25 (44)*
Interest expense, net96 100 (4)(4.0)
Income before taxes577 585 (8)(1.4)
Provision for taxes194 147 47 32.0 
Net income$383 $438 $(55)(12.6)%
* Calculation not meaningful.

Net Sales

Net sales were $3.9 billion for both the fiscal three months ended September 29, 2024 and October 1, 2023. For the fiscal three months ended September 29, 2024, Net sales decreased $16 million, or 0.4%, as compared to the fiscal three months ended October 1, 2023. Excluding the impact of unfavorable changes in foreign currency exchange rates of $50 million, or 1.3%, Organic growth was $34 million, or 0.9%. Changes in both Net sales and Organic growth were primarily attributable to value realization (defined as price, including mix) of 2.5%, partially offset by volume-related decreases of 1.6%. The increase in year-over-year value realization was primarily due to carryover price increases from the prior fiscal year as well as new pricing actions, while the volume-related decrease was primarily due to results in Skin Health and Beauty and Self Care, partially offset by growth in Essential Health. Net sales and Organic growth were primarily driven by growth in Essential Health across all product categories, led by Oral Care, and growth in Self Care primarily driven by Smoking Cessation and Cough and Cold. This was partially offset by sales declines in Skin Health and Beauty due to competitive pressures and slower than anticipated recovery from prior fiscal year execution challenges. For additional information about the Net sales of our three reportable business segments, see “—Segment Results” below.

Cost of Sales

Cost of sales were $1.6 billion and $1.7 billion for the fiscal three months ended September 29, 2024 and October 1, 2023, respectively, a decrease of $48 million, or 2.9%. Gross profit margin expanded 100 basis points to 58.5% for the fiscal three months ended September 29, 2024 as compared to 57.5% for the fiscal three months ended October 1, 2023. Changes in both Cost of sales and gross profit margin were primarily due to gains attributable to the realization of benefits associated with our supply chain optimization initiatives, and gross profit margin was also impacted by value realization.

48

Selling, General, and Administrative Expenses

Selling, general, and administrative expenses were $1.6 billion and $1.5 billion for the fiscal three months ended September 29, 2024 and October 1, 2023, respectively, an increase of $59 million, or 3.9%. Selling, general, and administrative expenses as a percentage of Net sales increased 170 basis points to 40.8% for the fiscal three months ended September 29, 2024 as compared to 39.1% for the fiscal three months ended October 1, 2023, primarily attributable to higher brand marketing expenses, driven by increased investment to support sales across segments and geographies. These cost increases were partially offset by initial savings from the 2024 Multi-Year Restructuring Initiative and a $59 million decrease in Separation-related costs.

Restructuring Expenses

Restructuring expenses were $31 million for the fiscal three months ended September 29, 2024, driven by costs incurred under the 2024 Multi-Year Restructuring Initiative related to global workforce reductions, changes in management structure, and the transition to centralized shared-service functions in lower-cost locations, as we take steps intended to enhance organizational efficiencies and better position Kenvue for future growth. See Note 16, “Restructuring Expenses and Operating Model Optimization Initiatives,” to the Condensed Consolidated Financial Statements included herein for additional information.

Other Operating Expense, Net

Other operating expense, net was $7 million and $9 million for the fiscal three months ended September 29, 2024 and October 1, 2023, respectively, a decrease of $2 million. See Note 10, “Other Operating Expense (Income), Net and Other (Income) Expense, Net,” to the Condensed Consolidated Financial Statements included herein for additional information.

Other (Income) Expense, Net

Other (income) expense, net was $(19) million and $25 million for the fiscal three months ended September 29, 2024 and October 1, 2023, respectively, a change of $44 million. The decrease in expense was primarily driven by a $22 million decrease in currency losses on transactions and a $21 million gain recognized on the release of tax indemnification reserves that were no longer considered to be probable. See Note 10, “Other Operating Expense (Income), Net and Other (Income) Expense, Net,” to the Condensed Consolidated Financial Statements included herein for additional information.

Interest Expense, Net

Interest expense, net was $96 million and $100 million for the fiscal three months ended September 29, 2024 and October 1, 2023 respectively, a decrease of $4 million. Interest expense in both fiscal periods was primarily comprised of interest expense recognized on the Senior Notes and notes issued under the Commercial Paper Program (as defined in Note 4, “Borrowings,” to the Condensed Consolidated Financial Statements included herein; see Note 4 for additional information).

Provision For Taxes

Provision for taxes was $194 million and $147 million for the fiscal three months ended September 29, 2024 and October 1, 2023, respectively, an increase of $47 million. The increase in provision for taxes was primarily due to changes to the jurisdictional mix of income and shortfall on stock-based compensation recorded during the fiscal three months ended September 29, 2024, as well as fewer releases of tax reserves due to the expiration of certain statutes of limitations and reduced tax benefits derived from the Separation as compared to the fiscal three months ended October 1, 2023. In addition, the worldwide effective income tax rates for the fiscal three months ended September 29, 2024 and October 1, 2023 were 33.6% and 25.1%, respectively. See Note 11, “Income Taxes,” to the Condensed Consolidated Financial Statements included herein for additional information.

Segment Results

Segment profit is based on Operating income, excluding depreciation, amortization of intangible assets, Separation-related costs, restructuring and operating model optimization initiatives, impairment charges, the impact of the conversion of stock-based awards, issuance of Founder Shares (as defined below), Other operating expense (income), net, and unallocated general corporate administrative expenses (referred to herein as “Segment adjusted operating income”), as management excludes these items in assessing segment financial performance. General corporate/unallocated expenses, which include expenses related to treasury, legal operations, and certain other expenses, along with gains and losses related to the overall management of our Company, are not allocated to the segments. In assessing segment performance and managing operations, management does not review segment assets.
49


See Note 15, “Segments of Business,” to the Condensed Consolidated Financial Statements included herein for additional information.

50

Fiscal Three Months Ended September 29, 2024 Compared with Fiscal Three Months Ended October 1, 2023

The following table presents Segment net sales and Segment adjusted operating income and the period-over-period changes in Segment net sales and Segment adjusted operating income for the fiscal three months ended September 29, 2024 and October 1, 2023. See Note 15, “Segments of Business,” to the Condensed Consolidated Financial Statements included herein for further details regarding Segment net sales and Segment adjusted operating income.

Fiscal Three Months EndedChange In Fiscal Period
September 29, 2024October 1, 2023
Change 2023 to 2024
(Dollars in Millions)AmountPercentAmountPercentAmountPercent
Segment Net Sales
Self Care$1,625 41.7 %$1,613 41.2 %$12 0.7 %
Skin Health and Beauty1,072 27.5 1,119 28.6 (47)(4.2)
Essential Health1,202 30.8 1,183 30.2 19 1.6 
Segment net sales
$3,899 100.0 %$3,915 100.0 %$(16)(0.4)%
Self Care$557 $604 $(47)(7.8)%
Skin Health and Beauty191 180 11 6.1 
Essential Health291 275 16 5.8 
Segment adjusted operating income(1)(2)
$1,039 $1,059 $(20)(1.9)%
Reconciliation to Income before taxes:
Less:
Depreciation(3)
94 72 
Amortization of intangible assets
66 81 
Separation-related costs
85 133 
Restructuring and operating model optimization initiatives38 3 
Conversion of stock-based awards(4)
6 (25)
Founder Shares(5)
7 — 
Other operating expense, net7 9 
General corporate/unallocated expenses82 76 
Operating income$654 $710 
Other (income) expense, net(19)25 
Interest expense, net96 100 
Income before taxes$577 $585 
(1) Effective in the fiscal three months ended September 29, 2024, we adjusted the allocation for certain brand marketing expenses within Selling, general, and administrative expenses to align with segment financial results as measured by the Company, including the chief operating decision maker (the “CODM”). Accordingly, we have updated the segment disclosures to reflect the updated presentation in all prior periods. Total Adjusted operating income did not change as a result of this update.
(2) Effective in the fiscal three months ended June 30, 2024, we adjusted the allocation for certain Research and development costs within Selling, general, and administrative expenses to align with segment financial results as measured by the Company, including the CODM. Accordingly, we have updated the segment disclosures to reflect the updated presentation in all prior periods. Total Adjusted operating income did not change as a result of this update.
(3) Depreciation includes the amortization of integration and development costs capitalized in connection with cloud computing arrangements.
(4) Segment adjusted operating income excludes the impact of the conversion of stock-based awards that occurred on August 23, 2023. The adjustment represents the net impact of the gain on reversal of previously recognized stock-based compensation expense, offset by stock-based compensation expense recognized in the fiscal three months ended September 29, 2024 relating to employee services provided prior to the Separation.
(5) On August 25, 2023, our Compensation & Human Capital Committee approved equity grants to individuals employed by Kenvue as of October 2, 2023 (the “Founder Shares”). On October 2, 2023, the Founder Shares were granted to all Kenvue employees in the form of stock options and PSUs to executive officers and either stock options and PSUs or RSUs to non-executive individuals.

51

Organic Growth

We assess our Net sales performance by measuring Organic growth, a non-GAAP financial measure, which measures the period-over-period change in Net sales excluding the impact of changes in foreign currency exchange rates and the impact of acquisitions and divestitures. Management believes Organic growth provides investors with additional, supplemental information that they may find useful in assessing our results of operations by excluding the impact of certain items that we believe do not directly reflect our underlying operations.

The following tables present a reconciliation of the change in U.S. GAAP Net sales to Organic growth for the fiscal three months ended September 29, 2024 as compared to the fiscal three months ended October 1, 2023:

Fiscal Three Months Ended September 29, 2024 vs October 1, 2023(1)
Reported Net sales change Impact of foreign currencyOrganic growth
(Dollars in Millions)AmountPercentAmountAmountPercent
Self Care$12 0.7 %$1 $11 0.7 %
Skin Health and Beauty(47)(4.2)(17)(30)(2.7)
Essential Health19 1.6 (34)53 4.5 
Total$(16)(0.4)%$(50)$34 0.9 %

Fiscal Three Months Ended September 29, 2024 vs October 1, 2023(1)
Reported Net sales changeImpact of foreign currencyOrganic growth
Price/Mix(2)
Volume
Self Care0.7 %— %1.8 %(1.1)%
Skin Health and Beauty(4.2)(1.5)2.0 (4.7)
Essential Health1.6 (2.9)3.7 0.8 
Total(0.4)%(1.3)%2.5 %(1.6)%
(1) Acquisitions and divestitures did not materially impact Net sales for the fiscal three months ended September 29, 2024 or October 1, 2023.
(2) Also referred to as value realization.

Self Care Segment

Self Care Segment Net Sales

The Self Care Segment Net sales were $1.6 billion for both the fiscal three months ended September 29, 2024 and October 1, 2023. For the fiscal three months ended September 29, 2024, Net sales increased $12 million, or 0.7%, as compared to the fiscal three months ended October 1, 2023. Excluding the impact of favorable changes in foreign currency exchange rates of $1 million, Organic growth was $11 million, or 0.7%. Changes in both Net sales and Organic growth were primarily driven by value realization of 1.8%, partially offset by volume-related decreases of 1.1%. The increase was primarily driven by performance in Smoking Cessation and Cough and Cold attributable to effective promotional strategies. The increase was partially offset by declines in antifungal products in Asia Pacific due to trade inventory fluctuations.

Self Care Segment Adjusted Operating Income

The Self Care Segment adjusted operating income decreased by $47 million, or 7.8%, to $557 million for the fiscal three months ended September 29, 2024 as compared to the fiscal three months ended October 1, 2023. The decrease was primarily driven by increased investment in our brands and volume-related decreases, partially offset by value realization and the realization of benefits associated with our supply chain optimization initiatives.

52

Skin Health and Beauty Segment

Skin Health and Beauty Segment Net Sales

The Skin Health and Beauty Segment Net sales were $1.1 billion for both the fiscal three months ended September 29, 2024 and October 1, 2023. For the fiscal three months ended September 29, 2024, Net sales decreased $47 million, or 4.2%, as compared to the fiscal three months ended October 1, 2023. Excluding the impact of unfavorable changes in foreign currency exchange rates of $17 million, or 1.5%, Organic growth decreased $30 million, or 2.7%. Changes in both Net sales and Organic growth were primarily driven by volume-related decreases of 4.7%, partially offset by value realization of 2.0%. The decrease was driven by underperformance in the United States attributable to competitive pressures and slower than expected recovery from prior fiscal year execution challenges. The decrease was partially offset by growth outside of the United States.

Skin Health and Beauty Segment Adjusted Operating Income

The Skin Health and Beauty Segment adjusted operating income increased by $11 million, or 6.1%, to $191 million for the fiscal three months ended September 29, 2024 as compared to the fiscal three months ended October 1, 2023. The increase was primarily driven by value realization and the realization of benefits associated with our supply chain optimization initiatives, partially offset by volume-related decreases.

Essential Health Segment

Essential Health Segment Net Sales

The Essential Health Segment Net sales were $1.2 billion for both the fiscal three months ended September 29, 2024 and October 1, 2023. For the fiscal three months ended September 29, 2024, Net sales increased $19 million, or 1.6%, as compared to the fiscal three months ended October 1, 2023. Excluding the impact of unfavorable changes in foreign currency exchange rates of $34 million, or 2.9%, Organic growth was $53 million, or 4.5%. Changes in both Net sales and Organic growth were primarily driven by value realization of 3.7% and volume-related increases of 0.8%. Momentum in Essential Health continued across all product categories and was led by strong performance in Oral Care attributable to product innovation and effective promotional strategies.

Essential Health Segment Adjusted Operating Income

The Essential Health Segment adjusted operating income increased by $16 million, or 5.8%, to $291 million for the fiscal three months ended September 29, 2024 as compared to the fiscal three months ended October 1, 2023. The increase was primarily driven by value realization, volume-related increases, and the realization of benefits associated with our supply chain optimization initiatives, partially offset by increased investment in our brands.


53

Results of Operations

Fiscal Nine Months Ended September 29, 2024 Compared with Fiscal Nine Months Ended October 1, 2023

Our results for the fiscal nine months ended September 29, 2024 and October 1, 2023 were as follows:

Fiscal Nine Months Ended
Change In Fiscal Period
September 29, 2024October 1, 2023
Change 2023 to 2024
(Dollars in Millions)AmountPercent
Net sales$11,793 $11,778 $15 0.1 %
Cost of sales4,904 5,178 (274)(5.3)
Gross profit6,889 6,600 289 4.4 
Selling, general, and administrative expenses4,804 4,555 249 5.5 
Restructuring expenses120 — 120 *
Impairment charges578 — 578 *
Other operating expense (income), net29 (7)36 *
Operating income1,358 2,052 (694)(33.8)
Other expense, net6 65 (59)(90.8)
Interest expense, net283 154 129 83.8 
Income before taxes1,069 1,833 (764)(41.7)
Provision for taxes332 496 (164)(33.1)
Net income$737 $1,337 $(600)(44.9)%
* Calculation not meaningful.

Net Sales

Net sales were $11.8 billion for both the fiscal nine months ended September 29, 2024 and October 1, 2023. For the fiscal nine months ended September 29, 2024, Net sales increased $15 million, or 0.1%, as compared to the fiscal nine months ended October 1, 2023. Excluding the impact of unfavorable changes in foreign currency exchange rates of $153 million, or 1.3%, Organic growth was $168 million, or 1.4%. Changes in both Net sales and Organic growth were primarily attributable to value realization of 3.1%, partially offset by volume-related decreases of 1.7%. The increase in year-over-year value realization was primarily due to carryover price increases from the prior fiscal year as well as new pricing actions, while the volume-related decrease was primarily due to results in Skin Health and Beauty and Self Care, partially offset by growth in Essential Health. Net sales and Organic growth were primarily driven by growth in Essential Health across all product categories, led by Oral Care. This was partially offset by sales declines in Skin Health and Beauty due to volume-related decreases in the United States attributable to the carryover effects from prior fiscal year execution challenges and current fiscal year competitive pressures. For additional information about the Net sales of our three reportable business segments, see “—Segment Results” below.

Cost of Sales

Cost of sales were $4.9 billion and $5.2 billion for the fiscal nine months ended September 29, 2024 and October 1, 2023, respectively, a decrease of $274 million, or 5.3%. Gross profit margin expanded 240 basis points to 58.4% for the fiscal nine months ended September 29, 2024 as compared to 56.0% for the fiscal nine months ended October 1, 2023. Changes in both Cost of sales and gross profit margin were primarily due to gains attributable to the realization of benefits associated with our supply chain optimization initiatives, and gross profit margin was also impacted by value realization.

Selling, General, and Administrative Expenses

Selling, general, and administrative expenses were $4.8 billion and $4.6 billion for the fiscal nine months ended September 29, 2024 and October 1, 2023, respectively, an increase of $249 million, or 5.5%. Selling, general, and administrative expenses as a percentage of Net sales increased 200 basis points to 40.7% for the fiscal nine months ended September 29, 2024, as compared to 38.7% for the fiscal nine months ended October 1, 2023, primarily attributable to higher brand marketing expenses, driven by increased investment to support sales across segments and geographies, and an additional quarter of incremental ongoing public
54

company costs not incurred last year. These cost increases were partially offset by initial savings from the 2024 Multi-Year Restructuring Initiative and a $134 million decrease in Separation-related costs.

Restructuring Expenses

Restructuring expenses were $120 million for the fiscal nine months ended September 29, 2024, driven by costs incurred under the 2024 Multi-Year Restructuring Initiative related to global workforce reductions, changes in management structure, and the transition to centralized shared-service functions in lower-cost locations, as we take steps intended to enhance organizational efficiencies and better position Kenvue for future growth. See Note 16, “Restructuring Expenses and Operating Model Optimization Initiatives,” to the Condensed Consolidated Financial Statements included herein for additional information.

Impairment Charges

Impairment charges were $578 million for the fiscal nine months ended September 29, 2024, which primarily included a non-cash charge of $488 million ($337 million after-tax) to adjust the carrying value of intangible assets and property, plant, and equipment related to the Dr.Ci:Labo® skin health business. The impairment was due primarily to revisions to internal forecasts for the business as a result of updates in our strategy to reach more consumers and appropriately address evolving market dynamics, including shifts in consumer sentiment in China as well as changing shopping patterns in the region. The increase also included the impact of a $68 million non-cash impairment charge related to our interim corporate headquarters in Skillman, New Jersey, which was classified as held for sale on February 21, 2024. Additionally, we recognized a non-cash impairment charge of $22 million related to certain software development assets. See Note 1, “Description of the Company and Summary of Significant Accounting Policies—Impairment Charges,” to the Condensed Consolidated Financial Statements included herein for additional information. There were no impairment charges recognized in the fiscal three months ended September 29, 2024.

Other Operating Expense (Income), Net

Other operating expense (income), net was $29 million and $(7) million for the fiscal nine months ended September 29, 2024 and October 1, 2023, respectively, a change of $36 million. The increase in expense was driven by the prior period reversal of a $45 million contingent liability that was no longer considered to be probable, the accounting impact of net economic benefit arrangements with J&J in connection with the Deferred Local Businesses (see Note 1, “Description of the Company and Summary of Significant Accounting Policies,” to the Condensed Consolidated Financial Statements included herein for additional information), and a $9 million gain recognized on the sale of a manufacturing facility in Lancaster, Pennsylvania in the fiscal nine months ended October 1, 2023, partially offset by lower litigation expense. See Note 10, “Other Operating Expense (Income), Net and Other (Income) Expense, Net,” to the Condensed Consolidated Financial Statements included herein for additional information.

Other Expense, Net

Other expense, net was $6 million and $65 million for the fiscal nine months ended September 29, 2024 and October 1, 2023, respectively, a decrease of $59 million. The decrease in expense was primarily driven by a $54 million decrease in currency losses on transactions and a $21 million gain recognized on the release of tax indemnification reserves that were no longer considered to be probable, partially offset by a $24 million increase in losses on investments. See Note 10, “Other Operating Expense (Income), Net and Other (Income) Expense, Net,” to the Condensed Consolidated Financial Statements included herein for additional information.

Interest Expense, Net

Interest expense, net was $283 million and $154 million for the fiscal nine months ended September 29, 2024 and October 1, 2023, respectively, an increase of $129 million. The increase in expense was driven by interest expense recognized on the Senior Notes and notes issued under the Commercial Paper Program, along with $33 million of interest income recognized in the fiscal three months ended July 2, 2023 in relation to the Facility Agreement (as defined in Note 4, “Borrowings,” to the Condensed Consolidated Financial Statements included herein) as well as interest income earned in the fiscal three months ended July 2, 2023 on debt proceeds in escrow. See Note 4, “Borrowings,” to the Condensed Consolidated Financial Statements included herein for additional information.

55

Provision For Taxes

Provision for taxes was $332 million and $496 million for the fiscal nine months ended September 29, 2024 and October 1, 2023, respectively, a decrease of $164 million. The decrease in provision for taxes was primarily due to lower year-to-date income in comparison to the prior fiscal period as a result of the Dr.Ci:Labo® skin health business impairment and the recording of a valuation allowance against a deferred tax asset related to future foreign tax benefits in the fiscal nine months ended October 1, 2023. The decrease is offset by fewer releases of tax reserves due to the expiration of certain statutes of limitations and reduced tax benefits derived from the Separation as compared to the fiscal nine months ended October 1, 2023 and shortfall on stock-based compensation recorded during the fiscal nine months ended September 29, 2024. In addition, the worldwide effective income tax rates for the fiscal nine months ended September 29, 2024 and October 1, 2023 were 31.1% and 27.1%, respectively. See Note 11, “Income Taxes,” to the Condensed Consolidated Financial Statements included herein for additional information.

56

Segment Results

Fiscal Nine Months Ended September 29, 2024 Compared with Fiscal Nine Months Ended October 1, 2023

The following table presents Segment net sales and Segment adjusted operating income and the period-over-period changes in Segment net sales and Segment adjusted operating income for the fiscal nine months ended September 29, 2024 and October 1, 2023. See Note 15, “Segments of Business,” to the Condensed Consolidated Financial Statements included herein for further details regarding Segment net sales and Segment adjusted operating income.

Fiscal Nine Months EndedChange In Fiscal Period
September 29, 2024October 1, 2023
Change 2023 to 2024
(Dollars in Millions)AmountPercentAmountPercentAmountPercent
Segment Net Sales
Self Care$4,958 42.0 %$4,914 41.7 %$44 0.9 %
Skin Health and Beauty3,229 27.4 3,377 28.7 (148)(4.4)
Essential Health3,606 30.6 3,487 29.6 119 3.4 
Segment net sales
$11,793 100.0 %$11,778 100.0 %$15 0.1 %
Self Care$1,692 $1,762 $(70)(4.0)%
Skin Health and Beauty502 530 (28)(5.3)
Essential Health914 736 178 24.2 
Segment adjusted operating income(1)(2)
$3,108 $3,028 $80 2.6 %
Reconciliation to Income before taxes:
Less:
Depreciation(3)
238 211 
Amortization of intangible assets
212 242 
Separation-related costs
231 333 
Restructuring and operating model optimization initiatives146 3 
Impairment charges
578 — 
Conversion of stock-based awards(4)
34 (25)
Founder Shares(5)
24 — 
Other operating expense (income), net29 (7)
General corporate/unallocated expenses258 219 
Operating income$1,358 $2,052 
Other expense, net6 65 
Interest expense, net
283 154 
Income before taxes$1,069 $1,833 
(1) Effective in the fiscal three months ended September 29, 2024, we adjusted the allocation for certain brand marketing expenses within Selling, general, and administrative expenses to align with segment financial results as measured by the Company, including the CODM. Accordingly, we have updated the segment disclosures to reflect the updated presentation in all prior periods. Total Adjusted operating income did not change as a result of this update.
(2) Effective in the fiscal three months ended June 30, 2024, we adjusted the allocation for certain Research and development costs within Selling, general, and administrative expenses to align with segment financial results as measured by the Company, including the CODM. Accordingly, we have updated the segment disclosures to reflect the updated presentation in all prior periods. Total Adjusted operating income did not change as a result of this update.
(3) Depreciation includes the amortization of integration and development costs capitalized in connection with cloud computing arrangements.
(4) Segment adjusted operating income excludes the impact of the conversion of stock-based awards that occurred on August 23, 2023. The adjustment represents the net impact of the gain on reversal of previously recognized stock-based compensation expense, offset by stock-based compensation expense recognized in the fiscal nine months ended September 29, 2024 relating to employee services provided prior to the Separation.
(5) On August 25, 2023, our Compensation & Human Capital Committee approved the Founder Shares. On October 2, 2023, the Founder Shares were granted to all Kenvue employees in the form of stock options and PSUs to executive officers and either stock options and PSUs or RSUs to non-executive individuals.

Organic Growth

The following tables present a reconciliation of the change in U.S. GAAP Net sales to Organic growth for the fiscal nine months ended September 29, 2024 as compared to the fiscal nine months ended October 1, 2023:

Fiscal Nine Months Ended September 29, 2024 vs October 1, 2023(1)
Reported Net sales change Impact of foreign currencyOrganic growth
(Dollars in Millions)AmountPercentAmountAmountPercent
Self Care$44 0.9 %$(32)$76 1.5 %
Skin Health and Beauty(148)(4.4)(41)(107)(3.2)
Essential Health119 3.4 (80)199 5.7 
Total$15 0.1 %$(153)$168 1.4 %

Fiscal Nine Months Ended September 29, 2024 vs October 1, 2023(1)
Reported Net sales changeImpact of foreign currencyOrganic growth
Price/Mix(2)
Volume
Self Care0.9 %(0.6)%2.8 %(1.3)%
Skin Health and Beauty(4.4)(1.2)2.0 (5.2)
Essential Health3.4 (2.3)4.8 0.9 
Total0.1 %(1.3)%3.1 %(1.7)%
(1) Acquisitions and divestitures did not materially impact Net sales for the fiscal nine months ended September 29, 2024 or October 1, 2023.
(2) Also referred to as value realization.

Self Care Segment

Self Care Segment Net Sales

The Self Care Segment Net sales were $5.0 billion and $4.9 billion for the fiscal nine months ended September 29, 2024 and October 1, 2023, respectively, an increase of $44 million, or 0.9%. Excluding the impact of unfavorable changes in foreign currency exchange rates of $32 million, or 0.6%, Organic growth was $76 million, or 1.5%. Changes in both Net sales and Organic growth were primarily driven by value realization of 2.8%, partially offset by volume-related decreases of 1.3%. The increase was primarily driven by our performance in Other Self Care primarily in Smoking Cessation due to effective promotional strategies and product innovation, as well as Allergy Care and Digestive Health. The increase was partially offset by declines in Pain Care resulting from trade inventory fluctuations primarily in the United States.

Self Care Segment Adjusted Operating Income

The Self Care Segment adjusted operating income decreased by $70 million, or 4.0%, to $1,692 million for the fiscal nine months ended September 29, 2024 as compared to the fiscal nine months ended October 1, 2023. The decrease was primarily driven by increased investment in our brands and volume-related decreases, partially offset by value realization and the realization of benefits associated with our supply chain optimization initiatives.

Skin Health and Beauty Segment

Skin Health and Beauty Segment Net Sales

The Skin Health and Beauty Segment Net sales were $3.2 billion and $3.4 billion for the fiscal nine months ended September 29, 2024 and October 1, 2023, respectively, a decrease of $148 million, or 4.4%. Excluding the impact of unfavorable changes in foreign currency exchange rates of $41 million, or 1.2%, Organic growth decreased $107 million, or 3.2%. Changes in both Net sales and Organic growth were primarily driven by volume-related decreases of 5.2%, partially offset by value realization of 2.0%. The decrease was driven by volume-related decreases in the United States attributable to the carryover effects from prior fiscal year execution challenges, as well as current fiscal year competitive pressures, coupled with market softness in
China primarily impacting the first half of the fiscal year. The decrease was partially offset by growth outside of the United States.

Skin Health and Beauty Segment Adjusted Operating Income

The Skin Health and Beauty Segment adjusted operating income decreased by $28 million, or 5.3%, to $502 million for the fiscal nine months ended September 29, 2024 as compared to the fiscal nine months ended October 1, 2023. The decrease was primarily driven by increased investment in our brands and volume-related decreases, partially offset by value realization and the realization of benefits associated with our supply chain optimization initiatives.

Essential Health Segment

Essential Health Segment Net Sales

The Essential Health Segment Net sales were $3.6 billion and $3.5 billion for the fiscal nine months ended September 29, 2024 and October 1, 2023, respectively, an increase of $119 million, or 3.4%. Excluding the impact of unfavorable changes in foreign currency exchange rates of $80 million, or 2.3%, Organic growth was $199 million, or 5.7%. Changes in both Net sales and Organic growth were primarily driven by value realization of 4.8% and volume-related increases of 0.9%. Momentum in Essential Heath continued across all product categories and was led by strong performance in Oral Care, attributable to product innovation and effective promotional strategies, and growth in Women’s Health.

Essential Health Segment Adjusted Operating Income

The Essential Health Segment adjusted operating income increased by $178 million, or 24.2%, to $914 million for the fiscal nine months ended September 29, 2024 as compared to the fiscal nine months ended October 1, 2023. The increase was primarily driven by value realization, volume-related increases, and the realization of benefits associated with our supply chain optimization initiatives, partially offset by increased investment in our brands.

Liquidity and Capital Resources

Prior to April 4, 2023, our working capital requirements and capital expenditures were satisfied as part of J&J’s corporate-wide cash management and centralized funding programs, and a substantial portion of our cash was transferred to J&J. Cash and cash equivalents held by J&J at the corporate level were not specifically identifiable to us.

Effective April 4, 2023, upon completion of the Consumer Health Business Transfer (as defined in Note 1, “Description of the Company and Summary of Significant Accounting Policies—Description of the Company and Business Segments,” to the Condensed Consolidated Financial Statements included herein), we no longer participate in J&J’s corporate-wide cash management and centralized funding programs.

Cash Flows

Summarized cash flow information for the fiscal nine months ended September 29, 2024 and October 1, 2023 were as follows:

Change In Fiscal Period
Fiscal Nine Months EndedChange 2023 to 2024
(Dollars in Millions)September 29, 2024October 1, 2023AmountPercent
Net income$737 $1,337 $(600)(44.9)%
Net changes in assets and liabilities$(833)$492 $(1,325)*
Net cash flows from operating activities$976 $2,218 $(1,242)(56.0)%
Net cash flows used in investing activities$(293)$(223)$(70)31.4 %
Net cash flows used in financing activities$(978)$(2,144)$1,166 (54.4)%
* Calculation not meaningful.

Operating Activities

Net cash flows from operating activities were $976 million and $2,218 million for the fiscal nine months ended September 29, 2024 and October 1, 2023, respectively, a decrease of $1,242 million. The decrease was primarily attributable to changes in
57

working capital balances driven by a net decrease in Accounts payable and Accrued liabilities due to the timing of payments and an increase in Trade receivables due to the timing of sales and collections.

Investing Activities

Net cash flows used in investing activities were $293 million and $223 million for the fiscal nine months ended September 29, 2024 and October 1, 2023, respectively, an increase of $70 million. Net cash flows used in investing activities were primarily driven by purchases of property, plant, and equipment in both the fiscal nine months ended September 29, 2024 and October 1, 2023, partially offset by proceeds from the sale of assets in the fiscal nine months ended October 1, 2023.

Financing Activities

Net cash flows used in financing activities were $978 million and $2,144 million for the fiscal nine months ended September 29, 2024 and October 1, 2023, respectively, a decrease of $1,166 million. Net cash flows used in financing activities for the fiscal nine months ended September 29, 2024 were primarily driven by $1,159 million of dividends paid and $114 million of payments made to purchase treasury shares, partially offset by $258 million of net proceeds from the issuance of commercial paper under the Commercial Paper Program (as defined below). Net cash flows used in financing activities for the fiscal nine months ended October 1, 2023 were primarily driven by $13.8 billion in distributions to J&J in connection with the Separation, $383 million of dividends paid, and Net transfers to J&J of $274 million, partially offset by approximately $7.7 billion of net proceeds from Senior Notes (as defined below), $4.2 billion of proceeds from the sale of common stock in connection with the Kenvue IPO, and $497 million of net proceeds from the issuance of commercial paper under the Commercial Paper Program. Net transfers to J&J were driven by cash pooling and general financing activities, indirect corporate cost allocations from J&J, and taxes deemed to be settled with J&J. For further details regarding Net transfers to J&J, see Note 9, “Relationship with J&J—Net Transfers to J&J,” to the Condensed Consolidated Financial Statements included herein.

Sources of Liquidity

Our primary sources of liquidity are cash on hand, which consisted of cash and cash equivalents of $1,057 million as of September 29, 2024, cash flows from operations, borrowing capacity under our Revolving Credit Facility (as defined below) of $4.0 billion, and authorized Commercial Paper Program issuance of $4.0 billion. As of September 29, 2024, we had no amounts outstanding under the Revolving Credit Facility and $887 million of outstanding balances under our Commercial Paper Program, net of a related discount of $3 million.

Our ability to fund our operating needs will depend on our ability to continue to generate positive cash flows from operations and on our ability to obtain debt financing on acceptable terms or to issue additional equity or equity-linked securities. Based upon our history of generating positive cash flows, we believe our existing cash and cash generated from operations will be sufficient to service our current obligations for at least the next 12 months.

Management believes that our cash balances and funds provided by operating activities, along with borrowing capacity and access to capital markets, taken as a whole, provide adequate liquidity to meet all of our current and long-term obligations when due, including third-party debt that we incurred in connection with the Separation, adequate liquidity to fund capital expenditures, and flexibility to meet investment opportunities that may arise. However, we cannot assure you that we will be able to obtain additional debt or equity financing on acceptable terms in the future.

Cash and cash equivalents decreased by $325 million during the fiscal nine months ended September 29, 2024 to $1,057 million as of September 29, 2024, as compared to $1,382 million as of December 31, 2023. Cash and cash equivalents held by our foreign subsidiaries was $1,047 million and $1,336 million as of September 29, 2024 and December 31, 2023, respectively.

Restructuring

On May 6, 2024, our Board approved the 2024 Multi-Year Restructuring Initiative to build on our strengths and optimize our cost structure by rebalancing resources to better position us for future growth. The initiative is expected to result in pre-tax restructuring expenses and other charges totaling approximately $550 million. We planned to incur approximately $275 million in pre-tax restructuring expenses and other charges in each of fiscal year 2024 and fiscal year 2025. We currently anticipate lower than expected spend in fiscal year 2024 due to the shift in timing of certain IT and project-related costs to fiscal year 2025 and lower than expected employee-related costs relating to severance spend due to employee redeployment and voluntary exits. Over the life of the initiative, a majority of the pre-tax expenses and other charges are expected to be paid in cash. These charges are expected to be funded primarily through cash flows generated from operations. We expect to reinvest all or a portion of the benefits associated with the 2024 Multi-Year Restructuring Initiative in future growth opportunities, including
58

immediate reinvestment behind advertising, product promotion, and healthcare professional engagement. Our estimates of the costs of the initiative and the expected benefits are preliminary estimates and are subject to a number of assumptions, including local law requirements in various jurisdictions. Actual charges may differ, possibly materially, from the estimates provided above. See Note 16, “Restructuring Expenses and Operating Model Optimization Initiatives,” to the Condensed Consolidated Financial Statements included herein for further information.

Supplier Finance Program

As a part of our ongoing efforts to maximize working capital and manage liquidity, we work with suppliers to optimize payment terms and conditions on accounts payable through a voluntary supplier finance program. The program provides some of our suppliers with the opportunity to sell receivables due from us (our accounts payables) to participating financial institutions at the sole discretion of both the suppliers and the financial institutions. We are not a party to the arrangements between the suppliers and the third-party financial institutions. Our obligations to the suppliers, including amounts due, and scheduled payment dates (which have general payment terms of 90 days), are not affected by a participating supplier’s decision to participate in the program. See Note 1, “Description of the Company and Summary of Significant Accounting Policies—Supplier Finance Program,” to the Condensed Consolidated Financial Statements included herein.

Senior Notes

On March 22, 2023, we issued eight series of senior unsecured notes (the “Senior Notes”) in an aggregate principal amount of $7.75 billion. The net proceeds to us from the Senior Notes were approximately $7.7 billion after deductions of discounts and issuance costs of $77 million. The net proceeds were reflected as Restricted cash on the Condensed Consolidated Balance Sheet prior to their release from escrow on April 5, 2023. Upon release from escrow, these funds were loaned to J&J through a facility agreement (the “Facility Agreement”) dated April 5, 2023. For further details on the Senior Notes, see Note 4, “Borrowings—Senior Notes,” to the Condensed Consolidated Financial Statements included herein.

Our Senior Notes are governed by an indenture and supplemental indenture between us and a trustee (collectively, the “Indenture”). The Indenture contains certain covenants, including limitations on us and certain of our subsidiaries’ ability to incur liens or engage in certain sale-leaseback transactions. The Indenture also contains restrictions on our ability to consolidate, merge, or sell substantially all of our assets. In addition, the Indenture contains other customary terms, including certain events of default, upon the occurrence of which the Senior Notes may be declared immediately due and payable.

Commercial Paper Program

On March 3, 2023, we entered into a commercial paper program (the “Commercial Paper Program”). Our Board has authorized the issuance of up to $4.0 billion in an aggregate principal amount of commercial paper under the Commercial Paper Program. Any such issuance will mature within 364 days from date of issue. The Commercial Paper Program contains representations and warranties, covenants, and defaults that are customary for this type of financing. The commercial paper notes issued under the Commercial Paper Program are unsecured notes ranking at least pari passu with all of our other senior unsecured indebtedness. For further details on the Commercial Paper Program, see Note 4, “Borrowings—Commercial Paper Program,” to the Condensed Consolidated Financial Statements included herein.

Prior to the Kenvue IPO, we issued $1.25 billion under the Commercial Paper Program which, collectively with the Senior Notes as further described above, are referred to as the “Debt Financing Transactions.”

Revolving Credit Facility

On March 6, 2023, we entered into a credit agreement providing for a five-year senior unsecured revolving credit facility (the “Revolving Credit Facility”) in an aggregate principal amount of $4.0 billion to be made available in U.S. dollars and Euros. For further details on the Revolving Credit Facility, see Note 4, “Borrowings—Revolving Credit Facility,” to the Condensed Consolidated Financial Statements included herein.

Facility Agreement

On April 5, 2023, we entered into the Facility Agreement, allowing us to lend the proceeds from the issuance of debt (including commercial paper) in an aggregate amount of $8.9 billion to J&J.

59

Upon completion of the Kenvue IPO on May 8, 2023, the Facility Agreement was terminated and the balance of the loans, and all accrued interest, were repaid by J&J for a total cash inflow of $9.0 billion. We remitted this cash back to J&J as a distribution in connection with the Separation.

Distribution to J&J

On May 8, 2023, in conjunction with the Consumer Health Business Transfer (as defined in Note 1, “Description of the Company and Summary of Significant Accounting Policies—Description of the Company and Business Segments,” to the Condensed Consolidated Financial Statements included herein), we distributed $13.8 billion to J&J from 1) the net proceeds received from the sale of the common stock in the Kenvue IPO, 2) the net proceeds received from the Debt Financing Transactions, and 3) any cash and cash equivalents in excess of the $1.17 billion retained by us immediately following the Kenvue IPO.

Interest Expense, Net

We recognized Interest expense, net of $283 million in the Condensed Consolidated Statement of Operations during the fiscal nine months ended September 29, 2024 which primarily includes interest expense, including amortization of discounts and debt issuance costs, recognized on the Senior Notes and interest expense recognized on notes issued under the Commercial Paper Program.

Compliance with Covenants

As of September 29, 2024, we were in compliance with all debt covenants, and no default or event of default has occurred.

Dividends

Quarterly dividends have been paid to our shareholders since the Kenvue IPO. A summary of cash dividends per share on the outstanding Kenvue common stock declared to shareholders by our Board and paid during the fiscal nine months ended September 29, 2024 is presented below:

Declaration Date
Record Date
Payment Date
Per Share Amount
January 25, 2024
February 14, 2024
February 28, 2024
$0.20
April 25, 2024
May 8, 2024
May 22, 2024
$0.20
July 25, 2024
August 14, 2024
August 28, 2024
$0.205

On October 17, 2024, we announced that our Board declared a dividend of $0.205 per share on our common stock. The dividend is payable on November 27, 2024 to shareholders of record as of the close of business on November 13, 2024.

Future Cash Requirements

We expect our future cash requirements will relate to working capital, capital expenditures, restructuring and integration, compensation and benefit-related obligations, interest expense and debt service obligations, litigation costs, the return of capital to shareholders, including through the payment of any dividend, and other contractual obligations that arise in the normal course of business. We may also use cash to enter into business development transactions, such as licensing arrangements or strategic acquisitions.

As of September 29, 2024, we expect our primary cash requirements for fiscal year 2024 to include capital expenditures. We have made payments of $302 million for property, plant, and equipment during the fiscal nine months ended September 29, 2024.

Share Repurchase Program

Our Board has authorized a share repurchase program, under which we are authorized to repurchase up to 27,000,000 shares of our outstanding common stock in open market or privately negotiated transactions. The program has no expiration date and may be suspended or discontinued at any time. The intent of this repurchase program is to offset dilution from the vesting or exercise of equity awards under the Kenvue 2023 Plan (as defined in Note 8, “Stock-Based Compensation,” to the Condensed
60

Consolidated Financial Statements included herein). We repurchased 5,700,000 shares of our outstanding common stock for $114 million during the fiscal nine months ended September 29, 2024.

Future Litigation

In the ordinary course of business, we are involved in litigation, claims, government inquiries, investigations, charges, and proceedings. See Note 14, “Commitments and Contingencies,” to the Condensed Consolidated Financial Statements included herein for further details regarding certain matters that are currently pending. Our ability to successfully resolve pending and future litigation may adversely impact our financial condition, results of operations, or cash flows.

Off-Balance Sheet Arrangements

We did not have during the periods presented, and we do not currently have, any off-balance sheet arrangements (as defined under the rules and regulations of the SEC) or any relationships with unconsolidated entities that have or are reasonably likely to have a material current or future effect on our financial condition, changes in financial condition, Net sales or expenses, results of operations, liquidity, cash requirements, or capital resources.

Other Information

Baby Powder Transition

On August 11, 2022, we announced the commercial decision to transition to an all cornstarch-based baby powder portfolio. As a result of this transition, talc-based Johnson’s® Baby Powder was discontinued globally in 2023. Talc-based Johnson’s® Baby Powder was previously discontinued during 2020 in certain markets, including the United States and Canada. We do not expect the impact of this change to have a significant impact on our results of operations.

Deferred Markets

In order to ensure compliance with applicable law, to obtain necessary governmental approvals and other consents, and for other business reasons, we deferred the transfer of certain assets and liabilities of businesses in certain non-U.S. jurisdictions, including China, Malaysia, and Russia, until after the completion of the Kenvue IPO. On September 11, 2023, J&J transferred the equity interests in the majority of the Deferred Legal Entities (as defined in Note 1, “Description of the Company and Summary of Significant Accounting Policies,” to the Condensed Consolidated Financial Statements included herein) to the Company that previously had been consolidated as Variable Interest Entities in the Condensed Consolidated Financial Statements. The Condensed Consolidated Financial Statements included herein include businesses in all jurisdictions in which we operate following the completion of the Separation, including any Deferred Local Business (as defined in Note 1, “Description of the Company and Summary of Significant Accounting Policies,” to the Condensed Consolidated Financial Statements included herein). For more information regarding Deferred Local Businesses, see “Risk Factors—Risks Related to Our Relationship with J&J—The transfer of certain assets and liabilities from J&J to us contemplated by the Separation has not been completed and may be significantly delayed or not occur at all” in our Annual Report and Note 1, “Description of the Company and Summary of Significant Accounting Policies,” to the Condensed Consolidated Financial Statements included herein.

Provision For Taxes

On December 15, 2022, the European Union (“EU”) Member States formally adopted the EU’s Pillar Two Directive, which generally provides for a minimum effective tax rate of 15%, as established by the Organization for Economic Co-operation Development (“OECD”) Pillar Two Inclusive Framework that was supported by over 130 countries worldwide. The EU effective dates are January 1, 2024, and January 1, 2025, for different aspects of the directive. On July 17, 2023, the OECD published Administrative Guidance proposing certain safe harbors that effectively extend certain effective dates to January 1, 2027. The OECD continues to release additional guidance, including guidance on safe harbors for which we may qualify, and many countries have already implemented legislation consistent with the OECD Pillar Two Framework. Due to these new rules, our provision for taxes could be unfavorably impacted as the legislation becomes effective in countries in which we conduct business. However, based on our current analysis, currently enacted laws for Pillar Two do not have a significant impact on the Condensed Consolidated Financial Statements. We are continuing to evaluate the Model Global Anti-Base Erosion Rules for Pillar Two and related legislation, and their potential impact on future periods.

61

Item 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK
Foreign Currency Risk

Because we manufacture and sell products and finance operations in a number of countries throughout the world, we are exposed to the impact on revenue and expenses of movements in currency exchange rates, including as a result of the strengthening of the U.S. dollar or fluctuations in foreign currency rates in numerous jurisdictions, particularly the European Union, the United Kingdom, Japan, China, Canada, Brazil, and India.

We manage the impact of foreign exchange rate movements on our earnings, cash flows, and fair values of assets and liabilities through operational means and through the use of various financial instruments, including derivative instruments such as forward and swap foreign exchange contracts. The financial instruments utilized are viewed as risk management tools and are not used for trading or speculative purposes. Forward and swap foreign exchange contracts are sensitive to changes in foreign currency rates. Gains or losses on these contracts are generally offset by the gains or losses on the underlying transactions, and therefore, would have no impact on future anticipated earnings and cash flows.

Inflation Risk

In recent years, the global macroeconomic environment has experienced significant inflationary pressures and may continue to increase the costs of raw materials, packaging components, and other inputs for our products. In recent years, we have experienced, and we continue to experience, higher than expected inflation, including escalating transportation, commodity, and other supply chain costs and disruptions that have affected, and continue to affect, our results of operations. We have partially offset the impact of inflation primarily through price increases, in addition to continued supply chain optimization initiatives.

However, if our costs continue to be subject to significant inflationary pressures, we may not be able to offset such higher costs through price increases, which could adversely affect our business, results of operations, or financial condition.

Interest Rate Risk

Our cash equivalents and marketable securities are subject to market risk due to changes in interest rates. Fixed rate securities may have their market value adversely affected due to a rise in interest rates, while floating rate securities may produce less income than expected if interest rates fall. Interest rate risk is managed through the maintenance of a portfolio of variable and fixed-rate debt composed of short and long-term instruments. The objective is to maintain a cost-effective mix that management deems appropriate. From time to time, we also hedge the anticipated issuance of fixed-rate debt, and those contracts are designated as cash flow hedges. As of September 29, 2024, our outstanding long-term debt portfolio was comprised primarily of fixed-rate debt, and therefore, any fluctuation in market interest rate is not expected to have a material impact on our results of operations. Our interest expense for any new floating rate debt we may incur in the future, including under the Revolving Credit Facility, could be exposed to changes in interest rates. Interest rate risk is highly sensitive due to many factors, including the monetary and tax policies of the United States and other countries, market and economic factors, and other factors beyond our control.

Commodity Price Risk

We are exposed to commodity and other price risk, including from resins, pulp and corn derivatives, vegetable oils and oleochemicals, and other inputs, including energy, labor, transportation (such as trucks, containers, and ocean freight), and logistics services. We use various strategic pricing mechanisms to manage cost exposures on certain material purchases with the objective of obtaining appropriate costs for these commodities.

Credit Risk

We are exposed to potential credit losses in the event of nonperformance by counterparties to our receivables, including our customers. Concentrations of credit risk arising from receivables from customers are limited due to the diversity of our customers. We perform credit evaluations of our customers’ financial conditions and may also obtain collateral or other security as appropriate. Notwithstanding these efforts, current adverse macroeconomic factors across the global economy may increase the difficulty in collecting receivables. We are also exposed to the risk of credit loss in the event of nonperformance by counterparties to financial instrument contracts; however, nonperformance is considered unlikely and any nonperformance is unlikely to be material as it is our policy to contract with diverse, credit-worthy counterparties based upon both strong credit ratings and other credit considerations.

62

Item 4. CONTROLS AND PROCEDURES
Evaluation of Disclosure Controls and Procedures

As of September 29, 2024, the end of the period covered by this report, management of the Company evaluated the effectiveness of the design and operation of its disclosure controls and procedures. The Company’s disclosure controls and procedures are designed to ensure that information required to be disclosed by the Company in the reports that it files or submits under the Securities Exchange Act of 1934, as amended (the “Exchange Act”), is recorded, processed, summarized, and reported, within the time periods specified in the SEC’s rules and forms. Disclosure controls and procedures include, without limitation, controls and procedures designed to ensure that information required to be disclosed by the Company in the reports that it files or submits under the Exchange Act is accumulated and communicated to the Company’s management, including its principal executive and principal financial officers, or persons performing similar functions, as appropriate, to allow timely decisions regarding required disclosure. The Company’s Chief Executive Officer, Thibaut Mongon, and Chief Financial Officer, Paul Ruh, reviewed and participated in this evaluation of Kenvue’s disclosure controls and procedures. Based on this evaluation, Messrs. Mongon and Ruh concluded that, as of the end of the period covered by this report, the Company’s disclosure controls and procedures were effective.

Changes in Internal Control Over Financial Reporting

During the fiscal three months ended September 29, 2024, the period covered by this report, there were no changes in the Company’s internal control over financial reporting that have materially affected, or are reasonably likely to materially affect, the Company’s internal control over financial reporting.

In the fiscal three months ended September 29, 2024, the Company began a multi-year implementation of a new global enterprise resource planning (“ERP”) system, which will replace and enhance the Company’s existing operating and financial systems. The ERP system is designed to accurately maintain and enhance the flow of financial information, enhance operational functionality, and accelerate information reporting to the Company’s management. The implementation is expected to occur in phases over the next several years.

The portion of the new ERP system implementation that has been completed to date did not result in significant changes to the Company’s internal control over financial reporting. As the phased implementation of the new ERP system continues, the Company will continue to assess whether this new ERP system implementation will materially affect, or is reasonably likely to materially affect, the Company’s internal control over financial reporting.

63

Part II—OTHER INFORMATION
Item 1. LEGAL PROCEEDINGS
The information called for by this item is incorporated herein by reference to Note 14, “Commitments and Contingencies,” to the Condensed Consolidated Financial Statements included herein.

Item 1A. RISK FACTORS
There have been no material changes in our risk factors from those disclosed under Item 1A “Risk Factors” included in our Annual Report on Form 10-K for the fiscal twelve months ended December 31, 2023 filed on March 1, 2024 with the SEC.

Item 2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS
There were no sales of equity securities by the Company during the fiscal nine months ended September 29, 2024.

Purchases of Equity Securities by the Issuer and Affiliated Purchasers

During the fiscal three months ended October 1, 2023, our Board authorized a share repurchase program, under which we are authorized to repurchase up to 27,000,000 shares of our outstanding common stock in open market or privately negotiated transactions. The program has no expiration date and may be suspended or discontinued at any time. The intent of this repurchase program is to offset dilution from the vesting or exercise of equity awards under the Kenvue 2023 Plan (as defined in Note 8, “Stock-Based Compensation,” to the Condensed Consolidated Financial Statements included herein).

The following table represents our purchases of common stock during the fiscal three months ended September 29, 2024:

(Shares in Thousands)
Period Total Number of Shares Purchased Average Price Paid Per Common Share
Total Number of Shares Purchased as Part of Publicly Announced Plans or Programs
Approximate Maximum Number of Shares That May Yet Be Purchased Under the Plans or Programs
July 1, 2024 - July 31, 2024
— $— — 22,050 
August 1, 2024 - August 31, 2024
1,100 $21.30 1,100 20,950 
September 1, 2024 - September 29, 2024
— $— — 20,950 
Total number of shares purchased
1,100 

Item 5. OTHER INFORMATION
Insider Trading Arrangements and Policies

During the fiscal three months ended September 29, 2024, none of the Company’s directors or officers (as defined in Rule 16a1(f) under the Exchange Act) adopted or terminated any contract, instruction, or written plan for the purchase or sale of the Company’s securities intended to satisfy the conditions of the affirmative defense provided by Rule 10b5-1(c) or any “non-Rule 10b5-1 trading arrangement,” as each term is defined in Item 408(a) of Regulation S-K.


64

Item 6. EXHIBITS
Exhibit NumberExhibit Description
3.1
3.2
31.1
31.2
32.1
32.2
101.INS
Inline XBRL Instance Document - the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document
101.SCH
Inline XBRL Taxonomy Extension Schema Document
101.CAL
Inline XBRL Taxonomy Extension Calculation Linkbase Document
101.DEF
Inline XBRL Taxonomy Extension Definition Document
101.LAB
Inline XBRL Taxonomy Extension Label Linkbase Document
101.PRE
Inline XBRL Taxonomy Extension Presentation Linkbase Document
104Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101)
* Filed herewith
** Furnished herewith


65

SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
 Kenvue Inc.
Date: November 7, 2024
/s/ PAUL RUH
Paul Ruh
 
Chief Financial Officer
(Principal Financial Officer) 
  
Date: November 7, 2024
/s/ HEATHER HOWLETT
 Heather Howlett
 
Chief Accounting Officer
(Principal Accounting Officer) 



66